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Tau and α-synuclein (SYN) are two intrinsically disordered proteins that aggregate in several common 
neurodegenerative diseases, including Alzheimer’s disease (AD) and Parkinson’s disease (PD). We 
investigated the functional roles and interactions of tau and SYN in mouse models of neurodegenerative 
disease. We first determined that reduction and ablation of tau in aging mice is benign, validating tau 
reduction as a safe potential therapeutic target. Tau ablation prevents many AD-like behavioral and 
biochemical alterations in the human amyloid precursor protein mouse model (hAPP-J20) of AD, but how 
tau mediates these phenotypes is unknown. Using mass spectrometry to identify and quantify endogenous 
post-translational modifications of tau, we found similar levels of tau modifications in hAPP-J20 and 
wildtype mice suggesting that abnormal tau modification may not mediate AD-like phenotypes in hAPP-
J20 mice. Because hyperphosphorylated and aggregated tau can also found in PD, we explored whether tau 
mediated PD-like phenotypes in a mouse model of toxic dopaminergic cell death and a wildtype SYN 
transgenic mouse model. Tau knockout tended to worsen toxicity in the dopaminergic cell death model and 
did not affect motor impairments in SYN transgenic mice, implying that tau does not mediate PD-like 
deficits in these models. We went on to describe SYN-induced cortical network dysfunction by 
electroencephalography and compared it to network dysfunction in patients with dementia with Lewy 
bodies (DLB), a disease closely related to PD. We identified two types of neural network dysfunction in 
SYN transgenic mice: a shift in power from higher to lower frequency brain oscillations and seizures. 
Human DLB patients show a similar shift in oscillatory power and signs of aberrant network excitability, 
implying that SYN accumulation may contribute to neural network dysfunction in DLB. Tau ablation and 
acute anti-epileptic treatment reduced epileptiform activity in SYN mice, but did not affect the oscillatory 
shift. We propose that tau mediates aberrant network excitability induced by Aβ in hAPP-J20 mice, 
however, SYN can induce oscillatory and motor network dysfunction independently of tau function. In 
human dementia patients, tau lowering therapies may benefit patients with Aβ pathology but additional 
SYN-targeted therapies would be required for patients with SYN pathology. 
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Part I: Tau, a microtubule-associated protein involved in disease  
The microtubule-associated protein tau was identified as a microtubule-assembly factor in the mid-
1970s
1,2
. Subsequently, hyperphosphorylated, insoluble, filamentous tau was shown to be the main 
component of neurofibrillary tangles (NFTs), a pathological hallmark of Alzheimer’s disease (AD)
3-7
. 
Neurodegenerative disorders with tau inclusions are referred to as tauopathies
8
. These include AD; 
frontotemporal lobar degeneration with tau inclusions (FTLD-tau) such as Pick’s disease, progressive 
supranuclear palsy and corticobasal degeneration; agyrophillic grain disease; some prion diseases; 
amyotrophic lateral sclerosis/parkinsonism–dementia complex, chronic traumatic encephalopathy; and 
some genetic forms of Parkinson’s disease
8-11
. Although associations per se cannot prove cause-effect 
relationships, tau inclusions are widely thought to contribute to the pathogenesis of these disorders because 
they occur in specific brain regions whose functions are altered by these conditions, and NFT formation 
correlates with the duration and progression of AD
12,13
. Tau inclusions also appear to modulate the clinical 
features of other neurodegenerative diseases. In dementia with Lewy bodies, an α-synuclein disorder, 
accumulation of insoluble tau inclusions is associated with a more AD-like phenotype
14
. 
Tau is expressed in the central and peripheral nervous system and, to a lesser extent, in kidney, lung 
and testis
15
. It is most abundant in neuronal axons
8,16
, but can also be found in neuronal somatodendritic 
compartments
17
 and in oligodendrocytes
18
. Tau can be subdivided into four regions: an N-terminal 
projection region, a proline-rich domain, a microtubule-binding repeat domain (MBRD), and a C-terminal 
region
19
. Alternative splicing around the N-terminal region and MBRD generates six main isoforms in adult 
human brain
20
. Tau isoforms are named by how many microtubule binding repeat sequences are expressed 
(termed R) and by which N-terminal exons are included (termed N) (Figure 1.1). For example, 3R tau has 
three microtubule binding repeat sequences, while 4R tau has four due to inclusion of exon 10. 0N tau 
includes no N-terminal exons, 1N tau exon 2, and 2N tau exons 2 and 3
8
. Tau mutations and post-
translational modification sites are numbered by their location in 4R2N human tau
8
. Six additional isoforms 
are formed by alternative splicing around exon 6, resulting in a total of 12 tau isoforms expressed in brain
21
, 







Figure 1.1. Tau structure and function. Tau is an intrinsically disordered protein that can be alternatively 
spliced at N terminal exons (N1, 2) and the microtubule repeat domains (R). The domains of tau bind 
many different types of molecules, suggesting a central role in signaling pathways and cytoskeletal 
organization. The diversity of tau binding partners is highlighted in Table 1.1. N-term, N-terminus; C-






Physiological tau has an intrinsically disordered structure and is subject to a complex array of post-
translational modifications. Many serine and threonine residues on tau are phosphorylated by a variety of 
kinases in both physiological and pathological conditions (for a comprehensive table of tau phosphorylation 
and corresponding kinases, see http://cnr.iop.kcl.ac.uk/hangerlab/tautable). Tau is also post-translationally 



















. The diversity of these 
modifications suggests that tau is highly regulated. 
Tau can bind to the outside and, possibly, also the inside of microtubules, with its N- and C-terminal 
regions projecting outward
32,33
. Its N-terminal region can associate with the cell membrane, likely as part of 
a membrane-associated complex (Figure 1.1), and regulate the spacing between microtubules
34-36
. Its 
proline-rich domain includes many phosphorylation sites
37,38
 and can bind to SH3 domains of other 
proteins
39
, including the tyrosine kinase Fyn
40
. Tau’s ability to bind microtubules depends on the MBRD 
and on adjacent regions
41
. The tandem repeat sequences within the MBRD are thought to directly bind 
microtubules through their positive net charge, which interacts with negatively charged residues in 
tubulin
32,42
. Phosphorylation of tau can decrease its binding to microtubules, allowing tau to diffuse out of 
the axon
43
, and is associated with tau aggregation in disease. Phosphorylation of tau in and around the 
MBRD may neutralize the positive charge
42
 and alter the conformation of the MBRD of tau
44
, detaching 
tau from microtubules. The detached tau mislocalizes, diffusing out of the axon
43
 and accumulating in 
neuronal cell bodies and neurites, and forms insoluble filaments and, ultimately, NFTs
8,45
. The MBRD also 
contains PHF6 (VQIVYK) and PHF6* (VQIINK), critical sequences that can assume the beta-sheet 
structures necessary for tau aggregation and formation of pathological inclusions
45,46
  
Evidence for multiple functions of tau 
Although tau has been studied ever more intensely in recent years, its precise functions and roles have, 





established in rather reductionist paradigms, and their in vivo significance remains uncertain. Other 
functions were revealed by analysis of tau knockout mice, but the precise mechanisms are poorly 
understood. A major advantage of tau knockout models is that they can reveal unique functions of tau that 
are not redundant with the functions of other proteins. For example, tau reduction prevents behavioral 
deficits in several models of AD (see below), suggesting that unique functions of tau are important in the 
pathogenesis of this condition. It remains controversial whether animal models with high levels of tau 
overexpression can provide relevant insights into human conditions in which such overexpression does not 
occur. However, the accumulation and abnormal distribution of hyperphosphorylated and aggregated tau in 
these models does simulate key aspects of human tauopathies. Concerns may also be raised about the 
relevance of studies investigating tau in non-neuronal cells. Although neurons are probably the most 
relevant cell type to study in relation to tauopathies, some tauopathies are associated with tau pathology in 
glial cells
47
 and the proteins that interact with tau in different cell types likely overlap.  
Tau has numerous binding partners (Table 1.1), including signaling molecules, cytoskeletal elements 
and lipids, suggesting that it is a multifunctional protein. Indeed, tau can bind to and affect cytoskeletal 
components and regulate signaling pathways by acting as a protein scaffold for signaling complexes; tau 
binding also activates or inhibits several enzymes.  
Cytoskeletal binding functions  
The most extensively described activity of tau—binding to microtubules—occurs in vitro and in vivo. 
In fact, the majority of tau in the cell is bound to microtubules.  In cell-free conditions, this microtubule 
binding activity promotes microtubule assembly and stability
1
. However, in cell culture, tau co-localizes 
with those microtubules that are most dynamic and most susceptible to drug-induced depolymerization
48
. 
Moreover, the population of tau-bound microtubules has the highest basal turnover rate of any microtubule 
population, both in rat primary neuronal culture and in mouse hippocampus in vivo
49
, raising doubts about 





knockdown of tau by siRNA is not 
lethal to primary neurons in culture and 
does not decrease the number of 
microtubules or their polymerization 
state
57,58
. Thus, microtubule stabilization 
may not be a unique or critical function 
of tau in vivo. 
The in vitro and in vivo functions of 
tau appear to overlap with those of 
MAP1B, another microtubule-
associated protein found in axons
59,60
. In 
mice, complete ablation of tau by 
homologous recombination does not 
significantly impair longevity or most 
critical brain functions, but clearly 
worsens the MAP1B knockout 
phenotype of premature mortality and 
brain dysgenesis
60
. Knockout of both tau and MAP1B results in severe brain dysgenesis and is lethal within 
the first month of life. Assuming that this phenotype relates to the microtubule-binding activities of tau and 
MAP1B, which is uncertain, it is reasonable to speculate that MAP1B is more important for microtubule 
stabilization than tau and that their overlapping functions are critical for postnatal brain maturation. 
However, because of the early lethality, it is impossible to draw firm conclusions from the double-knockout 
phenotype on the functions of tau and MAP1B in the adult or aging brain.  
In principle, tau’s binding to microtubules could regulate axonal transport. Tau can interfere with the 
binding of motor proteins to microtubules
61,62
, and there is a gradient of tau along the axon; the highest 
Table 1.1. Partial list of tau binding partners 





























p85α Regulatory subunit of PI3K
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levels are closest to the synapse
63
. This distribution might facilitate the detachment of motor proteins from 
their cargo near the presynaptic terminal, increasing axonal transport efficiency
61
. Independent of the 
microtubule binding ability of tau, the N-terminus of tau impairs fast-axonal transport through activation of 
protein phosphatase 1 and glycogen-synthase kinase 3β (GSK3β), a mechanism which may be relevant in 
overexpression or disease conditions
64
. However, ablation of tau does not alter axonal transport in primary 
neuronal culture
65
 or in vivo
66
, making an essential role of tau in this physiological function less likely. 
Tau can also bind to and bundle actin filaments
52,67,68
, activities mediated primarily by its MBRD
69,70
 
and assisted by the adjacent proline-rich domain
67
 (Figure 1.1). It is possible that tau connects microtubule 
and actin filament networks
69
.  
Modulation of signaling pathways through scaffolding  
Tau could also act as a protein scaffold, and regulation of its binding partners may alter signaling 
pathways. For example, tau modulates the activity of Src family kinases. In mouse brain tissues, tau co-
immunoprecipitates with both the tyrosine kinase Fyn and the scaffolding protein PSD95, and in the 
absence of tau, Fyn can no longer traffic into postsynaptic sites in dendrites (Figure 1.2)
71
. The authors 
speculated that tau normally tethers Fyn to PSD-95/NMDA receptor signaling complexes. Although very 
little tau is normally present in dendrites, it may be enough to ensure proper localization of postsynaptic 
components
71
. Similarly, tau acts as a protein scaffold in oligodendrocytes, connecting Fyn and 
microtubules to enable process extension
18
. In cell culture, tau binds to and activates both cSrc and Fyn and 
facilitates cSrc-mediated actin rearrangements following platelet-derived growth factor stimulation
72
. 
Tau may also regulate signaling cascades that control neurite extension, although this is a somewhat 
controversial area. Some investigators have reported a defect in neurite extension in tau knockout neurons 
in vitro
73









Figure 1.2. Endogenous tau exists in dendrites. Tau immunoprecipitates with PSD95, a postsynaptic 
protein, and regulates the association of PSD95 with NMDAR subunits and the tyrosine kinase Fyn. 
Overexpression of a human N-terminal truncation of tau (tau74, light grey) or knocking out tau (Tau
–/–
, 
dark grey) reduced the amount of NR1, NR2a, NR2b, and Fyn within PSD95 complexes. From Ittner, 
et.al. 2010
71






Knockdown of tau by siRNA decreased the length of neurites
57,75
 but not the number of microtubules
57,58
, 
and overexpression of tau promoted neurite extension in cell culture
76
. These effects may relate to tau’s 
ability to thwart microtubule-severing proteins
57
, but could also involve facilitation of nerve growth factor 
(NGF) signaling.  
In PC12 cells, overexpression of full-length tau was associated with normal neurite extension and an 
increased number of neurites per cell, whereas overexpression of the N-terminus of tau suppressed NGF-
induced neurite extension
76
. Thus, increased levels of tau may enhance NGF function, whereas the N-
terminus of tau may impair NGF signaling, possibly by a dominant-negative mechanism. Enhancement of 
NGF signaling by tau may involve increased association of tau with actin filaments, which occurs after 
stimulation with NGF and is mainly mediated by the MBRD
70
 rather than the N-terminus. In PC12 cells, 
tau facilitates signaling through receptors for NGF and epidermal growth factor (EGF), thereby increasing 
activity in the mitogen-activated protein kinase (MAPK) pathway
77
. Stimulation of PC12 cells with NGF or 
EGF causes tau phosphorylation at T231, a modification necessary for the growth factor-induced activation 
of the Ras-MAPK pathway
77
, nicely illustrating the functional significance of a single tau phosphorylation 
site. As tau is not known to directly interact with growth factor receptors, it may facilitate signaling by 
binding to adapter proteins such as Grb2
39
. The enhancement of growth factor signaling by increased tau 
expression may explain why several forms of chemotherapy-naive cancer cells overexpress tau
78,79
.  
Tau may contribute to neuronal migration during a critical period in embryogenesis. While mice with 
genetic tau ablation show normal brain anatomy, tau reduction at embryonic day 14 by shRNA 
electroporation impaired the migration of cortical neurons by embryonic day 18
80
. The neurons lacking tau 
had shorter neurites, and abnormal mitochondrial and cellular morphology
80
. It is unclear whether these 
neurons would have recovered over a longer time period, however, tau appears to play a specific, unknown 
role in the health and normal migration of cortical neurons during embryogenesis which may be 





Other roles of tau in signaling pathways 
Recent evidence suggests that tau plays a role in synaptic plasticity. Long-term potentiation (LTP) of 
synapses in the hippocampal CA1 region of acute slices caused translocation of tau into the post-synaptic 
density (PSD), possibly driven by post-synaptic actin polymerization
81
. In primary neuronal cultures, 
treatment with brain-derived neurotrophic factor (BDNF), a neurotrophin associated with LTP, increases 
tau protein levels and increases neuronal spine density in a tau-dependent manner
82
. However, the 
physiologic significance of the function is unclear; generally there is no effect of tau ablation on LTP in 
acute slices
83,84
 or in vivo
85
. Only one study has found tau ablation with enhanced green fluorescent protein 
(EGFP) knock-in to be associated with impaired LTP
51
. Endogenous tau may be required for long-term 
depression (LTD) of synaptic activity in vitro and in 7-11 month old mice in vivo
85
, though this finding has 
not been confirmed by studies of LTD in slices from older mice
51
. 
Tau binds phospholipase C (PLC) γ in human neuroblastoma (SH-SY5Y) cells
56
. Under cell-free 
conditions and in the presence of unsaturated fatty acids, tau activates PLCγ independently of the tyrosine 
phosphorylation usually required to activate this enzyme
55
. At high tau concentrations, this activation does 
not require fatty acids
55
 and may involve binding of tau to both the enzyme and the substrates 
phosphatidylinositol
53
 or phosphatidylinositol 4,5-bisphosphate
54
, which could facilitate the cleavage 
reaction. Activation of PLCγ by tau was particularly facilitated by arachidonic acid
55
. Arachidonic acid is 
released from phospholipids by cytosolic phospholipase A2, whose activity in the brain is increased in AD 
patients and related mouse models
86
. Thus, increased levels of tau and arachidonic acid may jointly 
increase signaling through the PLCγ pathway in AD.  
Tau can also act as a direct enzyme inhibitor. For example, it can bind to and inhibit histone 
deacetylase-6
87
, which deacetylates tubulin and may regulate microtubule stability
87
. Thus, tau may affect 
microtubule stability by a mechanism independent of tubulin binding, although reports regarding the levels 







Tau also appears to participate in the cellular response to heat shock. During heat shock of neurons, tau 
bound DNA and facilitated DNA repair, and tau knockout neurons showed increased DNA damage
89
. 
However, when cultured neurons were allowed to recover from heat shock, tau knockout actually protected 
against heat shock-induced cell damage, as determined by measurements of neurite length and lactate 
dehydrogenase release
90
. Compared with wildtype neurons, tau knockout neurons showed a delayed and 
prolonged activation of Akt and less GSK3β activity during recovery from heat shock
90
, suggesting that the 
protective effect of tau knockout may be upstream of Akt/GSK3β phosphorylation. In sensory neurons of 
C. elegans, overexpression of 4R0N tau decreased the response to touch, and this phenotype was 
exacerbated by heat shock when tested after a recovery period of 24 hours
91
. These results suggest that tau 
has a role in the cellular response to heat shock, both during the insult and in the subsequent recovery 
phase. 
The association of tau with DNA during cellular challenge may alter chromatin structure, possibly 
accounting for the effects of tau on DNA damage and heat shock recovery
89
. Tau can translocate into the 
nucleus in cellular stress conditions
89
. In transgenic Drosophila, mutant and wildtype tau overexpression 
was associated with loss of histone H3 dimethylation of lysine 9, which implies heterochromatin relaxation, 
and increased transcription of silenced genes
92
. The effect of tau on DNA structure under challenge 
conditions may partly account for the prevention of DNA damage in the J20 human amyloid precursor 
protein (J20-hAPP) mouse model of AD on a tau knockout background
93
. 
Adult Neurogenesis  
Tau affects adult neurogenesis. Three-repeat tau is expressed and highly phosphorylated in adult-born 
granule cells in the dentate gyrus
94,95
. In one strain of tau knockout mice, adult neurogenesis was found to 
be severely reduced
95
. However, tau does not appear to be needed for embryonic neurogenesis, as tau 





topic of intense study and debate
96
. Notably, adult tau knockout mice showed no deficits in a variety of 
learning and memory paradigms
71,83,97,98
. 
Mechanisms by which tau contributes to disease 
As mentioned above, tau probably fulfills multiple functions and may contribute to neuropathogenesis 
in multiple ways. In principle, this might include both gain- and loss-of-function effects, although the latter 
mechanism has recently been called into question by several lines of experimental evidence. Furthermore, 




Loss of function 
A prominent theory about tau pathology was that disease phenotypes were caused by loss of tau 
function due to hyperphosphorylation and sequestration of soluble tau
100
. In many tauopathies, tau is 




, and possibly other binding 
partners. Although it is conceivable that this process results in loss of specific tau functions, increased 





. Although phosphorylated tau from AD brains may seed the aggregation of control 
human tau
105
, we are unaware of any evidence that tau aggregation actually lowers levels of soluble tau in 
vivo.  
Recent experimental studies have shown more directly that loss of tau function is an unlikely cause of 
neurodegeneration and neuronal dysfunction. In our opinion, longevity and behavioral functions are among 
the most compelling outcome measures for the evaluation of biologically meaningful functions affecting 
the central nervous system. Complete ablation of tau in knockout mice does not cause premature mortality 
or major neurological deficits
66 ,73,74,83,98,106
. Four independent tau knockout lines have been established and 






reported to have motor deficits, hyperactivity in the open field test, and learning impairments in contextual 
fear conditioning at 10–11 weeks of age
106
. Using fear conditioning to assess learning and memory in 
hyperactive mice is problematic because the hyperactivity confounds the interpretation of diminished 
freezing
110
. Because tau ablation has so little impact on neural functions, two of the tau knockout lines were 




. Contexual fear 
Table 1.2. Behavioral tests in Tau knockout mice 
Behavioral Test Knockout 
Line
1 
Age (months) Result 
Anxiety    
Elevated Plus Maze 2 4–7 and 12–16  Normal anxiety and exploration
98
 





   
Balance Beam 1 10–11 weeks Impaired motor function
106
 
Open Field 1 10–11 weeks Hyperactive
106
 
 2 6, 12 and 24  Decreased movement velocity at 12+ months
107
 
 3 6  Normal activity
51
 
Pole Test 2 6, 12 and 24  Impaired motor function at 12+ months
107
 
Rotor Rod 2 10–12 Normal motor function
97
 
 2 6, 12 and 24  Impaired motor function at 12+ months
107
  
 3 6 Normal motor function
51
 
Wire Hang 1 10–11 weeks Impaired motor function
106
 





   
Contextual Fear 
Conditioning 
1 10–11 weeks Impaired learning/memory
106
 
 3 6  Impaired memory
51
 
Morris Water Maze 2 4-7  Normal learning/memory
98
 
 2 10–12  Normal learning/memory
97
 
 3 6  Enhanced learning in acquisition week 2
51
  





3 4.5–7.5  Normal learning/memory
83
 
Radial Arm Water 
Maze 
2 10–12  Normal learning/memory
97
 
T Maze 3 8  Normal learning/memory
71
 
None 4 – – 
1














conditioning deficits have been reported in the EGFP-tau knockout line at 6 months of age, however the 
same cohort showed improvement in the Morris water maze
51
, another test of hippocampal-dependent 
memory.  Although axonal abnormalities have been reported in the cingulate cortex and genu of the corpus 
callosum of 10- and 12-month-old tau knockout mice from line 2, these mice showed no behavioral deficits 
in the Rota rod test, Morris water maze, or radial arm water maze
97
. By contrast, a second study of 12 
month-old tau knockout mice from the same line showed extensive motor and memory impairments related 
to iron accumulation and loss of dopaminergic neurons in the substantia nigra
107
. To our knowledge, no 




Based on electrophysiological recordings in acute hippocampal slices, tau knockout mice and wildtype 
controls have similar NMDA/AMPA receptor currents, synaptic transmission strength, and short-term as 
well as long-term synaptic plasticity
83,84
.  
Surprisingly, tau knockout mice are more resistant to seizures elicited by disinhibition, excitotoxins, or 
amyloid- (A) peptides than wildtype mice (Figure 1.3A)
71,83,98
. Compared with wildtype controls, 
neurons in hippocampal slices from tau knockout mice are more resistant to disinhibition-induced bursting 
activity (Figure 1.3B), which may be due, at least in part, to an increased frequency of spontaneous 
inhibitory postsynaptic currents in tau knockout mice
83
. Mimicking the effects of genetic tau reduction, 
reducing tau in adult mice with anti-sense oligonucleotides (ASO) also reduced susceptibility to PTZ-
induced seizures
111
. These findings suggest that tau has a complex role in regulating neural network activity 
and that tau reduction could prevent aberrant neuronal excitability, synchrony, or both. 
The resistance of tau knockout mice to seizures may also relate to alterations in brain oscillatory 
patterns. Tau knockout mice have decreased peak frequency of theta waves in the hippocampus and 
decreased coherence of gamma waves in the frontal cortex
112
. The potential effects of these alterations on 






Figure 1.3. Tau reduction suppresses drug-induced seizures in mice and neuronal bursting activity in acute 
hippocampal slices.  A) Partial or complete reduction of tau in mice without hAPP expression delayed the 
onset and reduced the severity of seizures induced by pentylenetetrazole, a GABAA receptor antagonist 
98
. 
Reprinted from Roberson, et.al. 2007
98
 with permission from AAAS. B) Tau knockout reduced aberrant 
neuronal discharges in acute hippocampal slices after disinhibition with the GABAA receptor antagonist 
bicuculline, as illustrated by measurements of the coastline burst index 
83
. Reprinted from Roberson, et.al. 
2011
83
 with permission from the Society for Neuroscience. NTG, no hAPP expression; hAPPJ20, hAPP 
mice from line J20. 
 
Figure 1.4. Tau reduction does not change amyloid pathology but prevents Aβ-dependent and functional 
neuronal deficits. Tau reduction did not affect (A) Aβ deposition or (B) the number of plaques with 
dystrophic neurites (DN) in hAPP-J20 mice. However, even partial tau reduction prevented (C) memory 
deficits in the Morris water maze (72 hour probe trial) in hAPP-J20 mice 
98
 and (D) Aβ oligomer-induced 
axonal transport deficits in primary hippocampal neurons, although it had no effect on axonal transport at 
baseline 
65
. Reprinted A-C from Roberson, et.al. 2007
98
 and D from Vossel, et.al. 2010
65







In conventional tau knockout mice, other microtubule associated proteins might compensate for tau 
loss, particularly MAP1A and MAP1B. However, no changes in MAP1A, MAP1B or MAP2 protein levels 
were detected in 12-month-old adult tau knockout mice
73
. Acute tau reduction by intraventricular ASO 
infusion in adult mice was effective and well tolerated
111
. Notably, tau ASO treated mice performed at 
normal levels in a battery of sensory and motor tasks, had normal anxiety behaviors in the elevated plus 
maze and normal learning and memory in the Morris water maze
111
. The findings summarized above 
suggest that partial reduction of tau may be well tolerated and could effectively protect the brain against 
A, epileptogenesis and excitotoxicity.  
Tau functions enabling pathogenesis 
 In transgenic mice, wildtype levels of tau are required for A and apoE4 to cause neuronal, synaptic 
and behavioral deficits
58,65,71,83,88,93,98,99
. However, whether A and apoE4 contribute to AD-related 
cognitive decline through the same or distinct tau-dependent mechanism(s) remains to be determined. 
Acute exposure of neuronal cultures to A led to hyperphosphorylation
113
 and mislocalization of tau into 
dendritic spines
114
, which, at least in some dendrites, was associated with spine collapse and dendritic 
degeneration. Tau knockout neurons are resistant to spine loss and cytoskeletal alterations following Aβ 
treatment
115
.  As tau phosphorylation releases tau from many of its binding partners, it is tempting to 
speculate that tau is initially hyperphosphorylated in AD to reduce its function, in an effort to counteract 
A-induced neuronal dysfunction. With time, though, this compensatory mechanism fails because 
hyperphosphorylated tau becomes detrimental at concentrations sufficient to form toxic tau 
aggregates
58,65,71,83,88,98,99
.   
 In some mouse models of AD, tau reduction may also reduce APP cleavage. In mice expressing hAPP 
and presenilin 1 (PS1), tau ablation improved motor and working memory impairments, prevented spine 
loss and reduced neurodegeneration
116
. In addition to the inhibitory effects of tau ablation on Aβ-induced 





preventing the induction of beta-secretase 1 (BACE1) in hAPP/PS1 mice
116
. The mechanism by which tau 
ablation prevents BACE1 induction is unknown and is likely related to the mutant PS1 transgene as Aβ 
production and deposition are unaffected by tau ablation in transgenic models expressing hAPP alone
98
. 
 While tau is abnormally phosphorylated in apoE4 transgenic mice
117
, we have so far found no evidence 
of abnormal phosphorylation or aggregation of tau in hAPP-J20 mice, whose robust A-dependent 
neuronal and behavioral deficits were prevented by reduction of wildtype murine tau (Table 1.3 and Figure 
1.4)
83,98
. While we continue to search for a direct pathogenic tau mediator and a pathogenic mislocalization 
of tau in hAPP-J20 mice, the above findings raise the possibility that physiological functions of tau, rather 
Table 1.3. Electrophysiological abnormalities of hAPP-J20 mice prevented by tau knockout
83
. Similar 


















Action Potential-driven IPSC 
Frequency 
Normal  Normal 
Coastline Burst Index    
EEG epileptiform activity 
(cortex) 
Normal  Normal 
eEPSC Amplitude Normal  Normal 
eIPSC Amplitude Normal  Normal 
Long-term Potentiation  Normal  Normal 
mEPSC Frequency Normal  Normal 
mIPSC Frequency Normal  Normal 
NMDAR/AMPAR Ratio Normal  Normal 
Paired Pulse Ratio Normal  Normal 
sIPSC Frequency    
Synaptic Strength (CA1) Normal  Normal 
EPSC, excitatory post-synaptic current; IPSC, inhibitory post-synaptic current; e, evoked; m, miniature;  
s, spontaneous 
1
Recorded at perforant path to granule cell synapse in dentate gyrus unless indicated otherwise. All 










than an abnormal tau gain of function, permit A and other AD-related factors to elicit aberrant neuronal 
excitation
71,83,98
, abnormalities in axonal transport
65
, and impairment of inhibitory interneurons
99
 (Figure 
1.5). Phosphorylation of tau at S262, in the MBRD, mediates at least part of Aβ-induced spine loss in 
primary culture and in hAPP-J20 mice
118
, possibly by recruiting microtubule severing proteins into 
dendritic spines
115
, however, this phosphorylation was not altered in the hippocampus of hAPP-J20 mice
98
.  
Notably, even partial tau reduction improved longevity and cognitive functions in hAPP-J20 mice (Figure 
1.4)
98
. Tau knockout also improved longevity and cognitive functions in APP23 mice and in both lines 
markedly increased resistance to seizures in mice with or without hAPP
71,83,98
. For unclear reasons, tau 
reduction was not beneficial in the Tg2576 hAPP mouse model
97
.  
The tyrosine kinase Fyn appears to be important in the development of A- and tau-dependent 
neuronal deficits. Aβ oligomer treatment of primary neurons increases bromodeoxyuridine (BrdU) 
incorporation into DNA
119
, which could represent either DNA synthesis or repair. This DNA alteration 
depends on the activation of Fyn, PKA and CaMKII and their convergent phosphorylation of tau
119
. 
Neuronal overexpression of Fyn sensitizes hAPP mice to A-induced neuronal, synaptic, and cognitive 
deficits
120,121
 which are prevented by knocking out tau in hAPP-J9/FYN doubly transgenic lines
83
. Tau 
knockout prevented behavioral deficits in the Morris water maze and elevated plus maze of hAPP/FYN 
mice and premature mortality in two separate lines of hAPP/FYN mice
83
. In addition, tau knockout 
prevented spontaneous epileptic activity in hAPP/FYN mice and hAPP-J20 mice (Table 1.3)
83
. This 
striking antiepileptic effect could result from the reduction of tau in axons, dendrites, or both. Although tau 
knockout did not affect axonal transport at baseline
65,66
, it precluded A-induced deficits in the axonal 
transport of cargoes that could affect neuronal excitability (Figure 1.4D)
65
. Tau is also required for Fyn to 
gain access to and phosphorylate the NR2B subunit of dendritic NMDA receptors
71
. Consistent with our 
hypothesis that tau reduction protects against A by preventing neuronal overexcitation
98
, targeted 
perturbation of the NR/PSD-95 interaction, which prevents excitotoxicity, also prevented premature 
mortality and memory deficits in APP23 mice
71
. These findings suggest that modulating tau, its interaction 






Figure 1.5. Potential mechanisms of tau-dependent Aβ toxicity. Experiments in which neurons were 
acutely exposed to A suggest that A can trigger tau-mediated neurotoxicity by enhancing tau 
phosphorylation, which in turn directs pathogenic tau species into dendritic spines where they exert 
adverse effects (left). In hAPP mice, though, in which neurons are chronically exposed to elevated A 
levels, it has so far been impossible to find clear evidence for a similar process. Nonetheless, A-induced 
neuronal dysfunction in these models strictly depends on the presence of tau, raising the possibility that 
physiological functions of tau permit A to cause neuronal dysfunction (right). Such functions may 






The interaction between Fyn and tau may also contribute to FTLD. Several forms of FTLD-mutant tau 
and pseudohyperphosphorylated tau bind Fyn more tightly than wildtype tau
102
, which may increase 
neuronal Fyn activity. Furthermore, Fyn binds more tightly to 3R0N tau than 4R0N tau
102
, implying that 
FTLD mutations that alter tau splicing could also alter the activity or localization of Fyn. In mice 
overexpressing P301L 4R0N tau under the mouse prion promoter (JNPL3 model), phosphorylation of tau at 
Y18 by Fyn increases simultaneously with tau hyperphosphorylation on serine/threonine sites before the 
onset of behavioral deficits
122
. 
The physiological actin-bundling function of tau may also contribute to pathology. Filamentous actin 
inclusions, closely resembling Hirano bodies in AD, were found in Drosophila models overexpressing 
wildtype or R406W 4R0N tau and in mice overexpressing P301L 4R0N tau under the TRE promoter with 
the Tet-off element under the CaMKII promoter (rTg4510 model)
52
. Knocking out or destabilizing actin 
filaments in the Drosophila models prevented tau-induced degeneration
52
, implicating alterations in actin 
dynamics as a mediator of tau toxicity. 
Abnormal gain of function 
The largest amount of work in this field has focused on tau phosphorylation and aggregation. Tau is 
highly phosphorylated in fetal brain without eliciting toxicity and is also phosphorylated on many sites in 
adult brain, albeit with lower frequency
104,123
. Tau is transiently hyperphosphorylated during hibernation 
without long-term harm to neural networks
103
. Tau phosphorylation is also markedly increased in response 
to various stressors. In humans, tau becomes hyperphosphorylated and aggregated after head trauma, 
following earlier increases in APP expression, axonal swelling and microtubule disruption
9,124
. Tau also 
becomes hyperphosphorylated in mouse brain in response to hypothermia and experimental insulin-
dependent diabetes
125
. In cell culture and brain slice models of neuronal injury, tau is hyperphosphorylated 
during recovery from heat shock
90




, hypoxia, and glucose 
deprivation
126





treatment all cause tau mislocalization into dendrites
114
, a process that is likely triggered by 
hyperphosphorylation-induced dissociation of tau from microtubules and cell membranes. Thus, increased 
phosphorylation and redistribution of tau may be common responses to neuronal stress.  
Findings in Drosophila models suggest that tau phosphorylation may cause neurotoxicity in a 
combinatorial fashion rather than through the modification of individual phosphorylation sites and involves 
the folding of tau into an abnormal conformation resembling tau conformations found in AD
127
. 
Hyperphosphorylated tau has a tighter, more folded conformation and an increased propensity to 
aggregate
128
, as does tau with mutations found in FTLD
8
. In C. elegans, overexpression of wildtype or 
mutant 4R1N tau causes axonal degeneration and an uncoordinated phenotype indicative of neuronal 
dysfunction
129
. The extent of phosphorylation was similar across mutant and wildtype tau lines, but more 
insoluble tau was found in the former
129




Although filamentous tau inclusions are a pathologic hallmark of tauopathies, experimental evidence 
suggests that filamentous tau may not be responsible for neuronal dysfunction. In a regulatable P301L 
4R0N tau transgenic mouse (rTg4510 model), inhibiting tau production after filamentous tau inclusions had 
formed reversed behavioral deficits in the Morris water maze, even though inclusion formation 
progressed
130
. Acute tau reduction by methylene blue treatment in this model improved memory scores in 
correlation with the reduction of soluble tau in the brain but did not alter the number or length of tau fibrils 
or the amount of Sarkosyl-insoluble tau compared to untreated transgenic mice
131
. In other mouse lines, 
Tet-off transgenes were regulated by the CaMKII promoter to express either the 4R microtubule repeat 
domain of human tau with a deletion of lysine 280 (termed TauRD), which is highly prone to aggregation, 
or the TauRD construct with an additional two mutations (I277P/I308P) that prevent TauRD aggregation
132
. 
The pro-aggregation transgenic mouse, which formed hyperphosphorylated tau inclusions containing 
TauRD and endogenous mouse tau, developed synaptic loss
132
, memory deficits and electrophysiological 
deficits
133





off the transgene in the pro-aggregation mouse reversed behavioral and electrophysiological deficits 
without eliminating insoluble tau aggregates, which were composed entirely of endogenous mouse tau after 
the transgene had been turned off for 4 months
133
. These data highlight that tau aggregation causes toxicity, 
possibly through the formation of tau oligomers.  
This conclusion is also supported by studies using in vivo two-photon microscopy demonstrating that 
very few neurons containing tau inclusions in regulatable rTg4510 transgenic mice have caspase activation 
or membrane disruption
134,135
. Decreasing the levels of soluble tau reduced caspase activation in inclusion-
positive neurons without affecting the number or size of tau inclusions
135
, implicating soluble tau, not tau 
inclusions, in the activation of pro-apoptotic pathways. Neurons with or without tau inclusions in this 
regulatable P301L tau model showed similar electrophysiological deficits, relative to wildtype neurons
136
. 
Studies in young transgenic flies overexpressing wildtype or mutant 4R0N tau constructs also indicated that 
toxicity was conferred by soluble tau species, possibly dimers
137
. 
Collectively, these studies suggest that tau inclusions are not very toxic and that neuronal toxicity is 
caused by a smaller, soluble aggregate of a specific conformation of tau. Tau oligomers have been 
identified in in vitro and in vivo models as well as in AD brains
138-140
. In regulatable P301L 4R0N 




Tau can also be cleaved in various places by caspase-3, calpain, and cathepsin L, and several of the 
resulting fragments are thought to increase tau aggregation. In primary neurons exposed to A, calpain 
generates a 17-kDa tau fragment. However, the toxicity and in vivo relevance of this fragment are debated; 
its presence is variable in both control and AD brains
141,142
 and it appears to be absent from brains of hAPP-
J20 mice
98
. A treatment of cortical neurons causes caspase cleavage of tau at N421, and cleavage at this 
site facilitates the formation of tau aggregates in cell-free conditions
143
. Caspase activation precedes 





possibility that caspase cleavage is important for aggregation of FTLD-mutant tau in vivo
135
. In an 
inducible cell culture model overexpressing the microtubule repeat domain of tau missing K280, cytosolic 
cleavage by unknown proteases generated putative tau oligomers associated with lysosomal membranes 




Tau may also exert toxic effects from the extracellular milieu
145
. The death of degenerating neurons or 
extrusion of tau from living cells containing tau aggregates
146
 may result in the release of pathogenic tau 
species into the extracellular space, where they may adversely affect neighboring cells. For example, a 
peptide in the C-terminus of tau (amino acids 391–407) increased intracellular calcium concentrations by 
activating the muscarinic receptors M1 and M3
147
. Tau aggregates released from cells were taken up by and 
triggered tau aggregation within co-cultured cells that had no pre-existing tau aggregates
146
.  
Injection of insoluble P301S human 4R0N tau from transgenic mouse brainstem extracts into the 
hippocampus of transgenic mice expressing wildtype 4R2N human tau under the mouse Thy1.2 promoter 
caused intraneuronal formation of wildtype 4R2N human tau inclusions in the hippocampus that spread 
along synaptic connections to distant brain regions
148
. However, we are unaware of any evidence that this 
transfer of tau aggregation causes neuronal dysfunction or neurodegeneration. Injecting soluble P301S tau 
into the transgenic mice or insoluble P301S tau into nontransgenic mice failed to cause extensive 
pathology.  
Thus, artificial introduction of insoluble tau into the brain parenchyma triggers propagation of tau 
pathology along neuronal pathways, but only in the presence of the correct tau template. It is unknown 
whether the potential progression of AD from one brain region to another
149
 depends on similar processes, 
the presynaptic release of A
150
, or other mechanisms. Tau is physiologically released from neurons in 
response to neuronal activity in cultured neuron and in vivo
151,152
, so it is possible that the aberrant network 





Do FTLD mutations simulate tau pathology in AD? 
Interestingly, mutations in the tau gene cause FTLD disorders such as progressive supranuclear palsy, 
corticobasal degeneration, and frontotemporal dementia, but never AD. A rare tau variant, with a single 
base pair mutation in the tau coding sequence converting A152 to T, confers an increased risk for both FTD 
and AD but does not appear to be a causal mutation
153,154
. While the clinical spectrum associated with the 
many rare tau mutations varies, most FTLD disorders differ from AD both in the types of tau inclusions 
and in the brain regions affected
155
, indicating a possible divergence in the roles of tau in these conditions. 
The trigger for increased phosphorylation and aggregation of tau is also likely different in AD and FTLD.  
Two recent studies set out to compare the consequences of overexpressing wildtype human 4R2N tau 
versus P301L-mutant human 4R2N tau in transgenic mice. Each group generated two mouse lines with 
approximately matched tau expression levels and patterns directed by the Thy1 promoter
156
 or the CaMKII 
promoter
157
. In both studies, P301L tau mice differed from wildtype tau mice in tau phosphorylation 
patterns and in that P301L tau aggregated more readily than wildtype tau, consistent with previous 
findings
46
. Remarkably, in both studies, behavior was impaired earlier in wildtype tau transgenic mice than 
in P301L tau transgenic mice, even though tau was similarly expressed under the same promoter and only 
P301L mutant tau transgenic mice had tau aggregates. Thy1-wildtype-tau mice had early motor 
impairments and axonopathy, whereas Thy1-P301L-tau mice had late motor impairments, insoluble tau 
inclusions and no axonopathy
156
. CaMKII-wildtype-tau mice had earlier memory deficits in the Morris 
water maze and synaptic loss than CaMKII-P301L tau mice, but tau inclusions and neuronal loss were 
observed only in CaMKII-P301L tau mice
157
. These findings suggest that P301L tau causes neuronal loss 
through its propensity to aggregate and, possibly, to form toxic oligomeric tau species, whereas wildtype 
human tau may cause early neuronal and cognitive dysfunction without neuronal cell death, possibly by 





Another recent study compared transgenic mice expressing P301L human 4R0N tau (rTg4510 model) 
or wildtype human 4R0N tau directed by the TRE promoter and tTA (Tet-off) directed by the CaMKII 
promoter. Both lines showed deficits in the Morris water maze; however, the deficits worsened with aging 
in the P301L tau line but not in the wildtype tau line
158
. As in the lines described above, neurodegeneration 
was identified only in the P301L tau line but not in the wildtype tau line. In primary cultures, neurons 
expressing P301L tau showed tau in dendritic spines more frequently and had greater reductions of 
miniature excitatory postsynaptic potentials (mEPSCs) and dendritic GluR1, GluR2/3 and NR1 levels than 
neurons expressing wildtype tau
158
. Tau phosphorylation was required for tau to enter into dendritic spines 
and to impair mEPSCs in transfected primary rat neurons
158
. Consistent with these synaptic alterations, a 
line of mice expressing tau with G272V and P301L mutations had impaired NMDA receptor function and 
phosphorylation, and NR2B mislocalized into Sarkosyl-insoluble tau aggregates
159
. 
In slice cultures, wildtype human 3R0N tau and R406W human 4R2N tau each enhanced A-induced 
neuronal cell death in the hippocampal CA3 region, whereas P301L human 4R2N tau did not
160
. A 3R0N 
tau mutant that prevents phosphorylation and a 3R0N tau mutant that mimics hyperphosphorylation showed 
no synergistic neurotoxic effect with A, implying that dynamic tau phosphorylation may be required for 
the enhancement of A toxicity by tau
160
. These results are consistent with findings indicating that tau 
requires phosphorylation to enter the dendritic spine in order to affect synaptic function
158
 and that A 
oligomers acutely increase phosphorylation and mislocalization of wildtype tau into dendritic spines
114
.  
It may be that P301L tau is already phosphorylated and present in dendritic spines, and therefore no 
further toxicity is seen in the presence of A oligomers. Interestingly, the adverse effects of wildtype tau 
were dependent on the activity of both NMDAR and GSK3β, whereas the effects of R406W tau were 
dependent only on NMDAR activity, suggesting partly distinct mechanisms of toxicity
160
. These results 
imply that AD-relevant pathogenic mechanisms and therapeutic interventions might be missed in FTLD-





Treatments targeting tau 
Treatments targeting various aspects of tau biology are under intense investigation. Inhibitors of tau 
phosphorylation and aggregation and microtubule stabilizers are already in clinical trials for people with 
MCI, AD, or FTLD (for more information see http://www.alzforum.org/therapeutics), while tau reduction 
strategies are still in preclinical stages of development. Tau imaging compounds are currently undergoing 
testing in tau transgenic mice and in humans
161
, which should greatly facilitate the assessment of target 
engagement by tau therapies in clinical trials. As we learn more about how tau expression is regulated and 
about tau’s involvement in cell signaling and cytoskeletal organization, additional approaches are likely to 
emerge. 
Tau phosphorylation inhibitors 
The function and aggregation of tau appear to be regulated by phosphorylation, as reviewed above. Of 
the numerous tau kinases implicated in AD pathogenesis, the most widely studied are GSK-3β, CDK5, 
MARK, and MAPK
38,162
. Lithium, which inhibits GSK-3β and is used to treat bipolar disorder, improved 
behavior and reduced tau pathology in transgenic mice overexpressing P301L human 4R0N tau (JNPL3 
model)
163
. However, because lithium has multiple targets, the rescue observed may not have been solely 
due to a reduction in GSK3β activity. Lithium also has a narrow safety margin
164
, and reduction of GSK-3β 
impairs NMDAR-mediated long-term depression
165
 and memory consolidation
166
, raising concerns about 
potential side effects of GSK-3β inhibitors. In a similar vein, CDK5 inhibitors prevent A-induced 
hyperphosphorylation of tau and cell death in culture
167,168
, but CDK5 is essential for multiple cell signaling 
pathways and adult neurogenesis, limiting its appeal as a tau-targeting therapy for AD. However, CDK5 
and p25, a truncated form of the CDK5 subunit p35, can promote neurodegeneration through mechanisms 
that are independent of tau phosphorylation, involving inhibition of histone deacetylase 1 (HDAC1) and 
aberrant expression cell cycle genes
169
, raising possibilities for additional therapeutic intervention. 









 and lipid 
micelles
174
. Many of the drugs that block the aggregation of tau also block the pathological aggregation of 
other proteins under cell-free conditions, including A and α-synuclein
175
, suggesting that they might be of 
benefit in diverse proteinopathies. Some tau aggregation inhibitors are effective in Neuro2A cell lines 
overexpressing a 4R tau microtubule repeat domain fragment with a K280 deletion, which promotes its 
aggregation
176
. In human AD patients, the phenothiazine methylene blue showed some promise for slowing 
disease progression in a phase II clinical trial conducted for 1 year
177
. Methylene blue was originally 
thought to inhibit tau–tau interactions
178
, but it may also reduce soluble tau through other mechanisms
131
 as 
it is known to have many targets
179




The immunosuppressant FK506 reduces microgliosis and tau aggregation in transgenic mice 
overexpressing P301S human 4R1N tau under the mouse prion promoter (PS19 model)
181
. Since FK506 
affects diverse signaling pathways in many cell types, it may act directly on neurons or influence the 
neuronal environment by modulating microglial activation. Inhibition of tau aggregation may also be 
mediated by direct binding of tau to the FK506 binding protein 52
182
 or by inhibiting FK506 binding 
protein 51 (FKBP51), which promotes the formation of tau oligomers in conjunction with heat-shock 
protein 90
183
. Notably, tau levels are reduced in FKBP51 knockout mice
183
, so targeting FKBP51 may also 
contribute to the reduction of total tau. 
As discussed above, it is far from certain that filamentous tau is actually toxic. Indeed, it is not known 
which tau assembly or conformation is responsible for tau-dependent neuronal dysfunction and 
degeneration. Not surprisingly, it is equally uncertain whether the abundance of this entity is lowered by 
any of the available tau aggregation blockers. In fact, some tau aggregation inhibitors enhance the 
formation of potentially toxic tau oligomers
184
. This scenario is reminiscent of the current state of anti-A 





currently in clinical trials significantly reduce the abundance of A oligomers in human brain tissues, 
which are suspected to be the main mediators of A-induced neuronal dysfunction
185-188
. 
Reduction of overall tau levels 
In mice, genetic reduction of tau is well tolerated, increases resistance to chemically induced seizures, 
and markedly diminishes A- and ApoE-induced neuronal and cognitive impairments in vivo
71,83,98
. Similar 
tau reduction was achieved through intraventricular infusion of ASOs in adult mice, which provided 
resistance against PTZ-induced seizures without impairing memory in the Morris water maze
111
. 
Alternatively, tau levels could be reduced indirectly by targeting molecules that regulate the expression or 
clearance of tau.  
Tau is thought to be degraded via the ubiquitin-proteasome and lysosomal pathways. The ubiquitin 
ligase for tau was identified as the C-terminus of HSP70-interacting protein (CHIP)
189-191
. Reduction of 
CHIP levels increased the accumulation of tau aggregates in P301L human 4R0N tau mice (JNPL3 model), 
and CHIP levels are reduced in AD brains
192
. Furthermore, as its name suggests, CHIP works in 
combination with heat shock proteins to regulate tau degradation
193
; levels of heat shock protein 90 
(Hsp90) correlate inversely with the levels of soluble tau and tau oligomers
194
.  
In AD brains, tau is hyperacetylated, which should increase its half-life
23
 and decrease its microtubule 
binding 
24
. Because both acetylation and ubiquitination target lysine residues, acetylation of tau by the 
acetyltransferase p300 inhibits ubiquitination and stabilizes tau
23
, but can inhibit the aggregation of tau into 
filaments
195
. Acetylation by Creb binding protein (CBP) inhibits the binding of tau to microtubules and 
enhances tau aggregation, possibly due to acetylation of the 6 amino acid motif VQIINK (PHF6*)
24
. This 
motif is critical for the formation of tau oligomers and filaments
46,196
. While the effects of tau acetylation 
on aggregation may be site-specific, the combination of a tau acetylation inhibitor and a ubiquitination-





Larger aggregates of tau are not likely to be accessible to the proteasome but can be degraded by the 
lysosomal pathway, in which autophagosomes engulf the aggregates and fuse with lysosomes. In cells 
overexpressing the microtubule repeat domain of tau with a deletion of K280, aggregated tau is removed by 
the lysosomal pathway
144
. In slice culture, inhibition of the lysosomal pathway produces NFT-like tau 
deposition
197
. The lysosomal pathway of tau degradation is also involved in Niemann-Pick type C (NPC) 
disease, an autosomal recessive disorder associated with neurological symptoms and NFT formation in the 
brain
198
. NPC disease is caused by a loss of function of NPC1, a lysosomal trafficking protein
199
, 
suggesting that tau is degraded in lysosomes and that lysosomal dysfunction leads to tau accumulation. 
Consistent with this notion, phosphorylated tau is increased in the brains of NPC1-deficient mice and of 
NPC patients
200
. However, crossbreeding of NPC1-deficient mice with tau knockout mice worsened the 
phenotype
201
, suggesting that the role of tau in this disease is complex. The autophagic-lysosomal pathway 
has also been interrogated in a mouse model of tauopathy with parkinsonism overexpressing human 4R2N 
tau under the mouse Thy1 promoter with deletion of Parkin (PK−/−/TauVLW)
202
. Treatment of 3-month-
old PK−/−/TauVLW mice with trehalose, an mTOR-independent autophagy activator, for 2.5 months 
prevented dopaminergic neuron loss in the ventral midbrain, reduced phosphorylated tau and total tau in the 
striatum and limbic system, prevented brain astrogliosis and improved motor and cognitive behavior. 
Biochemical and electron microscopy data suggested that the protective effects of trehalose were mediated, 
at least in part, by autophagy activation
202
. 
Tau degradation can also be enhanced by specific activation of the immune system. Active 
immunization targeting phosphorylated tau reduced filamentous tau inclusions and neuronal dysfunction in 
transgenic mice overexpressing K257T/P301S human 4R0N tau under the rat tau promoter or P301L 
human 4R0N tau (JNPL3 model)
203,204
. The mechanism by which intracellular proteins, including tau and 
α-synuclein, are cleared by immunization is not known but may involve lysosomal degradation
205-207
. Once 
antibodies enter into brain, they could be taken up by receptor-mediated endocytosis and activate 
autophagy
207





used in combination with other biomarkers to diagnose AD
208
; phosphorylated tau and total tau ratios in the 
CSF can also predict disease severity
209,210
. Extracellular tau could come from the death of neurons or be 
released from live cells
211
. If there is an equilibrium between intracellular and extracellular tau, clearance of 
tau/antibody complexes from the extracellular space may ultimately lower intracellular tau levels
207,212
.  
Microtubule stabilizers  
Microtubule disruption has been observed in several models of AD and FTLD, including transgenic 
mice overexpressing wildtype human 0N3R tau under the mouse prion promoter (T44 model)
100
 or P301S 
human 4R1N tau (PS19 model)
181





 and tau hyperphosphorylation
214,215
 reduce the binding of tau to microtubules. 
Although tau overexpression seems to be associated with destabilization of microtubules, it is unclear 
whether this phenomenon is always pathogenic and whether it results from a loss- or gain-of-function of 
tau. Indeed, tau is necessary for A-induced microtubule disassembly in vitro
58
, suggesting that tau is 
actually required for microtubule destabilization. A loss-of-function mechanism seems also unlikely 
because tau knockout mice have a rather benign phenotype, and tau reduction protects neurons from A-
induced impairments ex vivo
58,65,84,88
 and in vivo
71,83,98
.  
Despite these caveats regarding underlying mechanism, microtubule stabilizers have shown promise in 
preclinical and clinical trials for AD. For example, paclitaxel prevented A-induced toxicity in vitro
114
 as 
well as axonal transport deficits and motor impairments in transgenic mice overexpressing wildtype human 
0N3R tau (T44 model)
100
. Epothilone D, which has better blood–brain barrier permeability, improved 
microtubule density and cognition in P301S human 4R1N tau mice (PS19 model)
216
. The peptide NAP 
stabilizes microtubules
217
 and reduces tau hyperphosphorylation
218
, suggesting that microtubule-stabilizing 
compounds can have more than one mechanism of action. While NAP showed some promise in a phase II 
clinical trial of amnestic mild cognitive impairment
219
, no efficacy was observed in a phase III clinical trial 
against the tauopathy PSP
220





Conclusions regarding tau 
While tau has long been implicated in neurodegenerative conditions, its functions in the adult brain and 
the precise mechanisms by which it contributes to neuronal dysfunction and degeneration in these disorders 
remain to be elucidated. A flurry of recent publications has challenged major dogmas in this field, 
including the notion that filamentous tau aggregates are the most pernicious forms of tau, that loss of tau 
function plays a major role in the pathogenesis of tauopathies, that tau enters dendritic spines only under 
pathological circumstances and that the adverse activities of tau aggregates are restricted to intracellular 
compartments. Provocative discoveries suggest that tau regulates neuronal excitability and that it is 
required for A and other excitotoxins to cause neuronal deficits, aberrant network activity and cognitive 
decline. Indeed, tau has ‘graduated’ from a putative microtubule stabilizer to a multifunctional protein with 
many interacting signaling networks and to a master regulator of the intracellular trafficking of organelles 
and molecules involved in synaptic functions at the pre- and postsynaptic level. The hunt has also been 
intensified for the most pathogenic forms of tau, some of which have been traced into dendritic spines, and 
more has been learned about the complex posttranslational modification of tau, particularly acetylation, 
which appears to regulate the ubiquitination, turnover and aggregation of tau. These and other findings are 
providing critical guidance in the development of better treatments for tauopathies aimed at tau itself, tau 
regulators or factors mediating its putative functions. Identifying the functions and precise roles of tau in 
neurodegenerative disorders will likely require the analysis of conditional knockout models and the clinical 
evaluation of pertinent drugs with well-defined modes of action. 
Part II: α-Synuclein, a pre-synaptic protein involved in disease 
Much like tau, α-synuclein (SYN) is an intrinsically disordered protein which becomes 
hyperphosphorylated, mislocalizes and aggregates in neurodegenerative disease. Neuronal aggregates of 
SYN, called Lewy bodies, are the primary pathologic feature of Parkinson’s disease (PD), Parkinson’s 
disease with dementia (PDD) and dementia with Lewy bodies (DLB), a closely related set of diseases 
differentiated by the relative onset of motor and cognitive symptoms and Lewy body distribution. Point 
mutations and increased SYN gene dosage cause familial Lewy body diseases
221-230









SYN is a small, 140 amino acid protein which primarily localizes to the neuronal pre-synapse under 
physiologic conditions. The structure of SYN can be divided into three regions: the N-terminal region, the 
hydrophobic NAC peptide and the C-terminal acidic region
233,234
. In solution, SYN is an intrinsically 
disordered protein; however, the combined N-terminal and NAC regions form an amphipathic helix when 
bound to anionic membranes, or two helices on highly curved anionic membranes
235-237
. There is some 
evidence that SYN forms a physiologic α-helical tetramer in vivo
238
, distinct from the β-sheet oligomers 
found in disease conditions, however this result is still highly controversial
239
.  
All 5 SYN mutations thought to cause PD are in the N-terminal region, but they appear to have varying 
effects on SYN structure
221,222,226-228,230,240
. The A30P SYN mutation disrupts α-helix formation, thereby 
reducing membrane binding
241
. The A53T SYN mutation allows for helix formation, but extends the β-
sheet-forming region of the NAC which can facilitate aggregation
241
. E46K, H50Q and G51D mutations all 
preserve α-helix formation, but E46K and H50Q both facilitate aggregation
242




SYN function and aggregation can be also modified by post-translational modifications. 
Phosphorylation of the C-terminal region changes its binding affinity for synaptic, cytoskeletal and 
mitochondrial proteins
243
. SYN aggregation may be inhibited by O-GlcNAcylation in the NAC region
244,245
 
and enhanced by C-terminal truncation
246
. While some C-terminal cleavage is present in normal brain, 
Lewy body pathology is associated with additional C-terminal cleavage products
247
 which may contribute 
to Lewy body aggregation. SYN in Lewy bodies also tends to be highly modified by phosphorylation and 
ubiquitination
247-249
, but the exact role of these modifications in pathology is unclear
250
. 
Evidence for multiple functions of SYN 
Much like tau, genetic ablation of SYN only produces subtle phenotypes. SYN knockout mice, 
generated from targeted gene knockout or spontaneous gene deletion, are viable and have normal fertility, 
brain anatomy and longevity
251,252





been widely used to study the effects of SYN knockout and to ablate endogenous SYN in transgenic 
models
252-254
. However, the exact range of this small deletion
252
 and any other genes affected by it are 
unknown, so studies using this model should be interpreted cautiously. 
Due to the subtle SYN knockout phenotype, researchers often study mice lacking other synuclein 
family members. β- and γ-synuclein share a high sequence similarity to SYN and have many of the same 
functions
255,256
, so researchers often use double- or triple-synuclein knockout (DKO or TKO, respectively) 
mice to investigate the physiologic roles of synuclein proteins. TKO mice have a more pronounced 
phenotype than SYN knockout mice, with motor impairments and mortality around 1 year of age
257
.  
SYN modulates synaptic vesicles 
Although the precise physiologic functions of SYN are still highly debated, most evidence points to a 
role in the regulation of synaptic vesicle dynamics. SYN was initially identified through its association with 
synaptic vesicles
233
, which may be mediated through an affinity for highly curved membranes
235,258
. 
However, much like other proteins which sense highly curved membranes, this affinity involves more than 
passive membrane binding. All three synuclein family members can induce membrane curvature at 
physiologically relevant concentrations, which is inhibited in the membrane-binding-defective A30P SYN 
mutant
256
. As endophilin A1, an endocytic membrane bending protein, is increased in TKO models and 
reduced by transgenic SYN expression in the TKO model, the authors suggest that SYN may have a role in 
endocytosis
256
. Exocytosis regulates the dispersion of both SYN and endophilin 1A from the synapse, 
suggesting that the two proteins share some regulatory mechanisms, and this regulation requires intact 
membrane binding
259,260
. However, most evidence indicates that SYN acts as a negative regulator of 
exocytosis
261
 without altering the rate of endocytosis or exocytosis
262
. While the molecular mechanisms of 
this exocytic regulation are still debated, it relies on membrane binding
262
 and may involve soluble NSF 
attachment protein receptor (SNARE) proteins.  
Analysis of a novel model of neurodegeneration led to evidence that SYN regulates SNARE assembly. 
Knockout of cysteine string protein α (CSPα), a SNARE chaperone and regulator of exocytosis
263
, causes 





ameliorates these phenotypes and an α/β-DKO mouse worsened them, suggesting SYN and CSPα have 
some functional redundancy
264
. On a molecular level, SYN overexpression rescued SNARE complex 
assembly in CSPα knockout mice without rescuing the loss of the SNARE protein SNAP-25
264
, leading to 
the discovery that SYN increases the formation of SNARE complexes
257
. This SNARE regulation requires 
C-terminal binding to synaptobrevin-2, a SNARE protein, and N-terminal membrane binding
257
. The 
physiologic significance of SNARE regulation by SYN remains unclear; one TKO model showed reduced 
SNARE complex assembly
257
, however, a second TKO model could not confirm this reduction
255
. 
SYN binding to membranes and SNARE proteins may negatively regulate exocytosis by altering 
vesicle clustering. Cell-free studies indicate that SYN clusters synaptobrevin vesicle-SNARE (v-SNARE) 
vesicles together through membrane and synaptobrevin binding
265
. In vivo this activity could alter vesicle 
density and the availability of synaptic vesicles for release. In the CA1 of SYN transgenic mice, vesicle 
density was shifted away from the pre-synaptic active zone and pre-synaptic release was decreased
262
. A 
second SYN transgenic mouse, with human SYN expression directed by a bacterial artificial chromosome 
on a mouse SYN knockout background (SYN BAC), showed increased vesicle clustering and decreased 
dopamine release at striatal synapses
266
. It is possible that vesicle clustering by SYN differentiates the 
resting or reserve pool of vesicles from the readily-releasable pool of synaptic vesicles (RRP). SYN 
transgenic mice have a smaller RRP without a change in synaptic vesicle number
262
, implying a larger 
number of vesicles in the reserve pool, while SYN knockout mice have a smaller reserve pool and fewer 
synaptic vesicles
267
. Notably, SYN monomers don’t alter vesicle fusion in cell-free conditions
265,268
, 
confirming that monomeric SYN does not interfere with the dynamics of SNARE function. 
Synuclein family proteins seem to play a specific role in the release of striatal dopamine. Though the 
magnitude of the effects on dopamine release vary depending on the strain background and knockout used, 
studies of SYN knockout and TKO mice have shown decreased levels of striatal dopamine and a blunted 
response to amphetamine, which enhances dopamine release
251,255
. This regulation was specific to striatal 
synapses because the dopamine content of the ventral tegmental area was unaffected in the TKO model
255
. 
Both the biochemical and behavioral phenotypes could result from enhanced basal release of dopamine in 
the striatum, which would deplete the synaptic stores of dopamine
251





of dopamine after a single stimulus
255
, while SYN knockout mice show enhanced synaptic release after a 
paired pulse stimulus
251
. The mechanism behind the specific modulation of striatal dopaminergic terminals 
by synuclein proteins remains controversial. While several studies point to the negative regulation of the 
RRP by SYN
251,253,262
, altered vesicle clustering could not be detected at striatal synapses in TKO mice
255
. 
However, the authors acknowledge that striatal synapses do not physically segregate the RRP and reserve 
pool of synaptic vesicles like hippocampal synapses
255
, so this subtle ultrastructural phenotype may be 
difficult to detect in a knockout model at striatal synapses. Altered vesicle clustering has been observed at 
striatal dopaminergic synapses in the SYN BAC model
266
. 
Other functions of SYN 
Using unbiased screening methods, SYN was identified as an inhibitor of phospholipase D2 (PLD2)
269
. 
PLD2 is a constitutively active enzyme which cleaves phosphotidylcholine into phosphatidic acid and 
choline. In cell-free conditions, all three synuclein proteins inhibit PLD2
269,270
. Inhibition by SYN requires 
N-terminal α-helical structure, is prevented by C-terminal phosphorylation, and is enhanced by the A53T 
SYN mutation
270
. Toxicity from overexpression of PLD2 in the substantia nigra of rats is prevented by co-
overexpression of SYN
271
, however, endogenous PLD2 inhibition by SYN has not been investigated.  
Post-mortem inhibition of PLD2 may confound the reported decrease in cortical acetylcholine levels in 
a SYN transgenic mouse
272
. After decapitation, acetylcholine was measured indirectly by an assay which 
converts acetylcholine to choline prior to generating a fluorescent indicator (A12217, Invitrogen). Our lab 
achieved a similar decrease in fluorescence using the same assay in the same line of mice after cervical 
dislocation, however, this was due to a change in the level of choline (data not shown). Acetylcholine was 
not quantifiable in our assay. Based on the literature, acetylcholine levels fall rapidly after death by 
decapitation or cervical dislocation, while choline levels rise due to enzymatic production
273
. We 
hypothesize that overexpressed SYN may inhibit this post-mortem production of choline, possibly though 
PLD2 inhibition. 
The pathologic interactions of SYN and mitochondria are well known, however, their physiologic 







mitochondria-specific lipid, and localizes to mitochondria
275
. C57Bl/6S mice, with a spontaneous deletion 
of SYN, have reduced levels of cardiolipin and impaired activity of the electron transport chain specifically 
when measured through complex I/III linked activity
276
. Linked complex I/III activity impairment was 
confirmed in cultures of primary fetal midbrain neurons treated with SYN shRNA
275
. However, the 
molecular function of SYN on mitochondria and significance of these mitochondrial impairments in vivo 
remains unclear. 
Mechanisms by which SYN contributes to disease 
As the primary protein aggregate in PD, PDD, DLB and MSA, SYN dysfunction is very likely to 
contribute to sporadic human neurodegeneration. Furthermore, gene multiplication and point mutations in 
the N-terminal region of SYN cause familial Lewy body disease
221-228,230,240
. As with tau, SYN 
pathogenesis may utilize several mechanisms, including loss- and gain-of-function. It is also possible that 
physiologic SYN functions enable disease pathogenesis after specific neuronal insults. 
Loss of function 
SYN is unlikely to cause neurodegenerative disease through a complete loss of function mechanism. 
Though SYN knockout mice have not been as thoroughly characterized as tau knockout lines, they have 
normal viability, fertility and brain anatomy
251,252
. Alterations specifically in striatal dopaminergic 
terminals in SYN knockout mice do show an important role for SYN in their function, however, the 
functional redundancy of other synuclein family members reduces the magnitude of the SYN knockout 
phenotype
255
. Conversely, overexpression of even low levels of SYN are sufficient to alter neuronal 
neurotransmitter release in multiple neuronal populations
262
 and higher levels of wildtype or mutant SYN 
can impair mouse behavior and cause premature mortality
272,277
. 
The A30P mutation causes a partial loss of SYN function. The normal pre-synaptic localization of 
SYN and its functions clustering v-SNARE vesicles and reducing neuronal exocytosis are all inhibited by 
the A30P SYN mutation
259,262,265
. The inhibition of exocytosis by SYN was preserved when transfecting the 
A30P mutant into PC12 cells
278
, but not when acutely transfected into primary cultured neurons
262
. 
However, the A30P mutation retains normal binding to synaptobrevin
257









 of SYN, all of which may contribute to the in vivo toxicity of A30P 
SYN.  
SYN functions enabling pathogenesis 
SYN function is required for the toxicity of some mitochondrial toxins, which are used to acutely 
model dopaminergic cell death in PD. SYN knockout mice are resistant to toxicity from 1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine (MPTP), 3-nitropropionic acid (3-NP) and malonate, but not rotenone
280-
282
. In the case of acute 3-NP and MPTP administration, the damage inflicted is SYN gene-dose 
dependent
282
. Though the mechanism of this resistance remains obscure, proposed mechanisms include an 
increase of the neuroprotective β-synuclein
283
 or reduced dopamine storage in the striatum of SYN 
knockout mice
280,282
, or the reduction of abnormal SYN species which inhibit ubiquitin-proteasomal 
degradation
281
 and generate radical oxygen species
282
. The neuroprotective effects of SYN ablation appear 
specific for dopaminergic nigrostriatal neurons, in agreement with a specific role for SYN in this neuronal 




SYN is required for the toxicity of leucine-rich repeat kinase 2 (LRRK2) in primary neuronal culture. 
The G2019S LRRK2 mutation in iPS-derived neurons or overexpression of LRRK2 in primary rat cortical 
cell culture increases SYN levels and causes SYN-dependent cell death
284
. Part of this protective effect was 
mediated by lower LRRK2 levels in TKO neurons and neurons treated with SYN shRNA, however, 
reduced LRRK2 expression did not explain all of the protective effect conferred by SYN reduction
284
. The 
authors speculate that LRRK2 and SYN functions may converge on a single toxic pathway such as 
disruption of protein degradation
284
. 
Gain of function 
Abnormal nuclear localization of SYN can result in toxicity. While a portion of SYN localizes to the 
nucleus under normal circumstances
233
, oxidative stress and A30P and A53T mutations in cell culture, or 
paraquat treatment of mice can induce higher nuclear localization of SYN
279,285-287
. Nuclear SYN was 
associated with reduced histone H3 acetylation
279







 and peroxisome proliferator-activated receptor gamma coactivator 1α (PGC1α)-driven genes
285
. 
In turn, impairment of PGC1α-mediated transcription was associated with altered mitochondrial structure, 
impaired mitochondrial complex I activity and cell death
285
.  Inhibition of histone deacetylases or adding a 
SYN nuclear export signal prevented SYN toxicity in cell culture and in transgenic Drosophila
279
.  
SYN aggregation is likely to be toxic in Lewy body disease. A53T, E46K and H50Q SYN all 
aggregate more rapidly than wildtype SYN
241,242,288,289
. Interestingly, SYN aggregation may require binding 
to synaptobrevin to induce toxicity. A study examining the relationship between SYN function and toxicity 
found that mutations which increased aggregation and bound synaptobrevin also induced motor deficits and 
loss of dopaminergic neurons when virally expressed in the substantia nigra of mice
290
. The effect of the 
mutations on membrane binding, pre-synaptic localization and SNARE assembly did not account for in 
vivo toxicity
290
. C-terminal truncation mutants, which enhance aggregation but do not bind synaptobrevin, 
produced a less reliable correlation between aggregation and toxicity; only one of four aggregating C-
terminal truncation constructs showed toxicity in vivo
290
. SNARE proteins are redistributed into SYN 




SYN oligomers have some unique properties which may make them more toxic than larger fibrils. 
SYN oligomers selectively permeabilize highly curved membranes to Ca
2+
 and other small ions
291
, which 
may interfere with synaptic transmission. Large oligomeric SYN species inhibit fusion of v-SNARE 
vesicles containing synatpobrevin to target-SNARE vesicles, possibly by preventing vesicle docking
268
. 
However, the best studied route of oligomeric SYN toxicity relates to mitochondrial impairment.  
Mitochondrial impairment is a common pathogenic mechanism for many of the pathways implicated in 
PD (for an in-depth review of SYN and mitochondria see Nakamura, et.al. 2012
292
). Oligomeric SYN 
species can selectively fragment mitochondria in vitro and in vivo without affecting the structure of other 
organelles
293
. Mitochondrial fragmentation is at least partly independent of Drp1, another protein 
implicated in the pathogenesis of PD, and relies on membrane binding; A30P mutant SYN could not induce 
mitochondrial fragmentation
293
 and may rely on other mechanisms of toxicity. In cell culture, SYN 
oligomer-induced fragmentation led to impaired of mitochondrial respiration and cell death
293





fragmentation of mitochondria was observed after A53T SYN transfection into primary neuronal culture, 
which led to induction of mitophagy, loss of mitochondria and a bioenergetic defect prior to cell death
294
. 
The mechanism of cell death after mitochondrial impairment may relate to the induction of reactive oxygen 
species
295
. Other studies have confirmed that SYN inhibited mitochondrial respiration, specifically complex 
I inhibition, in cell culture and transgenic mice, however, SYN oligomer levels did not correlate with 
mitochondrial defects
275,296
. However, the observation of oligomeric species on a denaturing gel may not 
reflect the actual oligomeric species in vivo. Increased SYN levels and decreased complex I activity were 
shown in mitochondria isolated from the substantia nigra of PD patients
275
, but the SYN species involved 
were not determined. 
Mutant or aggregated SYN can also inhibit protein degradation. In PC12 and primary midbrain 
neuronal cell culture, chaperone-mediated autophagy (CMA) can degrade SYN through lysosome-
associated membrane protein type 2A (LAMP2A) binding and translocation of SYN into lysosomes
297
. In 
the same PC12 culture system, A53T and A30P SYN bind tightly to LAMP2A but inhibit CMA
297
. This 
impairment in degradation may promote SYN aggregation, which in turn impairs 26S proteosomal 
degradation
298




Good evidence exists in humans and experimental models for the pathologic spread of SYN between 
neurons. The stereotyped progression of SYN pathology in many PD cases
299
 and the acquisition of Lewy 
body pathology by fetal neurons grafted into the substantia nigra of PD patients
300
 generated the hypothesis 
that SYN pathology could spread, prion-like, between neurons and seed aggregation in recipient neurons. 
Follow-up in vivo experiments supported this hypothesis. A prion-like spread of SYN pathology across 
multiple brain regions could be induced by injection of synthetic SYN fibrils into the striatum of a wildtype 
mouse
301
. Like prion diseases, the spread of SYN pathology in the injected mouse relied on the presence of 
endogenous SYN
301
. Mechanistic studies have implicated multiple parts of the endosomal-lysosomal 
degradation pathways in SYN release and uptake. SYN monomers and aggregates can be released from 
vesicles in SH-SY5Y cells in culture independently of the classical endoplasmic reticulum/Golgi secretion 
pathway
302
. This release is increased by blocking lysosomal degradation or autophagy
303-305





potential mechanism by which A30P and A53T SYN mutants may increase SYN release from neurons in 
disease conditions
297
. SYN monomers and aggregates have several potential fates once outside the cell. 
Free floating SYN monomers enter recipient cells by diffusion, while free floating SYN oligomers and 
fibrils are endocytosed and usually degraded in lysosomes
306
. Exosome-associated SYN oligomers are 
readily taken up by recipient neurons and are more toxic to H4 cells in culture than free floating 
oligomers
305
. Aggregates of G51D SYN are more toxic than wildtype SYN aggregated when applied to 
cells in culture
240
, though the mechanism is not known. 
Treatments targeting SYN 
Treatments targeting SYN follow similar strategies as treatments targeting tau, although there are 
fewer potential therapies in clinical trials. Most preclinical studies target SYN phosphorylation, aggregation 
or reduction of SYN levels, with a few studies focusing on the inhibition of SYN functions involved in 
disease or their downstream effects. Reducing the reactive oxygen species created downstream of SYN is 




SYN phosphorylation inhibitors 
The primary modification of SYN in Lewy bodies is phosphorylation of S129
247,249
. While the effects 
of this particular SYN phosphorylation are still controversial
250
, it may promote SYN aggregation
249
. 
Recently, PP2A was identified as the main enzyme responsible for dephosphorylation of SYN at S129
308
 
which led to PP2A activation as a therapeutic target for PD. FDA-approved drugs metformin and 
rapamycin activate PP2A through inhibition of mTOR and were shown to reduce pS129 SYN in cell 
culture and in wildtype mice
309
. 
Methylation of PP2A activates its enzymatic activity and reduces levels of SYN phosphorylation 
at S129
308
. A natural product library screened for inhibition of PP2A demethylation yielded eicosanoyl-5-
hydroxytryptamide (EHT), derived from coffee extracts, which decreased demethylated-PP2A levels in 
primary neuronal culture and in mice
308
. In SYN transgenic mice, EHT treatment lowered levels of pS129 





on the Rota rod test
308
. It should be noted, however, that the reported toxicity of S129 phosphorylated SYN 
varies between models
250
 and that polo-like kinase 2 expression, which reduces dopaminergic cell loss in a 
rat AAV SYN model, requires phosphorylation of S129 to target SYN for autophagic degradation
250
.  
SYN aggregation inhibitors 
Generally speaking, drug screening for chemical inhibitors of SYN aggregation has been hampered by 
the long incubation time for SYN aggregate formation in vitro. Many of the aggregation inhibitors tested 
against SYN aggregation have been selected due to prior efficacy against Aβ or prion protein aggregation 
and oligomer formation
310-313
. Reducing SYN aggregates using these broadly active aggregation inhibitors 
in an A53T SYN drosophila and an A30P SYN transgenic mouse improved performance in motor 
tasks
310,312
. In SYN transgenic zebrafish embryos, inhibition of SYN aggregation increased SYN 
degradation by the proteasome and improved survival
313
.  
Recently, a technique called protein misfolding cyclic amplification, originally developed for prion 
aggregation, was modified to enhance the formation of aggregates from SYN without requiring high levels 
of recombinant protein
311
. This assay formed proteinase K-resistant beta sheet aggregates of varying 
lengths within 12 hours, as measured by thioflavin T fluorescence, whereas normal aggregation conditions 
at the same SYN concentration could not reach the same aggregation levels within 6 days
311
. This assay 
should greatly facilitate future screens for SYN-specific aggregation inhibitors. 
SYN aggregation can also be inhibited by expression of β-synuclein
314
. A double transgenic mouse 
model expressing SYN and β-synuclein showed fewer SYN aggregates, improved synaptic density and 
improved motor performance compared to singly transgenic SYN mice
314
. 
Reducing SYN levels 
Improving clearance of SYN by autophagy and lysosomal degradation is another promising therapeutic 
strategy. Increasing autophagic degradation of SYN using a variety of mechanisms protects dopaminergic 
neurons in human neuronal culture and transgenic SYN models, though the species of SYN reduced depend 
on the methods used
315-317





human mesencephalic neurons when autophagy was induced with trifluoperazine
317
, reinforcing the 
importance of SYN oligomers in neuronal toxicity.  
Increasing the activity of the ubiquitin ligase Nedd4 reduces SYN levels and toxicity in cell culture and 
animal models
318,319
. Overexpression of Nedd4 can reduce SYN levels and dopaminergic cell death in 
drosophila and rat AAV-SYN injection models of PD
318
. Both Nedd4 overexpression and treatment with 
NBA2, a small molecule activator of the Nedd4 pathway, prevented nitrosative stress and ER dysfunction 
in A53T SYN iPS neurons
319
.  
SYN degradation can also be enhanced through increasing Hsp70 and CHIP activity. Chemically 
increasing Hsp70 expression using carbenoxolone, 115-7c or mannitol decreases SYN aggregation in cell 
culture and in mice
320,321
. While initially mannitol was thought to act through inhibiting SYN aggregation, 
treatment of SYN transgenic mice with mannitol up-regulates Hsp70 and decreases levels of soluble SYN 
monomers
321
. Overexpression of the Hsp70 interacting protein CHIP reduces SYN monomer and aggregate 
levels in H4 neuroglioma cell culture
322
. 
Active immunization also reduces abnormal SYN species. Immunization with recombinant SYN 
reduced SYN oligomers in brain and increased synaptic density
323
. However, further studies raised the 
concern that a T-cell response to active immunization, in this case nitrosylated SYN, may worsen 
dopaminergic cell loss during oxidative stress
324
. Immunization with a SYN AFFITOPE
®
, a short peptide 





 immunization of two lines of transgenic mice reduced SYN oligomers, and 
improved cognition in PDGF-SYN mice and motor impairments in Thy1-SYN mice
325
. Vaccination also 




Reducing SYN function in disease 
Reactive oxygen species generated by mitochondrial malfunction are thought to play a central role in 
dopaminergic cell death in PD. Overexpression of DJ1, another protein implicated in familial PD, reduced 







. Increasing DJ1 levels by treatment with phenylbutyrate, a histone deacetylase 
inhibitor, prevented neuronal loss in mice treated with MPTP and decreased SYN aggregation while 
improving motor function in a SYN transgenic mouse
327
. However, the study may be confounded by the 
use of an artificial Y39C mutation to enhance SYN aggregation through disulfide bond formation
327
 
because increased glutathione levels from DJ1 induction may reduce the artificial SYN disulfide bonds
326
. 
Phenylbutyrate has progressed to phase I clinical trials to assess the effects of treatment on SYN levels in 
the blood of PD patients
307
. 
Direct stabilization of a partially folded native state of SYN by small molecule binding can modulate 
SYN functions required for pathogenesis.  An in silico screen for small molecules that bound transiently 
folded SYN monomers uncovered ELN484228, a small molecule which inhibited some functions and 
toxicity of SYN without affecting SYN aggregation
328
. In a phagocytosis assay, which mimics the effects 
of SYN on vesicle dynamics, ELN484228 prevented the localization of SYN to phagocytic sites and SYN-
induced phagocytic impairment
328
. In primary neurons, ELN484228 reduced synaptic localization of SYN 
and reduced cell death and neurite retraction after transduction with A53T SYN
328
. Though this small 
molecule has yet to be tested in animal models, the use of small molecule structure modulators is a 
promising strategy for reducing SYN functions required for disease. 
Conclusions regarding SYN 
The relatively recent discovery of SYN as a major pathogenic protein in PD has been met with a huge 
effort by researchers to uncover the normal and pathogenic functions of SYN. While much of this research 
has focused on the pathological interaction between SYN and mitochondria, exciting new evidence has 
accumulated for the regulation of vesicle dynamics by SYN. Other intriguing experiments demonstrate the 
regulated release of cytosolic SYN into the extracellular space and how that process may become 
dysregulated in disease conditions, possibly contributing to the prion-like spread of SYN pathology. These 
and other findings may provide critical guidance in the development of better treatments aimed at reducing 





Part III: Pathologic interactions between SYN, tau and Aβ 
SYN was first identified in human disease not as the primary component of Lewy bodies, but as the 
precursor protein to the non-Aβ component of plaques in AD
234
. While the role of SYN fragments in Aβ 
plaques is still unknown, Lewy body and AD pathology frequently co-occur
14,329
 and the clinical 
contribution of each pathologic protein to dementia is still controversial
330
. Lewy body pathology occurs in 
up to 60% of AD cases
329
 and may be more common in cases with frequent neuritic plaques
331
. 
Aggregation of SYN is facilitated by Aβ1-42 in cell-free conditions, in cell culture and in mice doubly 
transgenic for SYN and human amyloid precursor protein (hAPP), which leads to high levels of Aβ and 
plaques
332
. SYN and Aβ synergistically worsened behavioral impairments and loss of cholinergic neurons 
in double transgenic mice without altering Aβ deposition
332
.  
The biochemical and clinical interactions of SYN and tau are also well established. Common variants 
of SYN and tau provide the strongest genetic risk factors for sporadic PD
333,334
 and the two proteins have 
been shown to co-aggregate in Lewy bodies
335-337
. This co-aggregation may be mediated by a physical 
interaction between the two proteins, which enhances the aggregation of both proteins in cell-free 
conditions and in vivo
277,338,339
. Notably, tau aggregates are induced only by specific strains of SYN 
aggregates
339
, which may account for the somewhat sparse co-localization and varied aggregation patterns 
of tau in Lewy bodies in human disease
340
. Despite the extensive interactions between these two proteins, 
the exact role of tau in Lewy body disease is unclear. In dementia cases, tau and Lewy body pathology may 
compete, rather than synergize, to dictate a clinical phenotype
14,330
. 
We carried out the following studies to clarify the functional interactions between Aβ, SYN and tau in 
mouse models of neurodegenerative disease (Figure 1.6). As the functional role of tau in mediating 
neurodegenerative disease was explored using a tau knockout mouse model, we began by investigating the 
effects of reduction or ablation of endogenous tau in aged mice (Chapter 2). For tau reduction to be used 
either to probe the role of tau in mediating neurodegenerative disease or as a potential therapeutic strategy, 
tau knockout mice should show no behavioral impairments and minimal biochemical alterations at all ages. 
While there was a consensus in the literature that tau reduction had no adverse effects at young ages, the 
effects of tau ablation in aged mice was controversial
97,107





endogenous tau reduction using behavior and biochemical measurements previously found to be altered in 
aged, impaired tau knockout mice
107
. 
As discussed previously, tau reduction in the hAPP J20 model prevents premature mortality and many 
behavioral and electrophysiologic deficits. Tau may mediate A-induced impairments through a toxic gain 
of function or tau may facilitate signaling in a pathway critical for A-induced pathology. We investigated 
whether abnormal modification of tau contributes to A-induced impairments in hAPP J20 mice using 
mass spectrometry to identify and quantify post-translational modifications of tau in wildtype and hAPP 
mice. An alternate gain-of-function hypothesis, in which altered tau localization may contribute to 
impairments in hAPP J20 mice, is being explored as part of an ongoing collaboration. 
Given the abnormal tau species found in PD and the extensive interactions between tau and SYN, we 
tested the hypothesis that tau mediates impairments in mouse models of PD and other synucleinopathies 
(Chapter 4). Tau lowering may constitute a valid therapeutic strategy for PD and DLB if tau were required 
for acute dopaminergic cell death or SYN-induced behavioral impairments. Conversely, tau 
phosphorylation and aggregation in synucleinopathies may constitute an epiphenomenon that contributes 
little to the pathogenesis of the disease. We explored the effects of tau reduction on motor behavior and 
immunohistochemistry in an acute model of dopaminergic cell death and in a transgenic model of 
synucleinopathy, which overexpresses human wildtype SYN in neurons.  
Finally, we determined whether SYN induced cortical neural network dysfunction in transgenic 
mice and compared it to neural network dysfunction in human DLB patients. While synucleinopathies 
are associated with dementia and SYN aggregates, the contribution of SYN to cognitive impairment and 
neural network dysfunction is unknown. Cortical network dysfunction in synucleinopathies is often 
attributed to co-occurring AD pathology or to loss of cholinergic innervation in the cortex. We used 
electroencephalography and biochemical markers to examine neural network dysfunction in SYN 
transgenic mice and compared them to signs of neural network dysfunction in human DLB patients 
(Chapter 5). Uniquely, tau ablation in this study was used for its anti-epileptic properties, rather than as a 
mediator of neural network dysfunction. We hope through these studies to provide insight into the 







Figure 1.6 Determining the pathologic interactions between Aβ, SYN and tau. 1) Is reduction or ablation 
of endogenous tau a safe therapeutic strategy in aged mice? 2) Does Aβ alter the post-translational 
modification state of tau in hAPP mice? 3) What types of neural network dysfunction are caused by SYN, 
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Reduction of the microtubule-associated protein tau prevents cognitive impairments in transgenic 
models designed to assess the pathogenic effects of amyloid- (A) or apolipoprotein E4
71,83,98,99
, proteins 
that – like tau itself – are thought to promote the development of Alzheimer’s disease (AD)
341
. Alzheimer’s 
disease is the most common neurodegenerative disease. It causes prolonged suffering and disability in the 
elderly and takes an enormous toll on patient families and society in general
342
. Its prevalence is expected 
to increase ≥3-fold by 2050
342
, threatening health care systems worldwide and underscoring the need to 
develop better strategies to prevent and halt this devastating illness
341,343
.  
Because tau reduction might be beneficial in AD and other “tauopathies”
344
, it is interesting to study 
the consequences of this intervention in experimental models, especially in regards to cognitive and motor 
functions. Up to 8 months of age, Tau
–/–
 mice had no impairments in the Morris water maze and other tests 
of learning, memory and exploratory behaviors
71,83,98,107
. At 10-12 months, Tau
–/–
 mice also performed like 
wildtype Tau
+/+
 controls in the Morris water maze and radial arm water maze
97
. However, a recent study 
identified Y-maze deficits in Tau
–/–
 mice at 12 months of age
107
. We were unable to find information in the 





 mice have also been reported to have motor deficits. One line of Tau
–/–
 mice showed deficits in 
rod walking and wire hang tests at 10-11 weeks of age
106
. However, no additional behavioral analyses of 





, the effects of tau ablation on motor behavior in aged Tau
–/–
 mice are controversial. One group 
found no impairment on the Rota rod at 10-12 months
97
, whereas another found deficits in the Rota rod, 
pole test and open field test at 12 months
107
. Lei, et al. (2012) attributed the deficits they observed to a loss 
of dopaminergic neurons in the substantia nigra caused by iron accumulation in the brain
107
.  







 mice in a battery of behavioral tests and evaluated motor components of 














 littermates were obtained from breedings between Tau
+/–
 mice (C57Bl/6J). 
To determine whether chronic reduction (Tau
+/–
) or ablation (Tau
–/–
) of tau impairs learning and memory in 
middle-aged or old mice, we behaviorally tested two independent cohorts of mice at 11-17 or 21-22 months 
of age. The Morris water maze and a novel object recognition test were used to assess spatial versus non-
spatial learning and memory, respectively. In the Morris water maze, tau ablation had no effect on learning 
and memory in 11–17-month-old mice (Figure 2.1A,B). Reduction and ablation of tau did not significantly 
affect learning and memory in 21–22-month-old mice either (Figure 2.1C,D).  Tau ablation did not affect 
learning and memory in the novel object recognition test in 11–17-month-old mice (Figure 2.1E) and 
neither did tau reduction or ablation in 21–22-month-old mice (Figure 2.1F). 
Ablation of tau and aging cause weight gain and subtle motor deficits 
To determine whether chronic reduction or ablation of tau impairs motor functions in middle-aged or 






 mice in several motor tests at 12-15 or 21-
22 months of age. Mice of all genotypes gained weight as they aged, but Tau
–/–





 mice at 12-15 months and showed a trend in this direction at 21-22 months (Figure 2.2A). 
Tau genotype did not significantly alter rearing or overall activity in the open field, although both were 
reduced by aging (Figure 2.2B,C) and Tau
–/–
 mice showed a trend towards increased rearing at the older 
age (Figure 2.2B). Aging also reduced the latency to fall off the Rota rod, as did tau ablation (Figure 2.2D). 
Because fall latency in 12–15-month-old Tau
–/–
 mice strongly correlated with body weight at 12-15 months 
of age (R
2
=0.64, p=0.001; Figure 2.3A), this deficit may be caused primarily by their increased weight.  
At 12-15 months, Tau
–/–




 mice, whereas at 
21-22 months all groups showed comparable latencies (Figure. 2.2E). In contrast to the Rota rod results, 
pole test performance in 12–15-month-old Tau
–/–
 mice did not correlate with body weight (Figure 2.3B). 







Figure 2.1. Lack of tau since early development does not impair learning and memory in middle-aged and 
old mice. (A-D) Independent cohorts of mice comprising the indicated genotypes were tested in the 
Morris water maze at 11-17 months (A, B; n=8 mice per genotype) or 21-22 months (C, D; n=11-13 mice 
per genotype) of age. mo, months (A, C) Learning curves during hidden-platform training. Repeated-
measures ANOVA: time effect (A, p<0.0001; C, p<0.0001), but no genotype effect (A, p=0.37; C, 
p=0.28) or interaction (A, p=0.95; C, p=0.70). (B, D) Memory retention in the probe trial (platform 
removed) 24 h after the end of the last training trial. Repeated measures ANOVA: quadrant effect (B, 
p=0.002; D, p=0.006), but no genotype effect (B, p=0.98; D, p=1.0) or interaction (B, p=0.98; D, p=1.0). 
T, target quadrant; O, other quadrant. Dotted line indicates chance. (E, F) The same groups of mice were 
trained in a novel object recognition paradigm and tested 48h later. Repeated measures ANOVA: object 
effect (E, p=0.002; F, p<0.0001), but no genotype effect (E, p=0.47; F, p=0.42) or interaction (E, p=0.91; 
F, p=1.0). N, novel object; F, familiar object. *p<0.05, **p<0.01 (Bonferroni post hoc test). Data are 








Figure 2.2. Complete, but not partial, tau reduction and aging are associated with weight gain and subtle 
motor deficits. Mice of the indicated genotypes were weighed and analyzed in different motor tests at 12-
15 or 21-22 months of age (n=11-14 mice per age and genotype). (A) Body weight. Two-way ANOVA: 
genotype (p=0.002) and age (p<0.0001) effects but no interaction (p=0.69). (B, C) Rearing (B) and total 
movements (C) were measured in the open field test. Two-way ANOVA: age effect (B, p<0.0001; C, 
p<0.0001) but no genotype effect (B, p=0.42; C, p=0.55) or interaction (B, p=0.09; C, p=0.44). (D) Rota 
rod test. Two-way ANOVA: genotype (p=0.01) and age (p<0.0001) effects but no interaction (p=0.67). 
(E) Pole test. Two-way ANOVA: age effect (p<0.0001) but no genotype effect (p=0.88) or interaction 
(p=0.31). (F) Balance beam. *p<0.05, **p<0.01, ***p<0.001 vs. age-matched wildtype mice or as 






correlation of latencies with body weight (R
2
=0.34, p=0.04; Figure 2.3C) again suggested that this may not 
represent a genuine motor deficit. Independent of genotype, the oldest age group could not complete the 
balance beam test. These findings suggest that complete tau ablation causes subtle motor deficits, in part, 
by increasing body weight. In contrast, partial reduction of tau had no adverse effects on motor functions 
even at 21-22 months of age. 
Motor deficits in Tau
–/–
 mice are probably not caused by dopaminergic dysfunction 
Motor deficits in aging Tau
–/–
 mice have been attributed to impairments of dopaminergic neurons 
projecting to the striatum
107







 mice at 9-11, 14-20 or 25-26 months of age. We found a gene dose-dependent 
trend for tau reduction to lower striatal dopamine levels as mice aged (11-16% reduction, Figure 2.4A), but 
this trend did not reach statistical significance. Western blot analysis revealed a statistically significant 
decrease in TH levels only in Tau
+/–
 mice (16% reduction, Figure 2.4B,C) at 25-26 months. Notably, these 
were the same Tau
+/–
 mice that, compared with age-matched controls, failed to show any behavioral 
deficits at 21-22 months of age, suggesting that this subtle TH loss may not have a significant impact on 
motor function. Because others recently reported a much greater (40%) loss of striatal dopamine and TH in 
12-month-old Tau
–/–
 mice from the same strain
107
, we confirmed by post hoc power calculations (see 
Methods for details) that our analysis of striatal dopamine and TH levels was powered to detect such a 
change in all of the groups, if it were present. In contrast to Lei and colleagues, we did not find any iron 
accumulation in the hippocampus, striatum or substantia nigra of 14-month-old Tau
–/–
 mice (Figure 2.5). 
To further test the hypothesis that motor deficits in Tau
–/–
 mice are caused by dopaminergic deficits, 






 mice with a combination 
of L-DOPA and benserazide. To determine the efficacy of the treatment, we used the pole test, because it 
was the only test in which 12–15-month-old Tau
–/–
 mice showed weight-independent motor deficits (Figure 
2.3B). In this second cohort, pole test latency also did not correlate with body weight in Tau
–/–
 mice, and 
acute i.p. injections of L-DOPA (20mg/kg) and benserazide (5mg/kg) did not improve latency to descend in 







Figure 2.3. Correlation between weight and motor performance in 12–15-month-old Tau
–/–
 mice (n=11-
14). (A) Rota rod (R
2
=0.64, p=0.001 by linear regression). (B) Pole test (R
2
=0.03, p=0.29). (C) Balance 
beam (R
2








Figure 2.4. Mild dopaminergic deficits do not contribute to motor deficits in Tau
-/-
 mice. (A-C) Levels of 
dopamine (A) and tyrosine hydroxylase (TH) in the striatum (B, C) were measured in mice of the 
indicated genotypes at 9-11 months (n=5 per genotype), 14-20 months (n=6-7 per genotype) or 25-26 
months (n=7-10 per genotype) of age. RU, relative units; TH, tyrosine hydroxylase. (A) Striatal dopamine 
levels determined by HPLC. Two-way ANOVA: no effects of genotype (p=0.10) or age (p=0.14) and no 
interaction (p=0.40). (B) Representative western blot showing tyrosine hydroxylase (TH) levels in the 
striatum of two mice per genotype (age 25-26 months). Alpha tubulin served as a loading control. (C) 
Quantitation of striatal tyrosine hydroxylase by western blot analysis (n=4-10 mice per genotype and age 
as specified above). Two-way ANOVA: interaction (p=0.011), but no effects of genotype (p=0.72) or age 
(p=0.26). Average signals in two 25-26 month wildtype mice on each blot were arbitrarily defined as 1.0 
and used to normalize signals across western blots. (D) Pole test deficits in middle-aged Tau knockout 
mice are not significantly improved by chronic treatment with L-DOPA/benserazide. Mice (n=11-14 per 
genotype, age: 12-15 months) were assessed in the pole test before and on the 7th day of treatment with L-
DOPA (200mg/L) and benserazide (50mg/L) in 0.2% ascorbic acid in their drinking water. Repeated 
measures two-way ANOVA: genotype effect (p=0.014) but no treatment effect (p=0.97) or interaction 
(p=0.71). *p<0.05 vs. age-matched wildtype mice (Bonferroni post hoc test of selected columns). Data are 





benserazide dissolved in their drinking water for 7 days. On average, the mice received roughly 24 
mg/kg/day of L-DOPA and 6 mg/kg/day of benserazide, which is close to the doses (20mg/kg/day L-












 mice again took longer to descend the pole, but L-
DOPA/benserazide treatment did not significantly improve their performance (Figure 2.4D). Thus, 




 mice have only subtle dopaminergic deficits and it is 





Several new findings and conclusions emerged from this study. Middle-aged and old Tau
–/–
 mice had 
age-appropriate spatial and non-spatial learning and memory. Motor deficits were subtle in middle-aged 
Tau
–/–
 mice and undetectable in old Tau
–/–
 mice, most likely because deficits caused by aging became more 
prominent than those caused by tau ablation. Because middle-aged Tau
–/–
 mice had no significant 
reductions in striatal levels of dopamine or TH and L-DOPA/benserazide treatment did not improve their 
motor deficits, it is unlikely that these deficits were caused by dopaminergic impairments. Some of these 
deficits may be caused by weight gain and others by alternative mechanisms that have yet to be identified.  
Reducing tau by half had no adverse effects on any of the outcome measures until 25-26 months of 
age. At this age, Tau
+/–
 mice showed a slight reduction in striatal TH levels but no behavioral deficits, 
compared with age-matched Tau
+/+
 mice, demonstrating that partial reduction of tau is well tolerated even 
in old mice. These results extend previous studies demonstrating that Tau
+/–
 mice showed no deficits in the 
Morris Water maze at 4-7 months
98
. They also have potential therapeutic implications, as 50% reduction of 
tau was sufficient to improve neuronal network activity and cognitive functions in human amyloid 
precursor protein transgenic mice
71,83,98
 and to improve axonal transport in primary neuronal cultures 









Figure 2.5. Lack of iron staining in the brains of 14-month-old Tau
–/–
 mice. (A) Tau
+/+
 mice that did (left) 
or did not (right) receive a cerebral needle stab injury were used as a positive control for cerebral iron 




 mice (n=3 mice 





The findings of the current study differ in several respects from those reported by Lei and 
colleagues
107
. Specifically, we did not find behavioral deficits in the open field test, abnormal iron 
accumulation in the brain, or significant decreases in  striatal levels of dopamine or TH in middle-aged and 
old Tau
–/–
 mice, compared with age-matched Tau
+/+
 controls. In addition, other types of subtle motor 
deficits we detected in 12–15-month-old Tau
–/–
 mice were not significantly improved by treatment with L-




 at comparable ages (12 and 24 
months versus 12-15 and 21-22 months), it is unlikely that these variables accounted for the differences in 
our results. Additional studies, including by independent groups, are needed to resolve the discrepancies, 
which might relate to a variety of other factors, including the diet and housing conditions of the mice and 
the methodological approaches used to study their phenotypes. 





 mice, it is possible that genetic reduction or ablation of tau slightly increases the 
susceptibility of dopaminergic neurons to various injuries, including those caused by aging, exposure to 6-
hydroxydopamine
345
 and iron accumulation
107
. However, we consider it unlikely that the motor 
impairments we observed in middle-aged Tau
–/–
 mice reflect extrapyramidal motor dysfunction because 
these mice showed only subtle trends towards dopaminergic deficits and their motor impairments did not 
improve with dopamine treatment. One potential cause of motor dysfunction is abnormal weight gain, 
which was evident in Tau
–/–
 mice at 12-15 months of age and correlated with their impairments on the Rota 
rod and balance beam. However, pole test deficits did not correlate with weight gain, suggesting the 
involvement of additional factors that remain to be defined. 
In conclusion, the genetic ablation of tau causes minimal neurological dysfunction in middle-aged, but 
not in old Tau
–/–
 mice, as compared with age-matched wildtype controls, and there is little evidence that 
partial reduction of tau is detrimental. To further assess the safety of this potential therapeutic strategy, it 
would be desirable to reduce tau levels in rodent models at different ages after their nervous system has 
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Abnormal modification and accumulation of the microtubule-associated protein tau is associated with 
Alzheimer’s disease (AD) and other neurodegenerative disorders collectively referred to as “tauopathies”. 
A large body of experimental evidence suggests that cerebral accumulation of amyloid- (A) peptides 
contributes causally to AD
346
 and that pathologic tau species may mediate the effects of Aβ on cognitive 
decline
12,13,71,83,84,98
, though the nature of the Aβ and tau species involved remain a topic of intense 
investigation. 
Transgenic mice with neuronal overexpression of human amyloid precursor protein (hAPP) bearing 
familial AD-linked mutations have pathologically elevated levels of A in the brain and develop a range of 
other AD-like abnormalities
347,348
. Although most lines of hAPP mice do not spontaneously develop 
abnormal modification or accumulation of endogenous mouse tau, genetic ablation of tau prevents or 
reduces behavioral impairments, synaptic deficits, neural network dysfunction and related molecular 
alterations in several lines of hAPP mice without affecting their levels of soluble A, amyloid plaques, or 
neuritic dystrophy
71,83,93,98,119
. In addition, tau reduction markedly increases resistance to seizure induction 
in various models of epilepsy
71,98,111,349,350
. Taken together, these findings led us to propose two possible 
mechanisms by which tau enables Aβ-induced impairments. In the first hypothesis, physiological forms of 
tau enable aberrant neural network activity caused by diverse pathogenic triggers
71
. The alternative 
hypothesis is that pathologically elevated levels of A change the posttranslational modification of tau 
causing an adverse gain of tau function, turning it into an active mediator of A-induced neuronal 
dysfunction
114
. As discussed elsewhere
341
, these possibilities are not mutually exclusive. Characterizing the 
posttranslational modifications of tau may help identify strategies to block the pathological processes it 
enables or mediates. 
Most studies of post-translational tau modifications have focused on the phosphorylation of abnormal 
tau or were carried out in cell-free conditions or cultured cell lines. While these studies have provided 
important information on abnormal tau, much less is known about the nature and extent of physiological 





widely as phosphorylation, including O-GlcNAc modification, ubiquitination, methylation and acetylation. 
Methylation of tau on lysine and arginine residues has been described very recently
351-353
, but the functional 
effects of these two types of methylation remain mostly unknown. O-GlcNAc modification has been 
proposed to prevent tau phosphorylation by occupying many serine and threonine residues
354-356
, thereby 
preventing the dissociation of tau from microtubules and tau aggregation. However, prior to our studies no 
O-GlcNAc sites had been found on endogenous tau, compared to 34 phosphorylation sites
352,357
. 
Ubiquitination of tau has been studied primarily on abnormal tau aggregates
31,358
, while tau acetylation has 
been primarily studied in cell culture with some acetylation observed on abnormal tau aggregates
23,24,195
. 
Interestingly, acetylation can oppose tau ubiquitination, which marks tau for degradation
23
, but almost 
nothing appears to be known about the baseline ubiquitination or acetylation state of physiological tau. 
Further complicating the interpretation of tau modifications, the quality of the site-assignment for tau 
modifications has often been suboptimal or uncertain. Assignment of tau phosphorylation sites in particular 
can be difficult due to the clustering of potential phosphorylation sites and the abundance of multiply 
phosphorylated peptides. Recent advances in mass spectrometry have enabled the calculation of confidence 
scores for modification site assignments, such as the Slip score or Ascore
359,360
. However, the tau 
modification sites in online databases do not yet include this information, making it difficult to assess the 
quality of the information provided
361-365
.  
Here we used mass spectrometry to extensively interrogate physiological modifications of endogenous 
tau in brain tissues from untreated wildtype and hAPP mice. We focused on mouse tau because working 
with mice made it possible to standardize peri-mortem variables and optimize sample preservation, the 
sequence of mouse tau is similar to human tau (89% identical, 92% similar, blastp vs. human tau 441), and 








Investigation of Endogenous Tau Modifications in Wildtype Mice 
 Our investigations into endogenous tau modification began by site mapping O-GlcNAc modification of 
endogenous rat tau. To identify O-GlcNAc modification on endogenous tau, we took advantage of a new 
technique recently developed by our lab for specific, high affinity enrichment of O-GlcNAc modified 
peptides (Figure 3.1A). Tau was enriched from rat brain by homogenization in 1% perchloric acid then the 
neutralized, concentrated supernatant was passed through a gel filtration column, which separates proteins 
based on size. The tau-containing fractions were combined and digested with trypsin, then tagged in 
successive steps with galactose-azide and a photo-cleavable biotin tag (Figure 3.1A). This tagging process 
allowed for high affinity avidin enrichment of O-GlcNAc modified peptides and facilitated the release of 
the tightly bound peptides by cleaving the biotin with exposure to ultraviolet light. From electron transfer 
dissociation mass spectrometry of the O-GlcNAc modified peptides we were able to assign a single O-
GlcNAc modification site on tau, S400 (Figure 3.1B), as well as novel O-GlcNAc modifications of α-
synuclein (SYN) and several other proteins. 
Next, using endogenous tau samples isolated from wildtype mouse hippocampus and cortex (Table 
B.2), we were able to identify and carry out site assignments for six different types of post-translational 
modifications: arginine methylation, lysine acetylation, lysine methylation, lysine ubiquitination, serine O-
GlcNAc modification, and serine / threonine / tyrosine phosphorylation (Figure 3.2, Tables 3.1,3.2). Lysine 
ubiquitination was inferred from the detection of GlyGly modified lysine, which results from trypsin 
cleavage of ubiquitin. Our experiments covered 96% of the tau sequence and assigned modifications at 63 
sites, which are listed in Table 3.2 by position within mouse tau 430 and the homologous position in human 
tau 441. As is the convention in tau literature, all amino acid numbering in the text refers to the 
homologous site in human tau 441. To our knowledge, 18 of the 63 sites have not been previously reported 
and all of these novel modifications occurred on arginine or lysine residues which are conserved in human 
tau (Table 3.1, bold and red font Table 3.2; instruction for access to all peptide identification data in 








Figure 3.1. Identification of O-GlcNAc modification of S400 on tau by chemical/enzymatic enrichment. 
(A) Flow chart showing the overall strategy. Inset, structure of the photocleavable PC-PEG-biotin-alkyne 
reagent. (B) Electron-transfer dissociation tandem mass spectrometry spectrum recorded on [M+3H]
3+
 
ions (m/z 474.2) for the derivatized peptide VVgSDTPR from the tau protein. CIP, calf intesting 








Figure 3.2. Post-translational modifications identified in endogenous mouse tau. Mouse tau was isolated 
from brains of wildtype mice and post-translational modifications were assigned by mass spectrometry. 
Modifications are shown on the longest tau isoform expressed in the mouse central nervous system (430 
amino acids). All unambiguously assigned endogenous tau modifications are shown in the top panel, while 
the lower panels show the same modifications separated by the type of residue modified. The N-terminal 
exons expressed in mouse tau 430 are shown in blue, the proline-rich region in green and the four 
microtubule binding repeats are shown in orange.  Only unambiguously assigned sites from wildtype mice 
reported (Table 3.2) are indicated, and all sites are positioned to scale. Note that some amino acid residues 
can be alternately modified and that these modifications are mutually exclusive, e.g., ubiquitination and 






Contrary to the prevailing literature view, O-GlcNAc modification in mouse brain was detected only at 
a single site at very low stoichiometry. Detection of this O-GlcNAc modification required enrichment for 
O-GlcNAc modified peptides from the digests of a few large-scale tau preparations (Table B.2). 
The majority of phosphorylation sites resided outside the microtubule binding repeat domain (MBRD) 
(Figure 3.2). To determine the likely site assignments for multiply phosphorylated peptides, we generated 
highly phosphorylated tau samples by subjecting wildtype mice to anesthesia/hypothermia
366
. Results 
obtained in this model suggested that the endogenous di-phosphorylation detected in the 210–224 region 
likely represents phosphorylation of T212 and T217. However, the model failed to resolve double- and 
triple-phosphorylated sites in the tryptic peptide representing residues 407–438. Because this peptide 
contained ten candidate serine/threonine sites for phosphorylation and showed partial methionine-
oxidation, only one phosphorylation site (S409) could be unambiguously assigned.  
Lysine modifications tended to be enriched in the microtubule binding repeat domain (MBRD), though 
the enrichment was not statistically significant. The vast majority of acetylation sites (86%) were 
alternately modified, usually by ubiquitination (Figure 3.2). Conversely, alternative modification of 










Human Tau 441 







3 1 (0.33) 3 (1.0) 1 (0.33) 0 (0) 
Lysine 
Acetylation 
14 11 (0.79)  14 (1.0) 10 (0.71) 12 (0.86) 
Lysine 
Methylation 
mono – 1   
di - 2 
3 (1.0) 3 (1.0) 2 (0.67) 3 (1.0) 
Lysine 
Ubiquitination 
15 3 (0.20) 15 (1.0) 11 (0.73) 11 (0.73) 
Serine O-GlcNAc 1 0 1 0 1 
Serine / Threonine 
/ Tyrosine 
Phosphorylation 
27 27 (1.0) 25 (0.93) 2 (0.07) 1 (0.04) 
Numbers in parentheses indicate the proportion of total for each modification. MBRD, microtubule binding 
repeat domain. 
a





ubiquitination sites always included acetylation. Acetylation and ubiquitination targeted the same lysine 
residue more often than would be predicted by chance (p=0.00002 by Pearson’s Chi-squared test) and 
lysine methylation targeted residues that were targeted by both acetylation and ubiquitination (p=0.0005 by 
Likelihood Ratio test). 
Table 3.2. Endogenous tau modifications in wildtype and hAPP mice. 







(Human 441 isoform) 
DHGLKESPP GlyGly 1 33a 44 
DHGLKAEEA GlyGly 1 33b 44 
PGSETSDAK Phospho 1 50|52|53a 61|63|64367 
SDAKSTPTAE Phospho 1 57|58a 68|69357 
DAKSTPTAE Phospho 1 58a 69357 
GIGDTPNQE Phospho 1 100c 111357,368 
VTQARVASK Methyl 1 115c 126 
IATPRGAAS Methyl 1 144 155 
RGAASPAQK Phospho 1 148 -d369 
RGAASPAQKGTSNATRIPA Phospho 2 148,158e -d,169357,369 
SPAQKGTSN Acetyl 1 152 16323,24 
SPAQKGTSN Dimethyl 1 152 163351 
IPAKTTPSPKTP Phospho 2 164|165,167 175|-,-d370 
IPAKTTPSPKTPPGS Phospho 3 164,167,170 175,-d,181368,370,371 
KTTPSPKTP Phospho 1 167 -d370 
KTTPSPKTPPGS Phospho 2 167,170  -d,181368,370,371 
PSPKTPPGS Phospho 1 170 181368,371 
PSPKTPPGSGEPPKSGERS Phospho 2 170,180 181,191368,371,372 
RSGYSSPGSPGTP Phospho 2 187,191 198,202369 




SGYSSPGSP Phospho 1 188 199373 
SGYSSPGSPGTP Phospho 2 188,191 199,202369,373 
SSPGSPGTP Phospho 1 191 202369 
SSPGSPGTPGSR Phospho 2 191,194 202,205368,369 
GSPGTPGSR Phospho 1 194 205368 
PGSRSRTPSLPTPPTR Phospho 2 199|201|203|206 210|212|214|217368,372,374,375 
SRSRTPSLP Phospho 1 201 212372,375 
SRTPSLPTP Phospho 1 203 214368 
PSLPTPPTR Phospho 1 206 217368 
REPKKVAVV Acetyl 1 214 225 





AVVRTPPKSPSASKSRL Phospho 2 220|224|226|228 231|235|237|239357,367,375 
AVVRTPPKSPSAS Phospho 2 220,224 231,235375 
AVVRTPPKSPSASKSRL Phospho 2 220,228 231,239367,375 
PKSPSASKS Phospho 1 226 237357 
NVRSKIGST Acetyl 1 248 25923,24 
NVRSKIGST GlyGly 1 248 259 
NVRSKIGST Methyl 1 248 259352 
SKIGSTENL Phospho 1 251 262371,376 
TENLKHQPG GlyGly 1 256 267 
IINKKLDLS Acetyl 1 270 28123,24 
IINKKLDLS GlyGly 1 270 281 
IINKKLDLS Methyl 1 270f 281 
NVQSKCGSK Acetyl 1 279 29023,24 
NVQSKCGSK GlyGly 1 279f 290 
KDNIKHVPG Acetyl 1 287 29823 
KDNIKHVPG GlyGly 1 287 298 
QIVYKPVDL Acetyl 1 300 31124 
QIVYKPVDL Dimethyl 1 300 311352 
QIVYKPVDL GlyGly 1 300 31131,351,358 
VDLSKVTSK Acetyl 1 306 31723 
VDLSKVTSK GlyGly 1 306 317358 
KVTSKCGSL Acetyl 1 310 32123 
KVTSKCGSL GlyGly 1 310 321 
SKCGSLGNI Phospho 1 313f 324377,378 
NIHHKPGGG Acetyl 1 320 33123 
NIHHKPGGG GlyGly 1 320 331 
NIHHKPGGG Methyl 1 320f 331 
VKSEKLDFK Acetyl 1 332 343 
VKSEKLDFK GlyGly 1 332 343 
KLDFKDRVQ Acetyl 1 336 347 
KLDFKDRVQ GlyGly 1 336 347 
DFKDRVQSK Methyl 1 338 349353 
RVQSKIGSL GlyGly 1 342 353351,358 
SKIGSLDNI Phospho 1 345 356368 
GGGNKKIET Acetyl 1 358 36923,24 
GGGNKKIET GlyGly 1 358 369 
KKIETHKLTFREN Phospho 1 362|366 373|377378 
IETHKLTFR GlyGly 1 364 375 
NAKAKTDHG Acetyl 1 374 38523 
NAKAKTDHG GlyGly 1 374 385 
AKAKTDHGAEIVYKSPVVS Phospho 2 375,385f 386,396375,378-380 
AKAKTDHGAEIVYKSPVVSGDT
SPRHL 
Phospho 3 375,385,392|393 386,396,403|404375,378-380 





AEIVYKSPVVSGDTSPRHL Phospho 3 383,389,392|393 394,400,403|404381 
AEIVYKSPVVSGDTSPRHL Phospho 3 383,385,392|393f 394,396,403|404381 
IVYKSPVVS Phospho 1 385 396368,371 
IVYKSPVVSGDTS Phospho 2 385,389 396,400368,371 
IVYKSPVVSGDTSPRHL Phospho 2 385,392|393 396,403|404368,371 
IVYKSPVVSGDTSPRHL Phospho 3 385,389,393 396,400,404368,371 
IVYKSPVVSGDTSPRHL Phospho 3 385,389,392|393 396,400,403|404368,371 
SPVVSGDTS HexNAc 1 389 400 
SPVVSGDTS Phospho 1 389 400368,371 
SPVVSGDTSPRHL Phospho 2 389,392|393 400,403|404368,371 
SGDTSPRHL Phospho 1 393f 404 
PRHLSNVSSTGSIDMV Phospho 2 398|401|402|403| 
405 
409|412|413|414|416357,382 
PRHLSNVSSTGSIDMV Phospho 3 398|401|402|403| 
405f 
409|412|413|414|416357,382 
SSTGSIDMV Phospho 1 405g 416357 
PTM, post-translational modification. Novel modification sites found in wildtype mice are in bold and red 
font (HexNAc site was identified in rat), sites found only in hAPP mice are italicized and in blue font. Sites 
for which unambiguous assignment was not possible are indicated with a vertical bar between alternative 
assignments.  
a
 Mouse tau isoform A peptide 
b
 Mouse tau isoform B,C or D peptide 
c
 Mouse tau isoform A,B,C or D peptide 
d
 Not conserved in human tau 
e
 Site identified in PSD experiments 
f 
Modified species was only observed in hAPP samples 
g 
Peptide site was unambiguously assigned with AspN digestion 
Similar Tau Modifications in Wildtype and hAPP Transgenic Mice 
 We next used our extensive dataset to investigate whether tau modifications are altered by 
neuronal overexpression of hAPP/A in vivo. We identified 5 additional tau modifications in hAPP mice 
which had not been observed in wildtype mice (Table 3.2 italicized and in blue font, Table B.2). However, 
the abundance of these modifications approached the lower limit of detection and we could not determine 
whether they were truly specific to hAPP mice or whether they were present in wildtype mice just below 
the detection threshold.  
Our combined list of tau modifications from wildtype and hAPP mice was used for quantitative 
comparison between hAPP mice and wildtype controls (Table 3.2). Because some spectra in these 
experiments could not be unambiguously assigned in all mice, modified peptides containing the same 






Figure 3.3. Comparison of post-translational modifications in hAPP and wildtype mice. Tau was isolated 
from hAPP and wildtype mice and the levels of all quantifiable post-translational modifications were 
assessed by mass spectrometry. (a) Tau was isolated from whole lysate either by selective solubility in 
perchloric acid in wildtype mice and symptomatic hAPP (PCA cohort, n=3 per group, age 6 months) or by 
immunoprecipitation in randomly selected wildtype and hAPP mice (IP cohort, n=10-12 mice per group, 
ages 7-10 months).  (b) Tau was immunoprecipitated from the post-synaptic density of randomly-selected 
wildtype and hAPP mice using 3 separate cohorts (n=10-12 mice per group, ages 7-10 months). After 
correcting for multiple comparisons, no p-values were ≤0.05. Modified amino acids are indicated if 
conserved in human tau 441 and unambiguously assigned, with multiple unambiguous modifications 
marked with ‘+’; if the site is ambiguous, a range containing the modified sites is indicated with a ‘di-‘ or 
‘tri-‘ marking dual and tri-modified peptides, respectively. Ac, modified by acetylation; GG, modified  by 
GlyGly; Me, modified by methylation; p, modified by phosphorylation; WT, wildtype;  hAPP, human 







Figure 3.4. Differential modification of tau in the post-synaptic density. (a) Western blot showing PSD95, 
tau and α-synuclein levels at each step of post-synaptic density fractionation in a replicate cohort of mice 
and (b) quantification (n=8 mice, ages 5-6 months). Quantitative values were normalized to 
cytosolic/membrane fraction for each mouse. (c) Quantification of the 5 most commonly found tau 
modifications in the post-synaptic density fraction compared to hippocampal and cortical whole lysate 
(n=10-12 mice per group, ages 7-10 months). Due to site ambiguity, a range containing the modified sites 
is indicated and a ‘di-‘ or ‘tri-‘ denotes dual and tri-modified peptides, respectively.  **p≤0.01, 
***p≤0.001 by Student’s t-test with a Holm correction for multiple comparisons. Cyt/Mem, cytosolic- and 
membrane-containing fraction; Cyt, cytosolic fraction; Mem, membrane fraction; Syn, synaptosomal 
fraction; Non-PSD, fraction remaining after PSD extraction; PSD, post-synaptic density; RU, relative 
units. Quantitative values are means ± SEM, though some error bars of fractionated samples are too small 






32 different peptide modifications across two independent experiments (Table 3.3A, B.3), we found no tau 
modifications that were significantly and consistently different between hAPP mice and wildtype controls. 
  Recent studies suggest that even small amounts of abnormal tau may be highly pathogenic when they 
are associated with the post-synaptic density (PSD)
114,158
. Therefore, we also compared tau modifications in 
PSD fractions isolated from the hippocampus and cortex (Figure 3.4A,B) of hAPP mice and wildtype 
controls. Tau levels were similar in the PSD of hAPP mice and wildtype controls (replicate cohort age 5-6 
months, n=8 mice per genotype, data not shown). Because of the low amount of tau isolated from PSD 
fractions, only the most abundant modifications could be compared. A total of 16 modified peptides were 
measured over the course of 3 independent experiments (Figure 3.3B, Table 3.3, B.2). Besides acetylated 
K281 detected in a single experiment, all peptide modifications identified in the PSD were 
phosphorylations. None of the tau modifications detected in PSD fractions were significantly and 
consistently different between hAPP mice and wildtype controls (Figure 3.3B). Phosphorylation at S416 
tended to be found more often in the PSD of hAPP mice (35%) compared to wildtype controls (16%), so 
this site may merit further investigation despite the lack of a significant alteration between genotypes. 
Many modified tau peptides could not be quantified because of the high variability in the detection of 
low abundance modifications among animals. Five modifications could be quantified in all unfractionated 
whole lysate and PSD experiments, and another four in both of the whole lysate experiments. The majority 
(7/9) of these modifications were mono-phosphorylations. The most consistent mono-phosphorylations 
were identified in peptides containing residues 175–191, 195–205 or 400–404, and the most consistent di- 
and tri-phosphorylations in peptides containing residues 386–404 (Figure 3.4C). The four additional 
modifications quantified in whole lysate, but not PSD, experiments were mono-phosphorylations in 
peptides containing residues 210–217 or 231–237, and at S356 and S416. Notably, di-phosphorylation in 
the 386-404 region was enriched in the PSD, while tri-phosphorylation of the 386-404 region was depleted 






Table 3.3. Tau modifications quantified in hAPP and wildtype mice.  
















DHGLKESPP GlyGly 1 33a 44 + - 
DHGLKAEEA GlyGly 1 33b 44 + - 
PGSETSDAK Phospho 1 52a 63 + - 
SDAKSTPTAE Phospho 1 57|58a 68|69 + - 
GIGDTPNQE Phospho 1 100c 111 + - 
IATPRGAAS Methyl 1 144 155 + - 
RGAASPAQKGTSNATRIPA Phospho 2 148,158d -e,169 - + 
IPAKTTPSPKTPPGSGEPPKSGE
RS 
Phospho 1 164|170|174|180 175|181|185|191 + + 
IPAKTTPSPKTPPGS Phospho 2 164|167|170 175|-e|181 + - 
IPAKTTPSPKTPPGS Phospho 3 164,167,170 175,-e,181 + - 
PSPKTPPGSGEPPKSGERS Phospho 2 170,180 181,191 - + 
SGERSGYSSPGSPGTPGSR Phospho 1 184|187|191|194 195|198|202|205 + + 










PGSRSRTPSLPTPPTR Phospho 1 199|201|203|206 210|212|214|217 + + 
PGSRSRTPSLPTPPTR Phospho 2 199|201|203|206 210|212|214|217 + - 
AVVRTPPKSPSASKS Phospho 1 220|224|226 231|235|237 + + 
AVVRTPPKSPSASKSRL Phospho 2 220|224|226|228 231|235|237|239 + - 
NVRSKIGST Acetyl 1 248 259 + - 
SKIGSTENL Phospho 1 251 262 + - 
IINKKLDLS Acetyl 1 270 281 + + 
IINKKLDLS GlyGly 1 270 281 + - 
VKSEKLDFK Acetyl 1 332 343 + - 
KLDFKDRVQ Acetyl 1 336 347 + - 
KLDFKDRVQ GlyGly 1 336 347 + - 
SKIGSLDNI Phospho 1 345 356 + + 
IETHKLTFR GlyGly 1 364 375 + - 
NAKAKTDHG Acetyl 1 374 385 + - 
AKAKTDHGAEIVYKSPVVSGD
TSPRHL 












IVYKSPVVS Phospho 1 385 396 + + 
SPVVSGDTSPRHL Phospho 1 389|392|393 400|403|404 + + 
PRHLSNVSSTGSIDMV Phospho 2 398|401|402|405 409|412|413|416 + + 
SSTGSIDMV Phospho 1 405f 416 + + 
PTM, post-translational modification; Quant, quantified. Sites for which unambiguous assignment was not 
possible are indicated with a vertical bar between alternative assignments. 
a






Peptide from mouse isoforms B, C or D 
c
Peptide from mouse isoforms A, B, C or D 
d
Identified in PSD experiments 
e
Not conserved in human tau 
f
Site unambiguously assigned with AspN digestion 
Discussion 
Our study describes six distinct types of physiological tau modifications at 63 sites on endogenous 
mouse tau, approximately one quarter of which represent novel modifications. Because we wanted to carry 
out an unbiased assessment of endogenous tau modifications, we did not enrich for specific modification 
types during most of our site assignment experiments. However, some samples were enriched for O-
GlcNAc because the unexpectedly low stoichiometry of this modification warranted more detailed 
investigation.  
There is robust targeting of acetylation, ubiquitination and methylation to the same set of lysine 
residues on endogenous tau, suggesting cross-talk between these three modifications. Previous findings 
obtained in cultures of primary neurons and HEK293 cells suggested a potential competition between 
acetylation and ubiquitination of specific lysines in tau
23
. Our tau modification data suggests that 
acetylation and ubiquitination also compete for lysine modification on tau in vivo. Nearly all acetylation 
sites on tau were alternately modified with ubiquitin, including three of the four KXGS motifs, which 
regulate neurite extension and the binding of tau to microtubules
383,384
. In support of the hypothesis that 
acetylation may compete with KXGS phosphorylation
195
 we did not detect any peptides modified by both 
phosphorylation and acetylation in our study. However, it’s possible that any such doubly modified 
peptides in the MBRD would be too low in abundance on tau to detect even without competitive 
modification.   
We found that methylation targets two critical lysine residues on endogenous tau also targeted by 
acetylation and ubiquitination. These highly regulated, triply-targeted lysine residues reside in the first 
KXGS motif and in the PHF6 sequence, two regions that regulate the microtubule binding function and 
aggregation of tau. Lysine modification of the first KXGS motif (K259-S262) may prevent the binding of 
tau to microtubules, similar to the effect of KXGS phosphorylation
383









) sequence, which is critical for tau aggregation
385
, inhibits both the binding of tau to 
microtubules and tau aggregation
24
. It is possible that modification of K311 has similar effects. K281, 




) and targeted by acetylation and ubiquitination in wildtype 
mice, may also control tau aggregation
46
. We found this residue to be methylated at low levels only in 
hAPP mice. Notably, different types of lysine modifications at triply-targeted residues probably have 
different effects on tau function. However, the alternate modification of lysines residues by at least three 
different processes suggests that these residues may play a strategic role in the regulation of tau.  
The complex effects of acetylation on tau aggregation highlight the challenges involved in 
investigating tau modification by enzyme manipulation without assessing site-specific modifications. 
Acetylation of tau by CREB-binding protein (CBP) enhances tau aggregation
24
, whereas acetylation of tau 
by p300 inhibits aggregation
195
, possibly due to the acetylation of different lysine residues. Indeed, the 
contributions of different lysine modifications to tau function are likely to vary by modification type and 
location and deserve to be further explored in both health and disease. 
Another modification that has been proposed to have a strategic role in tau regulation is O-GlcNAc 
modification. In these studies, we were able to identify only a single O-GlcNAc modification site at S400, 
which has been subsequently confirmed by antibody labeling
386
. Results obtained in vitro and in vivo after 
pharmacological blockade of OGAse, the O-GlcNAc removing enzyme, suggested a potential inverse 
relationship between O-GlcNAc modification and phosphorylation at many sites on tau
354-356
. However, 
chronic treatment of mice with OGAse inhibitors increased O-GlcNAc on S400 of tau without changing tau 
phosphorylation, the first indication that these modifications are not necessarily reciprocal
387
. Our data is 
inconsistent with the hypothesis that O-GlcNAc modification can block pathologic tau phosphorylation by 
occupying many potential phosphorylation sites. The relative abundance and number of sites occupied by 
phosphorylation on endogenous tau contrasts with the single residue modified by O-GlcNAc, which was 
only detectable after specific enrichment. Nonetheless, the conservation of O-GlcNAc on tau across 
species
30,244,386
 suggests that this modification does fulfill an important function. Recent in vitro and in vivo 








Arginine methylation is the most recently described modification of tau
353
. The MBRD arginine 
methylation site on tau (Table 3.2) was found in a broad survey of arginine methylation in mouse brain
353
. 
We found only arginine mono-methylation of tau, which could be catalyzed by type I or type II protein 
arginine methyltranseferases
390
, and the functional impact of this mono-methylation is unknown. Because 
two of the arginine methylation sites clustered just N-terminal to the proline-rich region it is tempting to 
speculate that arginine methylation could affect the binding of tau to membrane proteins, which is mediated 
by the N-terminal region
76
, or to SH3 domain-containing proteins, mediated by the proline-rich region
39,102
. 
Conceivably, arginine methylation could also alter the nucleo-cytoplasmic shuttling of tau
89,390
, the 
regulation of which is unclear. 
Most of the tau phosphorylations were observed at sites adjacent to MBRD domains, consistent with 
previous reports
391
. A recent study observed 31 phosphorylation sites in human brain tissue from 
cognitively normal individuals
352
, similar to the 27 sites we observed. Among their 4 cognitively normal 
samples, only 6 of the 31 described phosphorylation sites were found in all samples, 4 known 
phosphorylation sites and 2 novel sites
352
. The 4 known sites (T181, S202, T231 and S404) were consistent 
with 4 of our most commonly detected singly modified phosphopeptides quantified in whole lysate, 
suggesting that the phosphorylation state of endogenous tau is similar in wildtype mouse brain and normal 
human brain tissue. 
Notably, we did not detect any difference in tau modifications between symptomatic hAPP-J20 mice 
and wildtype controls, consistent with our earlier findings
98
. We have previously reported similar levels of 
hippocampal tau phosphorylation in young, symptomatic hAPP mice by western blot and local increases in 
tau phosphorylation near neuritic plaques in old mice
98
. By contrast, other studies have found increased tau 
phosphorylation in hAPP mice by western blot
392,393
, including in the hippocampus of young symptomatic 
hAPP-J20 mice
394
. Using quantitative mass spectrometry, we assessed many more tau modifications than 
we could previously assess by western blot analysis and we were able to quantify 31 peptide modifications. 
The few modifications found only in hAPP mice were enriched in MBRD modifications, particularly lysine 
methylation, which could suggest some dislocation of tau from microtubules in hAPP mice. However, these 





specific to hAPP mice. We found no quantitative change in tau modification in either unfractionated whole 
lysates or PSD preparations from hAPP-J20 mice relative to wildtype controls. These findings support our 
hypothesis that normally modified endogenous tau fulfills a physiological function that allows A and 
other epileptogenic factors to elicit aberrant network activity
83,98,111,341,350
. However, we cannot exclude the 
possibility that the less abundant modifications which we could not quantify may contribute to a gain-of-
function mechanism. Nor can we exclude the possibility that tau modifications could be altered at other 
ages, other brain regions or in other cellular compartments, including the cytosolic compartment of 
dendritic spines, or that tau mislocalization could result in an adverse gain of tau function in hAPP mice. 
Even if tau modifications are not altered in hAPP mice, these modifications may play an important role 
in Aβ-induced pathology in vivo. Because tau modifications regulate tau function and localization, 
including the entry of tau into dendritic spines
158
, altering normal tau modifications may interfere with Aβ-
induced pathology. We did not find a significant difference in S262 phosphorylation in hippocampal and 
cortical whole lysates from hAPP and wildtype mice. However, a recent study was able to reduce spine loss 
in CA3 pyramidal neurons of hAPP-J20 mice by transfection of tau with a serine to alanine mutation at 
position 262, which prevents S262 phosphorylation
118
. Regulation of tau functions by phosphorylation of 
S262, including neurite extension
384
 and microtubule binding
383
, may be critical for Aβ-induced pathology 
but not actively regulated by chronic Aβ in vivo. 
The extensive modification of tau in normal brains suggests that tau regulation is important, although 
the exact functions of tau in the adult brain are unclear. It is interesting in this regard that many, if not all, 
of these modifications are sub-stoichiometric. Phosphorylation of tau was the most abundant modification 
identified in our study; however, normal tau isolated from human brain tissue appears to carry only an 
average of 2–4 phosphorylations per molecule
395
, which we found to be spread out over approximately 9 
abundant sites and more than 18 less abundant sites. Lysine and arginine modifications on physiological tau 
were even less abundant and O-GlcNAc was not detectable without targeted enrichment. Because several 
tau modifications, particularly those located within the MBRD, prevent tau from binding to 
microtubules
24,383
 we speculate that many of the modifications we found belong to a small, highly regulated 





neuronal compartments. Additional studies are clearly needed to further elucidate the regulation and 











Tau Reduction Does Not Prevent Motor Deficits in Two Mouse Models 
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Neurodegenerative disorders are on the rise, most likely because greater longevity is increasing the age 
of populations around the world and age is a major risk factor for these conditions
396-398
. Alzheimer’s 
disease (AD) and Parkinson’s disease (PD) are the most prevalent of these disorders and no treatments are 
available to prevent them or halt or reverse their progression. If these diseases had pathogenic mechanisms 
in common, drugs might be developed to target these mechanisms for the benefit of both patient groups. It 
is interesting in this regard that AD and PD overlap clinically. A proportion of patients show manifestations 
of both diseases
399-403
, and first-degree relatives of patients with early-onset AD are at increased risk of 
developing PD
404
. The two diseases also overlap pathologically. A substantial proportion of AD patients 
have Lewy bodies in their brain, which are hallmarks of PD
329,405,406
. Conversely, a proportion of PD 
patients have amyloid plaques in their brain, which are hallmarks of AD
407,408
. Both AD and non-demented 
PD patients have hyperphosphorylated tau
7,37,409,410
, which aggregates in AD and in some cases of PD 
without dementia
3,5,6,10,335,336,411
. In addition, specific variants of the human tau (MAPT) gene appear to be 
genetic risk factors for PD
333,412-414
. 
Reduction of endogenous murine tau prevents cognitive deficits and various pathological alterations in 
several transgenic mouse models of AD
71,83,98,99
. Furthermore, neuronal overexpression of human -
synuclein in transgenic mice causes phosphorylation and aggregation of endogenous tau
277,410,415,416
. In light 
of these findings and a recent report that tau reduction prevented dendritic degeneration in a neuronal 
culture model of mutant LRRK2-linked PD
417
, we wondered whether tau reduction is also beneficial in 
mouse models of PD.  
Human PD is characterized, among other things, by motor abnormalities such as slowed movements, 
rigidity, unstable posture and abnormal gait
418
. Pathologically, PD is characterized by loss of dopaminergic 
neurons in the substantia nigra, degeneration of their tyrosine hydroxylase (TH)-containing projections into 
the striatum and aggregation of α-synuclein into Lewy bodies
418
.  
Several of these abnormalities can be simulated in rodent models through administration of 
neurotoxins that target dopaminergic neurons or neuronal expression of transgenes that encode relevant 





mice causes loss of TH-positive terminals in the striatum on the ipsilateral side and motor deficits
419
. This 
model can be used to address the question whether tau reduction protects dopaminergic neurons in the 
substantia nigra against neurotoxins and whether tau reduction can prevent motor deficits caused by 
dopaminergic cell loss. Either of these effects could be beneficial in PD. In a different PD-related model, 
neuronal expression of human wildtype α-synuclein (SYN) causes motor deficits in transgenic mice
420-422
. 
This model can be used to address the question whether tau is necessary for α-synuclein-induced 






 backgrounds to 
determine whether tau reduction diminishes the severity of their motor deficits and pathological alterations. 
Results 
Tau ablation does not prevent motor deficits caused by 6-OHDA and worsens some deficits 







 mice received unilateral injections of 6-OHDA into the striatum and were examined for 
motor abnormalities in the open field, Rota Rod and pole tests beginning 3 days (Figure 4.1) and 24 days 
(Figure 4.2) thereafter. Acutely, 6-OHDA injected mice of all three genotypes showed reduced movements 
and in the open field (Figure 4.1A,B) and reduced latency to fall off the accelerating Rota Rod (Figure 
4.1C). 6-OHDA increased the latency to descend the pole in the pole test only in mice with reduced tau 
levels, but not in wildtype mice (Figure 4.1D). In vehicle injected mice, tau ablation reduced activity in the 
open field (Figure 4.1A) but did not significantly affect performance in the other tests (Figure 4.1B-D).  
After the recovery period, all groups of mice showed a similar level of activity in the open field 
(Figure 4.2A). Tau ablation also had no effects on recovery of motor functions in the other tests at this 




 mice showing no significant differences in rearing, Rota 
Rod fall latency or pole descent latency (Figure 4.2B-D). 
To assess the effect of 6-OHDA on striatal projections from dopaminergic neurons in the substantia 
nigra, we immunostained brain sections from the behaviorally tested mice for TH (Figure 4.3A). Vehicle 
treated mice showed no loss of TH staining (Figure 4.3A, quantification not shown). 6-OHDA treatment 








Figure 4.1. Tau reduction does not prevent motor deficits induced by acute striatal 6-OHDA injection. 
Mice (n=9-12 per treatment and genotype) received a unilateral striatal injection of 6-OHDA or vehicle at 
2.6–5.8 months of age and were tested behaviorally beginning 3 days later. A) Total movements in the 
open field were reduced by 6-OHDA treatment and by tau reduction (p<0.0001 for treatment effect, 
p=0.01 for genotype effect, and p=0.054 for interaction by two-way ANOVA). B) Rearing in the open 
field was reduced by 6-OHDA regardless of tau levels (p<0.0001 for treatment effect, p=0.09 for genotype 
effect, and p=0.15 for interaction by two-way ANOVA after cube-root transformation). C) Latency to fall 
off an accelerating Rota Rod was reduced by 6-OHDA but not by tau reduction (p<0.0001 for treatment 
effect, p=0.40 for genotype effect, and p=0.22 for interaction by two-way ANOVA after cube-root 
transformation). D) Latency to descend in the pole test was increased by 6-OHDA and by tau reduction 
(p<0.0001 for treatment effect, p=0.05 for genotype effect, and p=0.11 for interaction by two-way 
ANOVA). *p<0.05, **p<0.01, ***p<0.0001 vs. vehicle-treated mice of same tau genotype or as indicated 















Figure 4.2. Tau reduction does not alter recovery of motor function after 6-OHDA injection. Mice (n=7-
12 per genotype and treatment) received a unilateral striatal injection of 6-OHDA or vehicle at 2.6–5.8 
months of age and were tested behaviorally beginning 24 days later. A) Total movements in the open field 
were similar in all groups. B) Rearing in the open field was reduced by 6-OHDA and this abnormality was 
improved by tau ablation (p=0.003 for treatment effect, p=0.04 for genotype effect, and p=0.44 for 
interaction by two-way ANOVA after log transformation). C) Fall latency on the accelerated Rota Rod 
was decreased by 6-OHDA treatment regardless of Tau genotype (p<0.0001 for treatment effect, p=0.71 
for genotype effect, and p=0.15 for interaction). D) Latency to descend in the pole test was increased by 
6-OHDA mostly in Tau
+/–
 mice (p<0.0001 for treatment effect, p=0.04 for genotype effect, and p=0.09 for 
interaction). *p<0.05, **p<0.01, ***p<0.0001 vs. vehicle-treated mice of same Tau genotype or as 






in 6-OHDA injected mice with reduced tau levels (Figure 4.3B). Thus, tau ablation does not prevent, and 
may partly enhance, acute motor and pathological deficits induced by 6-OHDA injection. 
Tau reduction does not prevent motor deficits in human wildtype α-Synuclein transgenic mice 







 background. Motor functions of the resulting offspring were assessed at 3.0-4.5 
months of age. Independent of Tau genotype, SYN expression caused abnormalities in fall latency in the 
Rota Rod test (Figure 4.4A), stride length (Figure 4.4B), hind limb clasp reflex (Figure 4.4C), latency to 
cross a balance beam (Figure 4.4D) and foot slips on the balance beam (Figure 4.4E). Tau reduction did not 
significantly modulate these effects (Figure 4.4A-E). In mice without SYN, tau ablation increased latency 
to cross and foot slips on the balance beam (Figure 4.4D and E), but had no significant effect on the other 
measures.  
To assess the effect of tau ablation on the pathology of SYN mice, we examined striatal TH staining in 
the behaviorally tested mice. Compared with wildtype mice, SYN mice showed no decreases in striatal TH 
staining on any of the Tau backgrounds (data not shown), consistent with previous findings in SYN/Tau
+/+
 




These findings demonstrate that tau reduction does not protect mice against motor deficits and 
pathological alterations caused by striatal injection of 6-OHDA or transgene-mediated neuronal expression 
of SYN. Thus, wildtype murine tau does not appear to contribute causally to PD-like motor deficits and 
pathological alterations in these models. In contrast, endogenous tau is required for amyloid- (A) 
peptides to impair neurons in primary cultures
58,65,88
 and in human amyloid precursor protein (hAPP) 
transgenic mice 
71,83,98
. It is also needed for apolipoprotein E4, the most important genetic risk factor for 
AD, to cause cognitive decline and neuronal loss in knockin mice
99
. However, tau reduction did not alter 
the age of disease onset or mortality in a mouse model of amyotrophic lateral sclerosis
83
, providing further 
support for the conclusion that tau specifically contributes to functional and pathological abnormalities in 








Figure 4.3. Tau reduction does not prevent loss of tyrosine hydroxylase after striatal injection of 6-
OHDA. Mice (n=7-12 per treatment and genotype) received a unilateral striatal injection of 6-OHDA or 
vehicle at 2.6–5.8 months of age and were analyzed by tyrosine hydroxylase immunohistochemistry and 
light microscopy 50 days later. A) Representative photomicrographs from a vehicle-injected wildtype 
mouse and 6-OHDA injected mice of different Tau genotypes demonstrating loss of tyrosine hydroxylase 
immunoreactivity in the striatum. B) The effect of 6-OHDA was quantitated by expressing the area of 
tyrosine hydroxylase immunostaining on the lesioned side as a percentage of that on the unlesioned side of 
the brain. 6-OHDA caused loss of tyrosine hydroxylase immunoreactivity in the striatum and there was a 
trend toward greater losses in groups with reduced tau levels. ***p<0.0001 vs. 100% (no loss of 
dopaminergic projections) by one-sample t-test with a Benjamini-Hochberg correction. One-way ANOVA 









Figure 4.4. Tau reduction does not prevent motor deficits in SYN transgenic mice. SYN mice on 
different Tau backgrounds (n=12-15 per group) were analyzed behaviorally at 3.0–4.5 months of age. A) 
Transgenic expression of SYN impaired performance on an accelerating Rota Rod, reducing fall 
latencies. Tau reduction was associated with non-significant trends towards improved fall latencies in 
mice with SYN and towards impaired fall latencies in mice without SYN (p<0.0001 for SYN effect, 
p=0.96 for Tau effect, and p=0.04 for genotype interaction by two-way ANOVA). B) SYN mice had 
shortened stride lengths regardless of Tau genotype (p<0.0001 for SYN effect, p=0.014 for Tau effect, 
and p=0.97 for interaction by two-way ANOVA). C) SYN mice showed prominent increases in hind limb 
clasp reflex and tau reduction showed a non-significant trend to worsen this abnormality (p<0.001 for 
SYN effect, p=0.45 (Tau
+/–
) and p=0.91 (Tau
–/–
) for Tau effects, and p=0.46 (Tau
+/-
) and p=0.48 (Tau
-/-
) 
for SYN interaction by probit regression). D, E) Transgenic expression of SYN and tau reduction both 
increased (D) the latency to cross a balance beam (p<0.0001 for SYN effect, p=0.07 for Tau effect, and 
p=0.94 for interaction by two-way ANOVA) and (E) the number of foot slips while crossing a balance 
beam (p<0.0001 for SYN effect, p=0.022 for Tau effect, and p=0.19 for interaction by two-way ANOVA 
after square root transformation). Between 33-54% of mice in each SYN group had to be excluded from 
balance beam analysis because they dragged their hind limbs across the beam. *p<0.05, **p<0.01, 
***p<0.0001 vs. mice without SYN on the same Tau genotype or as indicated by bracket (Bonferroni test 
(A, B, D, E) or Welch’s t-test with a Benjamini-Hochberg correction (C) for selected comparisons of + 










It is important to consider the limitations of the mouse models used in this study and the extent to 
which one can extrapolate from these models to human PD. Because the 6-OHDA model is caused by an 
acute insult, it probably does not simulate the etiology of sporadic PD, a notoriously chronic condition. 
However, it is a robust model of dopaminergic cell loss and of motor deficits resulting from deficient 
dopaminergic input to the striatum, two cardinal features of PD. Our data suggest that wildtype tau does not 
enable the neural network dysfunction that underlies such motor deficits. This result was not predictable as 
tau enables neuronal hypersynchrony in models of AD
83
 and neuronal hypersynchrony has also been 
implicated in the pathophysiology of PD
424,425
. The differential effects of tau reduction in models of AD 
versus PD suggest that tau plays distinct roles in their pathogenic mechanisms. The SYN mice used in this 
study model -synuclein-induced behavioral alterations and may be relevant to the early pathogenesis of 
PD and other synucleinopathies. However, they do not replicate PD-like neurodegeneration in the 
substantia nigra at this age
426
, possibly due to low α-synuclein expression levels in this structure. Our 
results indicate that tau does not enable or mediate early -synuclein-induced motor deficits in this model. 
Notably, we cannot exclude a pathogenic role of tau in humans with PD or other synucleinopathies or 
that tau reduction might be of benefit in specific forms of PD, for example, those caused by LRRK2 
mutations
417
. It is therefore interesting to comment on potential risks of tau reduction beyond lack of 
therapeutic benefit in forms of PD simulated by the models examined in the current study. Of all the 
functional outcome measures we evaluated in 6-OHDA injected mice and untreated SYN mice, tau 
reduction significantly worsened only one: descent latency of 6-OHDA injected mice in the pole test 
(Figure 4.1D), suggesting that the risk of enhancing PD-like alterations by tau reduction may be low. Tau 
reduction also had rather subtle effects on pathological measures in the PD models analyzed here. Although 
tau reduction appeared to exacerbate the 6-OHDA-induced loss of TH immunoreactivity in the striatum, 
this trend did not reach statistical significance. 
Furthermore, tau reduction per se had relatively subtle effects in only two of our behavioral tests in 
vehicle injected controls and untreated mice lacking SYN. In vehicle injected mice, tau reduction was 
associated with decreased total movements in the open field acutely after the injection (Figure 4.1A), but 





impaired performance on the balance beam (Figure 4.3D, E). However, these impairments were much less 





 mice by two-tailed t-test). Thus, tau reduction was well tolerated 
overall and caused only minimal motor deficits. Additional studies are needed to further explore the 
potential therapeutic value of this strategy in different neurological conditions. 
Because tau reduction effectively prevented AD-like abnormalities in hAPP transgenic mice but not 
PD-like deficits in the models analyzed here, it is tempting to speculate that tau plays different roles also in 
the human conditions and that tau reduction might be beneficial in AD, but not in the most common forms 
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Dementia with Lewy bodies (DLB) belongs to a family of common neurodegenerative diseases called 
synucleinopathies, which are pathologically characterized by the mislocalization and aggregation of the α-
synuclein (SYN). DLB, Parkinson’s disease (PD), and Parkinson’s disease with dementia (PDD) are 
closely related synucleinopathies, but are distinguished by differences in the relative onset of motor and 
cognitive impairments and in the distribution of SYN pathology
330
. While much is known about the motor 
impairments in PD, very little is known about the mechanisms of cognitive impairment and cortical 
network dysfunction in DLB and PDD. DLB and PDD patients have dementia with visual hallucinations, 
attentional fluctuations, and parkinsonism
330
. These symptoms are associated with a prominent slowing of 
cortical oscillations on electroencephalography (EEG), resulting in a shift in spectral power from higher 
(alpha, beta, gamma) to lower (delta, theta) frequency bands
427,428
. However, it remains uncertain whether 
the neural network and cognitive dysfunction in these conditions are actually caused by SYN. 
EEG slowing in neurodegenerative diseases is often attributed to the loss of cholinergic neurons 
projecting to the cortex. In some Alzheimer’s disease (AD) patients, treatment with inhibitors of 
acetylcholinesterase, administered to compensate for cholinergic denervation, can improve frontal EEG 
activity and some cognitive functions
429,430
. DLB patients have a greater loss of cholinergic neurons
431
 and 
more EEG slowing than AD patients
427,428
. Although DLB and PDD patients show loss of cholinergic 
projections in most cortical areas
431,432
, cholinergic treatment normalizes brain activity only over the frontal 
cortex, as measured by resting-state fMRI
433
, suggesting that other mechanisms contribute to network 
dysfunction in other cortical regions. 
Pharmacologically decreasing presynaptic release of neurotransmitters decreases the power of high-
frequency brain oscillations on EEG
434
. Notably, neuronal overexpression of SYN impairs presynaptic 
release
261,262
 and causes behavioral deficits in SYN transgenic mice
272,435
. These findings raise the 
possibility that SYN causally contributes to neural network dysfunction in DLB and PDD patients. To test 
this hypothesis, we performed EEG recordings and analyzed the expression of neuronal activity-dependent 






To detect changes in spectral power distribution in DLB patients across a wide frequency range, we 
recorded EEGs with a high sampling frequency in human subjects (Table 5.1) while they were awake but 
had their eyes closed. Average spectral power analysis revealed the average dominant peak frequency to be 
in the alpha range (8–12 Hz) in control subjects and in the theta range (4–8 Hz) in DLB subjects (Figure 
5.1A), consistent with previous findings
427,428
. Typical EEG analysis breaks spectral power into frequency 
bands, but this provides a relatively poor overall view of spectral power alterations. This is especially true 
in DLB where the relative power of many frequency bands is altered
427,428
. Therefore, we analyzed the 
cumulative distribution function (CDF) of spectral power, which provides a continuous picture of the 
spectral power changes from 0 to 100 Hz. DLB patients showed a marked left-shift in the spectral power 
distribution towards slower frequencies as compared to controls (Figure 5.1B). Although DLB subjects had 
more variable total power than controls (p=0.0007, F test), total power was not different between the 
groups, indicating that their altered power distribution cannot be attributed to a change in total power.  
To assess whether neuronal accumulation of SYN could causally contribute to these network abnormalities, 
we recorded EEGs from 4- to 8-month-old transgenic mice in which the Thy-1 promoter directs expression 
of human wildtype SYN in neurons
435,436
. At this age, these mice are cognitively impaired and show 
abnormal neuronal SYN accumulation in the hippocampus and cortex
272,435
. EEG and video recordings 
were obtained while mice were resting in a state of quiet wakefulness or early sleep. Similar to humans 
with DLB, SYN mice showed a slowing in the dominant resting rhythm and a marked left shift in the 
spectral power distribution (Figure 5.1C–E). This shift consisted of an increase in delta power and a 
decrease in the power of theta and higher frequency bands (Figure 5.1C,E). Total spectral power was 
comparable in NTG and SYN mice, indicating that the power shift in SYN mice reflects primarily a change 
in power distribution. 
Table 5.1. Human EEG cohort 
Diagnosis (n) Control Cases (8) DLB Cases (4) 
Age (mean ± SD) 68.4 ± 3.0 73.3 ± 8.3 
Gender (M/F) 5/3 2/2 
Education (Years) (mean ± SD) 17.3 ± 3.0 21.5 ± 8.1 
Handedness (R/L) 4/4 4/0 






Figure 5.1. Dementia with Lewy bodies (DLB) in humans and neuronal expression of wildtype human -
synuclein (SYN) in transgenic mice cause a similar left shift in EEG spectral power. (A,B) Brain 
oscillations in patients with DLB (n=4, solid line) and control subjects (n=8, dashed line) were recorded by 
high sampling frequency EEG/MEG. (A) Relative power (in percent of total power) of brain oscillations of 
different frequencies recorded by EEG over the parietal cortex (0–40 Hz zoom shown for clarity). (B) The 
cumulative distribution function (CDF) of relative power was calculated from high sampling frequency 
EEG recordings and revealed a shift to lower frequencies in DLB patients (p<0.0001 by Kolmogrov-
Smirnov test). (C–E) SYN mice (n=14, solid line and black bars) and NTG littermates (n=9, dashed line 
and white bars) were analyzed by EEG at 4–8 months of age. (C) Relative power (in percent of total 
power) of brain oscillations of different frequencies recorded over the parietal cortex (0–40 Hz zoom 
shown for clarity). (D) Cumulative distribution function of relative power revealed a shift to lower 
frequencies in SYN mice (p<0.0001 by Kolmogrov-Smirnov test). (E) Relative power (in percent of total 
power) of brain oscillations of different frequency bands. Delta 0.5–4 Hz, Theta 4–10 Hz, Alpha 10–13 
Hz, Beta 13–20 Hz, Gamma 20.1–99.9 Hz. A–D: Black curves represent means and shadings 95% 
confidence intervals. E: *p<0.05, **p<0.01 vs. NTG (repeated-measures mixed-effects model of relative 






Unexpectedly, EEGs recorded from SYN mice also revealed epileptiform spikes, multi-spike 
complexes and seizures (Figure 5.2A–E). During the first 24 h of recording, 25% (7/28) of SYN mice and 
0% (0/14) of NTG controls had at least one seizure. The seizures we observed in SYN mice were of two 
types. The first, more common type (Figure 5.2D) had a typical electrographic seizure pattern and was 
usually accompanied by forelimb clonus, abnormal tonic posture and tail extension. These seizures were 
typically of moderate intensity and rarely caused only behavioral arrest or escalated into full 
running/jumping activity. The second type of seizure (Figure 5.2E), which we refer to as a myoclonic burst 
seizure, consisted of periodic, large amplitude spikes or multi-spike complexes and was accompanied by 
myoclonic jerks typically involving the neck, shoulder and forelimb. Myoclonic burst seizures did not 
usually evolve into other types of seizures. Both types of seizures symmetrically involved both 
hemispheres. During a 24-h recording session, most SYN mice with seizures demonstrated only one or the 
other of these seizure types.  
We next looked for immunohistochemical changes in the hippocampus that are typically caused by 
epileptic activity
437-440
. Compared with NTG controls, SYN mice had reduced levels of calbindin in granule 
cells of the dentate gyrus and the stratum radiatum of CA1 (Figure 5.3F–H), increased or ectopic 
expression of neuropeptide Y (NPY) in the molecular layer of the dentate gyrus and the mossy fiber 
pathway (Figure 5.2F,I–J), and fewer cfos-positive granule cells (Figure 5.2F,K). All of these changes are 
seen in the presence of recurrent seizure activity
437,438,441
. An independent line of transgenic mice 
expressing SYN under the PDGF promoter showed similar hippocampal alterations (Figure 5.3), making it 
unlikely that the abnormalities we detected in the Thy1-SYN line were caused by insertional mutagenesis 
or other positional effects resulting from the integration of the transgene into the genome. 
To determine whether epileptic activity is sufficient to cause a left shift in spectral power, we 
examined transgenic mice with neuronal expression of mutant human amyloid precursor protein (hAPP) 
from line J20
83,347,439,442
. These mice exhibit robust epileptic activity and have dysregulated gamma 
activity
439,443
. A side-by-side comparison of EEG recordings in SYN and hAPP mice matched for age and 
background strain revealed clear differences in resting spectral power. SYN mice again showed a left shift 






Figure 5.2. Epilepsy and related immunohistochemical alterations in SYN mice. (A–E) Representative 
EEG traces showing normal activity in a NTG mouse (A) and frequent epileptiform spikes (arrowheads in 
B), multi-spike complexes (arrowheads in C), a seizure (D) accompanied by tail extension and bilateral 
forelimb clonus (not shown), and a myoclonic burst seizure (E) in SYN mice. (F–K) Hippocampal 
changes in neuronal activity-dependent proteins in SYN mice (n=11–15 mice per genotype, age 5–7 
months). Hippocampal sections from SYN and NTG mice were immunostained for calbindin, NPY or cfos 
and analyzed by densitometry (calbindin/NPY) and cell counting (cfos). (F) Representative images from 
NTG and SYN mice. Scale bars: 0.5 mm (Calbindin/NPY) and 0.1 mm (cfos). Calbindin was measured in 
the molecular layer of the dentate gyrus (G) and the stratum radiatum of CA1 (H), NPY in the mossy 
fibers (I) and the molecular layer (J), and cfos-positive cells in the granular layer (K). LPC, left parietal 
cortex; RPC, right parietal cortex; DG, dentate gyrus; OD, optical density; RU, relative units. *p<0.05, 







Figure 5.3. Neuronal expression of SYN directed by the PDGF promoter also causes hippocampal 
changes in activity-dependent proteins in an independent line of transgenic mice. (A–D) Hippocampal 
sections from PDGF-SYN mice and NTG controls were immunostained for calbindin or NPY and 
analyzed by densitometry (n=8 mice per genotype). Calbindin was measured in the molecular layer of the 
dentate gyrus (A) and the stratum radiatum of CA1 (B), and NPY in the mossy fibers (C) and the 
molecular layer (D) of the dentate gyrus. DG, dentate gyrus; OD, optical density; RU, relative units. 
**p<0.01, ***p<0.001 (Student’s t-test). The age of mice ranged from 3–17 months and was not 
significantly different between NTG and SYN mice (mean ± SEM: 9.1 ± 1.39 for NTG and 10.4 ± 1.75 





resting spectral power distribution (Figure 5.4A). Therefore, neuronal expression of transgene-derived 
proteins and epileptic activity are not sufficient to cause a left shift in spectral power during a resting EEG.  
We next assessed more directly if epileptic activity contributed to spectral changes in SYN mice. 
Acute injection of phenobarbital (5 mg/kg, i.p.) decreased interictal epileptiform events by 55% but did not 
affect spectral power in SYN mice (Figure 5.4B–C). Similarly, ablation of the microtubule-associated 
protein tau, which has been shown to reduce epileptic activity in a variety of seizure models
71,83,98,111,350
, 
tended to reduce interictal events by roughly 50% but, if anything, tended to slightly increase the left shift 
in spectral power in SYN mice (Figure 5.4D–E). Tau ablation also reduced some seizure-related 
biochemical alterations in the hippocampus of SYN mice (Figure 5.4F–H), although alterations in granule 
cell calbindin and mossy fiber NPY were not affected (data not shown). Thus, neither acute nor chronic 
reduction of epileptiform activity altered spectral power in SYN mice, suggesting that epileptiform activity 
may not be a critical cause or mediator of the left shift in spectral power. 
Inhibiting cholinergic signaling in rats caused a left shift in spectral power similar to the shift we 
observed in untreated SYN mice
444,445
. We therefore wondered whether increasing cholinergic 
neurotransmission by inhibiting acetylcholinesterase might reverse spectral changes in SYN mice. 
Donepezil, an acetylcholinesterase inhibitor, was injected daily (1 mg/kg, i.p.) for 14 days and EEG 
recordings were performed just before the treatment began (baseline), after the last injection, and after a 
washout period of 7 days. Donepezil did not reverse the spectral power shift in SYN mice, although there 
was a trend toward a right-shift in the power distribution in both NTG and SYN mice (Figure 5.4I). 
Although oscillatory abnormalities in DLB patients have been well documented
427,428
, few studies have 
examined neural network excitability in these patients. One small study raised the possibility of an 
increased incidence of seizures in DLB patients
446
 and a second group documented cortical myoclonus, a 
form of cortical hyperexcitability, in DLB patients
447
. To look for additional evidence of aberrant network 
excitability in these patients, we examined calbindin levels in their dentate gyrus. Patients with temporal 
lobe epilepsy or AD show reduced calbindin levels in dentate granule cells, and such calbindin reductions 
are thought to reflect aberrant hippocampal excitability
348,448,449







layer (G), and cfos-positive cells in the granular layer (H). (I) Donepezil (1 mg/kg, i.p.) was injected once 
daily for 14 days in SYN mice and NTG controls (n=3–6 mice per genotype and treatment, age 4–6 
months). Spectral power distribution in NTG and SYN mice is shown for the last day of donepezil 
treatment (NTG, blue dashed line; SYN, red solid line) and after 7 days of drug washout (NTG, black 
dashed line; SYN, black solid line). Kolmogorov-Smirnov test with Holm correction revealed a genotype 
effect during (p=0.002) and after (p<0.005) donepezil treatment, but no effects of treatment in SYN mice 
(p=0.84) or NTG controls (p=0.90). 0–40 Hz zoom shown for clarity. A,C,E,I: Quantitative values are 
means. B,D,F–H: *p<0.05, **p<0.01 vs. NTG or as indicated by brackets (Tukey test), ***p<0.001 vs. 
pre-injection baseline (one-sample t-test). Bars represent means ± SEM. ML, molecular layer; OD, optical 
density; RU, relative units. 
 
Figure 5.4. Modulation of epileptic activity does not 
shift spectral power. (A) Thy1-SYN mice (black 
solid line), hAPP-J20 mice (red dotted line) and 
their combined NTG littermate controls (black 
dashed line) were compared by EEG (n=3–7 mice 
per group, age 4–5 months). SYN mice showed a 
left shift, whereas hAPP mice did not (NTG vs. 
SYN p<0.0003, hAPP vs. SYN p<0.0003, NTG vs. 
hAPP p=0.06, by Kolmogrov-Smirnov test with 
Holm correction). (B,C) Acute injection of 
phenobarbital (5 mg/kg, i.p.) reduced interictal spike 
activity (B) but did not alter the spectral power 
distribution (C, p=0.70 by Kolmogrov-Smirnov test) 
in SYN mice (pre-injection, black solid line; post-
injection, red dotted line; n=6–10 mice, age 3–7 
months). (D, E) Genetic ablation of tau caused a 
trend towards reduced epileptic activity (D, p=0.17 
by Tukey test multiply adjusted p value) and a trend 
toward an increased left shift in spectral power 
distribution (E, p=0.09 by Kolmogrov-Smirnov test) 
in SYN mice (Tau
+/+
, black solid line; Tau
–/–
, red 
dotted line; n=6–7 mice per genotype, age 4–7 
months). Dotted line in D represents the average 










littermates (No SYN, white bars; SYN, black bars; 
n=10–13 mice per genotype, age 4–5 months) were 
immunostained for calbindin, NPY or cfos and 
analyzed by densitometry (calbindin/NPY) or cell 
counting (cfos). Calbindin was measured in the 





mRNA levels in the dentate gyrus obtained postmortem from humans with neocortical DLB pathology and 
low or high levels of AD pathology (Table 5.2). Dentate gyrus samples from AD cases and from people 
without neurodegenerative disease were used as positive and negative controls, respectively
348,449
. DLB 
cases without AD pathology showed markedly reduced levels of calbindin mRNA in the dentate gyrus, 
similar in extent to reductions seen in AD (Figure 5.5). The most striking loss of calbindin mRNA was 
observed in DLB cases with a high level of AD pathology (Figure 5.5).  
To further assess whether aberrant network excitability may contribute to SYN-related dementia, we 
reviewed the charts of patients who were seen at the UCSF Memory and Aging Center between 2007 and 
2012 and who met research criteria for DLB
330
 (Table 5.3). We searched the charts for myoclonus and 
seizure disorders, both of which are thought to result from aberrant network excitability
447,450,451
.  
Table 5.2. Human postmortem tissues  
Diagnosis (n) Age 
(mean ± SD) 
Sex (M/F) RNA Integrity Number 
(mean ± SD) 
No neurodegenerative disease (3) 84 ± 5.0 2/1 7.8 ± 0.2 
DLB with marked AD pathology (6) 78 ± 4.5 5/1 6.1 ± 2.0 
DLB with minimal AD pathology (5) 77 ± 5.4 4/1 5.3 ± 0.6 
AD (7) 79 ± 2.9 2/5 6.5 ± 1.3 
 
Table 5.3. Humans with DLB analyzed 
Characteristic DLB (158) 
Age at Onset Model 
(p-value) 
Sex (M/F) 94/64 0.002 
Education (Years) (mean ± SD)
1 
15.5 ± 3.9 0.42 
Handedness (R/L/A) 140/14/4 0.95 
Patients with fluctuations (%) 100 (61.7%) 0.60 
Patients with a seizure disorder (%) 5 (3.2%) 0.71 
Patients with myoclonus (%)
2 
34 (21.5%) 0.007 
Age at onset of cognitive decline (mean ± SD)
3
 69.7 ± 8.85 - 
DLB, dementia with Lewy bodies; R, right-handed; L, left-handed; A, ambidextrous 
1
One DLB patient was missing education information. 
2
One DLB patient had both myoclonus and a seizure disorder. 
3






Figure 5.5. Reduction of calbindin mRNA levels in the dentate gyrus of humans with DLB and/or AD 
pathology. Calbindin mRNA levels in postmortem tissue samples were quantified by qRT-PCR and 
normalized to 18S RNA as a loading control. n=3 controls without neurodegenerative disease, n=5–7 
cases per disease group. In cases with DLB plus high AD pathology (DLB+AD), there was an interaction 
between AD and Lewy body pathology (p<0.001 by two-way ANOVA). ***p<0.001 vs control (Tukey 





Myoclonus was noted in 21.5% (34/158) of patients with clinically diagnosed DLB, consistent with the 
estimated prevalence of myoclonus in pathologically-confirmed cases of diffuse Lewy body disease
452
. 
Myoclonus and male gender were associated with a lower age of onset of cognitive impairment (65.9 ± 
8.22 with myoclonus, 70.68 ± 8.77 without myoclonus; 67.9 ± 8.77 male, 72.4 ± 8.32 female) in a mixed 
effects linear model (Table 5.3). The incidence of myoclonus in DLB was markedly higher than that in an 
age-matched reference population (Table 5.4 and Caviness, et.al. 1999
453
). 
Roughly 3% (5/158) of patients with DLB were noted to have a seizure disorder. An additional 7.6% 
(12/158) of DLB patients were suspected to have a seizure disorder but were not formally diagnosed. The 
first unprovoked seizure in epileptic DLB patients typically occurred near the time of dementia diagnosis 
(median –1 year relative to diagnosis, range –4 to +1), but was not related to the age of onset of cognitive 
impairment (73.0 ± 7.55 with epilepsy vs. 69.6 ± 8.89 without epilepsy). The incidence of new-onset, 
unprovoked seizures in our DLB population tended to be higher than that of an age-matched general 
population (Table 5.4 and 
454
). However, the magnitude of the effect was difficult to evaluate due to the 
small number of events during the incidence study period.  
Autopsies were obtained in 12 DLB patients and revealed a high diagnostic accuracy for neocortical 
Lewy bodies: 11 out of 12 cases were confirmed pathologically; one case showed only AD pathology. 
Based on McKeith criteria
330
, there was a high likelihood that Lewy body pathology accounted for 
dementia in 6 cases and an intermediate likelihood for the remaining 5 cases, which had high levels of 
concomitant AD pathology. Four DLB patients with myoclonus that came to autopsy all had neocortical 
Lewy bodies; two of them also had numerous plaques and tangles, one had a high level of plaques without 
Table 5.4. Incidence of seizures and myoclonus in humans with DLB by age 
Clinical Sign Age
1
 n Population Incidence
2 
Relative Rate (95% CI) 
Seizures 70-79 1 71 234.7 1.5 (0.2-11.2)
3 
 
80+ 2 36 925.9 5.4 (1.3-22.8)
3
 
Myoclonus 50-69 7 42 2777.8 1450.1 (424.5-4953.7)
4 
 70+ 11 102 1797.4 248.3 (96.2-640.4)
4 
1
Age-ranges dictated by epidemiological studies in control populations 
2
per 100,000 person-years 
3











tangles, and one had no appreciable AD pathology. However, the low number of autopsies precluded us 
from reliably assessing the relative contributions of DLB and AD pathology to clinical features.  
Discussion 
Our study demonstrates that neuronal overexpression of wildtype human SYN causes a left shift in 
spectral power in transgenic mice that closely resembles spectral alterations in humans with DLB. This 
finding supports the hypothesis that accumulation of SYN, which characterizes DLB pathologically, is at 
least partly responsible for network dysfunction in DLB patients. We further obtained evidence for aberrant 
network excitability in SYN mice and in humans with DLB.  
The most direct evidence for aberrant network excitability in SYN mice consisted of interictal spikes 
and intermittent seizures that were associated with typical alterations on EEG and in motor behavior. These 
functional changes were accompanied by immunohistochemical alterations in the hippocampus that 
typically result from aberrant network excitability, including reduced calbindin levels. Reduced calbindin 
expression in the dentate gyrus was also detected in DLB patients. Notably, it is likely that calbindin 
depletion in the hippocampus is a more sensitive indicator of aberrant network excitability then routine 
scalp EEG, which can easily miss intermittent epileptiform events and is notoriously insensitive to epileptic 
activity in deeper brain regions such as the hippocampus
455,456
.  
A limitation of our mouse experiments is that all spectral analyses were performed on EEG recordings 
obtained over the parietal cortex of resting mice. We focused on this brain region because it shows a 
spectral shift in DLB (Figure 5.1 and Bonanni, et.al. 2008
428
), and on resting behavior in mice to mimic 
human EEG conditions. Recordings from other brain regions and task-related spectral analyses may 
provide additional insights into neuronal network dysfunction. For example, EEG recordings over the 
frontal cortex might be more suitable for assessing potential contributions of cholinergic deficits to spectral 
alterations in SYN mice, and analysis of individual EEG recordings in actively exploring mice could help 
reveal the kind of dysregulation of gamma oscillations we observed in hAPP-J20 mice
443
. 
While overexpression of human SYN caused obvious seizure activity in transgenic mice, the more 





aberrant network excitability such as myoclonus. Myoclonus in DLB and PD consists of a sudden brief jerk 
that is accompanied by a sharp transient in the contralateral sensorimotor cortex on EEG
447,450
. This type of 
myoclonus, called cortical myoclonus, may be caused by aberrant cortical excitability
447,450,451
 and has been 
successfully treated with anti-epileptic drugs
457-459
.  Interestingly, levels of SYN in the sensorimotor cortex 
were higher in PD patients with myoclonus than in those without
460
. Increased cortical SYN pathology may 




In patients with early AD and a seizure disorder, a substantial proportion of the seizure activity was 
non-convulsive and could have easily been missed on routine exams
456
. This caveat may also apply to 
DLB. Indeed, symptoms similar to those associated with non-convulsive seizures, such as staring spells and 
disorganized speech, can occur during the episodes of fluctuating consciousness often seen in DLB 
patients. These episodes make it particularly difficult to distinguish between epileptic and non-epileptic 
symptoms. Among the DLB cases we reviewed, 2 out of 5 patients with a diagnosed seizure disorder had 
only non-convulsive seizures and another 10 patients were suspected to have this type of seizure. Although 
we compared the incidence of myoclonus and seizures to the best reference populations we could find in 
the literature
461
, our relative rate calculations may be confounded by differences in racial and age 
distributions in the San Francisco Bay Area versus Rochester, Minnesota and Umeå, Sweden
453,454
. A 
prospective clinical study is needed to more accurately determine the incidence of seizures and myoclonus 
in DLB patients.  
We previously identified co-pathogenic interactions between A and SYN in hAPP/SYN doubly 
transgenic mice
332
 that may be relevant to the frequent co-occurrence of DLB and AD pathology
14,329,462
. 
Because clinical assessment alone cannot reliably detect the co-occurrence of these pathologies
14
, an 
obvious limitation of our study is the lack of autopsy confirmation of most cases we analyzed by chart 
review or EEG. However, spectral slowing has been documented in autopsy-confirmed cases of DLB
463
 
and was confirmed here with a different approach to spectral analysis. Furthermore, the reduction in 





SYN pathology is sufficient to cause aberrant network excitability. Again, a prospective study of DLB with 
imaging for AD pathology and/or autopsy confirmation is needed to further test this hypothesis.  
In conclusion, our analysis of experimental models clearly demonstrates that SYN accumulation 
causes both a shift in the EEG spectrum towards slower brain oscillations as well as aberrant network 
excitability. We also obtained evidence suggesting that the mechanisms underlying these network effects 
may be at least partly distinct. While treatments targeting SYN should block both types of network 
dysfunction, drugs with different modes of action may have to be combined in order to block divergent 
branches of the SYN-induced pathogenic cascade further downstream. Recent evidence suggests that the 
hyperactivation of specific neural networks may contribute to cognitive deficits in early stages of AD and 
that specific anti-epileptic drugs may be able to reverse synaptic, network and cognitive dysfunction in this 
condition and related models
442,456,464
. Although acute or chronic reduction in epileptiform activity in SYN 
mice did not affect their abnormal spectral distribution, it should be noted that the interventions used in this 
study achieved only a partial suppression of epileptiform activity in these mice. Additional studies are 
needed to further evaluate the interdependence between the different types of DLB-associated network 
dysfunctions and to determine the extents to which they contribute to the cognitive decline and behavioral 
































Tau and α-synuclein (SYN) are both critical proteins for the development of several common 
neurodegenerative diseases. Our studies provide further insights into the different functional roles of tau 
and SYN in these diseases. Genetic tau ablation, which is relatively benign by itself, reduces epileptiform 
activity and interrupts Aβ-induced pathogenic mechanisms, raising the possibility that Aβ converts tau into 
an active mediator of its pathogenic effects. Our studies suggest that abnormal tau modification by Aβ-
induced signaling pathways may not be required for tau to enable Aβ-induced adverse effects because tau 
was similarly modified at many sites in hAPP and wildtype mice. However, as we discuss below, the study 
of tau modifications was suggestive, rather than conclusive. Tau does not mediate oscillatory neural 
network abnormalities and motor impairment in SYN mice, though tau ablation tends to reduce epileptic 
activity in these mice consistent with its anti-epileptic effects. 
We were able to conclusively demonstrate that tau reduction is safe in aged tau knockout mice under 
normal conditions. Tau ablation had no effect on learning or memory, and caused mild weight gain and 
motor impairments that were indistinguishable from wildtype mice by 21 months of age. These mild 
impairments were not L-DOPA responsive, nor were they associated with loss of striatal dopamine, loss of 
tyrosine hydroxylase, or iron accumulation. In agreement with the first studies of aged tau knockout mice
97
, 
tau ablation is benign in the absence of iron accumulation. Tau reduction, which more closely models a 
therapeutic situation, caused no behavioral alterations whatsoever.  
We were unable to fully address whether altered tau modifications may contribute to impairments in 
the human amyloid precursor protein (hAPP) J20 model of AD. We mapped more than 63 endogenous tau 
modifications in hAPP and wildtype mice, but we could only compare 31 of these modifications in whole 
cortical and hippocampal lysate. These 31 modifications failed to show significant, consistent changes 
between genotypes. In the post-synaptic density, we compared 16 tau modifications between the two 
genotypes, which also failed to show significant changes. There were 5 modifications mapped only in 
hAPP mice, 4 of which were in the MRBD. Nearly half of all lysine methylation sites mapped (2/5) were 
found in the MRBD only in hAPP mice, suggesting that lysine methylation may be increased in hAPP 
mice. However, these modifications were low abundance, appeared rarely in our hAPP samples and were 





were truly specific to hAPP mice. Our data supports the hypothesis that tau mediates impairments in hAPP 
mice through its normal function, however, we cannot exclude that low abundance tau modifications are 
altered, or that tau modifications are altered at another age, in another cellular compartment, or that changes 
in tau localization can mediate impairments in hAPP mice. We were able to map many novel tau 
modifications on endogenous tau which should facilitate future studies of tau regulation. 
Tau did not mediate motor impairments or dopaminergic cell death in two mouse models of PD-like 
pathology. Tau ablation tended to worsen motor impairments and acute dopaminergic cell death induced by 
6-hydroxydopamine treatment, implying that tau may be required for the preservation of dopaminergic cell 
health in specific stressor conditions. Tau ablation had no effect on the motor impairments in a SYN 
transgenic model, implying that SYN does not require tau for some types of neural network dysfunction. 
The extent to which these findings generalize to other toxic models of dopaminergic cell death or other 
synucleinopathy models remains to be determined. However, our findings imply that tau-targeted therapies 
would not benefit motor impairments in synucleinopathy patients. 
In addition to motor impairments, SYN induces a left-shift in the spectral power of cortical oscillations 
and seizures in transgenic mice. DLB patients showed a similar left-shift in spectral power and calbindin 
reduction in the dentate gyrus, indicative of aberrant network excitability. This reduction occurred in the 
absence of significant AD pathology, though co-occurrence of DLB and AD pathology synergistically 
lowered calbindin in the dentate gyrus. Myoclonus, a clinical sign of aberrant network excitability, was 
present in nearly one quarter of DLB patients, however future studies with a higher proportion of autopsies 
or with imaging for AD pathology will be required to determine the degree of aberrant network excitability 
attributable to SYN pathology.  Aberrant network excitability in SYN mice could be reduced by acute 
administration of phenobarbital or tau ablation; neither intervention significantly altered the spectral power 
shift. Aberrant network excitability in hAPP mice was insufficient to cause a left shift in spectral power, 
which suggests, in combination with the previous results, that spectral power alterations are not caused by 
aberrant network excitability. While our suppression of epileptiform activity is similar to the 50% 
suppression of epileptiform activity required to rescue cognitive impairment in hAPP mice
442





that a reduction greater than 50% in SYN mice is required to alter spectral power. Future studies are needed 
to determine how SYN causes these two, potentially distinct, types of neural network dysfunction. 
After our publication in 2013, two other investigators published studies regarding the effects of tau 
reduction in aging mice. One study of tau knockout mice at 22-25 months of age confirmed the absence of 
cognitive or motor deficits, iron accumulation or loss of tyrosine hydroxylase (TH), while the mice retained 
the seizure resistance characteristic of younger tau knockout mice
349
. The second study found mild motor 
impairment and TH loss at 8-9 months of age, with cognitive impairments by 21 months of age
465
. 
Interestingly, TH-positive neurons did not die in motor-impaired tau knockout mice because TH staining in 
the substantia nigra could be restored by dietary supplementation of docosahexaenoic acid and α-lipoate 
starting at 14-15 months of age
465
. Some of the contradictory findings in tau knockout mice may be due to 
the differential susceptibility of tau knockout neurons to different types of stress. As we suggested earlier, 
dopaminergic neurons in tau knockout mice may be particularly susceptible to specific challenge 
conditions, which may include iron accumulation
107
, neuroinflammation or a high fat diet deficient in 
neuroprotective fish oils
465
. One caveat to the cognitive and dopaminergic impairments in tau knockout 
mice is that they have only been described when unrelated mice on the same genetic background were 
compared
107,465
, while littermate-controlled studies of aged tau knockout mice show normal cognition and 
no neuronal loss
107
 (Chapter 2). Future studies should determine whether neuroinflammation or cerebral 
iron accumulation can induce robust deficits in tau knockout mice compared to wildtype littermates. 
Notably, no behavioral deficits have been shown in tau hemizygous mice at any ages (Chapter 2) and tau 
reduction continues to confer resistance to PTZ-induced seizures at old ages
349
. The normal behavior of 
aged tau hemizygous mice suggests that tau reduction in aged humans may be safe, while the resistance to 
induced aberrant network excitability suggests that tau reduction may continue to be effective against an 
important mechanism of AD pathogenesis at older ages. 
Tau appears to be a specific mediator of AD and aberrant network excitability. Tau is phosphorylated 
in response to many different challenging conditions in vitro and in vivo, and is increased in many 
neurodegenerative conditions, including AD, PD, prion diseases and in glia in multiple sclerosis
466,467
 





premature mortality in models of AD and epilepsy
71,83,98,99,350







 and PD (Chapter 4) do not seem to benefit from tau 
reduction. Tau ablation tended to worsen acute motor impairment and dopaminergic cell loss in the 6-
hydroxydopamine model of PD (Chapter 4), and significantly worsened behavioral scores and spinal axon 
damage in the acute phase of an experimental autoimmune encephalomyelitis model of multiple 
sclerosis
467
. This confirms our hypothesis that tau reduction is not a general neuroprotective intervention, 
but interferes with specific pathways involved in aberrant network excitability. These findings also imply 
that tau may not be the primary mediator of cellular toxicity in PD, multiple sclerosis or prion diseases, 
even when hyperphosphorylated tau is present. It is possible that hyperphosphorylated tau requires a 
specific cellular environment or localization to confer toxicity, or that the hyperphosphorylated tau in PD, 
multiple sclerosis and prion diseases is not toxic. The modification and aggregation states which are 
required for tau to cause toxicity are not known. 
The numerous and varied endogenous tau post-translational modifications imply a multiplicity of 
highly regulated tau functions. We described a large number of modifications on endogenous tau, including 
the largely unexamined arginine methylation. This recently discovered
353
 type of tau modification has no 
known competing arginine modifications and clusters in the N-terminal projection domain of tau, which 
presents an exciting opportunity to discover novel mechanisms of tau regulation. Future studies using 
immunohistochemistry and mass spectrometry should determine whether arginine methylation alters the 
subcellular localization of tau or the affinity of tau for Fyn, tubulin, actin and other binding partners.
 
Endogenous tau modification in the MRBD may create a small pool of tau not bound to microtubules. 
Tau phosphorylation and acetylation in the MBRD can prevent the binding of tau to microtubules
24,383
 and 
were found on a fraction of endogenous tau in our study. MRBD modification may serve to direct a portion 
of tau to other locations or functions in the cell. For example, phosphorylation of S262 in the MBRD 
prevents tau from binding to microtubules
383
 but is necessary for proper neurite extension
384
, suggesting 
that S262 phosphorylation directs tau away from microtubules into a signaling pathway for neurite 
extension. We speculate that tau pathology in disease may emerge from such non-microtubule-bound tau, 





Future studies are needed to dissect the role of tau and tau modifications in aberrant network 
excitability. Tau facilitates genetically- and chemically-induced epileptic activity
71,111,350
 (Chapter 5). As 
tau modifications may play a role in the impairments of hAPP transgenic mice, tau modifications may also 
play a role in the facilitation of epileptic activity, regardless of whether chronic epileptic activity alters tau 
modifications. Dynamic changes in tau phosphorylation are observed after acute induction of seizures by 
kainic acid injection; tau phosphorylation is reduced within 6 hours after injection, then elevated 10-48 
hours after injection
468
. Whether acute epileptic activity changes other tau modifications is not known. The 
tau modification state in chronic epileptic models is also unclear, however, the similar modification levels 
of hAPP and wildtype tau would indicate the chronic epilepsy may not alter tau modifications. Determining 
which tau modifications are required for aberrant excitatory activity may provide alternate therapeutic 
strategies for the treatment of epilepsy and AD.  
Tau ablation did tend to reduce epileptic activity and the associated hippocampal remodeling in SYN 
mice without affecting motor deficits or spectral alterations. The mechanisms by which SYN produces 
these diverse types of network dysfunction remain unclear. While SYN-induced seizures may seem 
inconsistent with the notion that SYN decreases pre-synaptic release, it is possible that specific populations 
of interneurons may be preferentially affected by SYN or that a chronic, widespread decrease in pre-
synaptic release causes compensatory remodeling resulting in aberrant network excitability. Future studies 
using depth electrode recordings in awake, behaving SYN mice are necessary to determine the brain 
regions involved in generating SYN-induced epileptic activity. 
The mechanism of SYN-induced spectral dysfunction (Chapter 5) is obscure. There are few 
mechanistic studies examining cortical brain oscillations in rodents. Lesions of the nucleus basalis of 
Meynert and cannabinoid treatment both simulate aspects of the oscillatory changes in SYN mice but both 
change the total power of the EEG signal, which is not altered in SYN mice. Lesion of the nucleus basalis, 
which drastically reduces cortical cholinergic innervation, increases delta and theta power and lowers beta 
power in rats, but it also appears to raise the total EEG power
445
. Widespread reduction of pre-synaptic 
release by cannabinoid injection lowers the power of high frequency oscillations, but it also lowers the total 
EEG power
434





spectral alterations in SYN mice. We speculate that SYN could decrease cortical presynaptic release, 
thereby reducing the power of high frequency oscillations, and release the suppression of delta power 
during wakefulness by decreasing pre-synaptic release in another brain region, possibly the thalamus. A 
less likely scenario is that SYN mice lose coordination of neuronal firing at high frequencies without 
altering basal release, which could preserve total oscillatory power but decrease high frequency 
oscillations. Or SYN could cause spectral alterations through a completely different mechanism altogether. 
In addition to determining the mechanism of spectral alterations, the relative contributions of spectral 
dysfunction and epileptiform activity on cognitive and motor abnormalities should also be examined. 
In conclusion, we propose the following model for SYN, tau and Aβ interactions in neurodegenerative 
disease (Figure 6.1). SYN and Aβ can both cause neural network dysfunction and, when acting on the same 
network, can synergize to increase aberrant network excitability in humans. Aβ acts through tau to induce 
neural network dysfunction without necessarily altering the basal modifications of tau, while SYN-induced 
spectral and motor dysfunction is independent of tau. Further studies are required to determine whether 
interfering with network excitability improves cognition in the setting of SYN pathology.  
Tau lowering is a promising therapeutic strategy for aberrant network excitability in human epilepsy 
and AD. Our studies and others
111,349
 indicate that partial reduction of tau is likely to be safe in adults and 
the elderly population. Our studies also suggest that tau lowering may be more effective than targeting 
abnormal tau phosphorylation or aggregation because deficits in hAPP mice are mediated by monomeric 
tau with no detectable changes in phosphorylation. Tau lowering would specifically target aberrant network 
excitability, but would not be effective against most SYN-induced neural network dysfunction. Given the 
high prevalence of SYN pathology in AD
329
 and AD pathology in Lewy body dementia
14
, many dementia 









Figure 6.1. Model of pathologic interactions between Aβ, α-synuclein and tau in neurodegenerative 
disease. We propose the following model of neurodegeneration: Aβ causes neural network dysfunction 
through tau without altering tau modifications, and α-synuclein (SYN) causes motor and spectral 
















Chart review and analysis of clinical data 
We searched the electronic database of the UCSF Memory and Aging Center  for patients who were seen 
between 2007–2012, who met McKeith criteria
330
 for DLB on their latest evaluation during that period, and 
who had a clinical diagnosis of DLB (n=178) (Figure A.1). Of these, 16 DLB patients were removed 
because the records were incomplete. We searched the remaining patient records for seizures, epilepsy, 
myoclonus, head trauma, and fluctuations using the word stems “seiz-“, “spells”, “epil-“, “eeg”, “myo-“, 
“head”, and “fluc-”. A seizure disorder, aka epilepsy, was defined as two or more unprovoked seizures or 
one unprovoked seizure with EEG evidence of epileptiform activity
469
. We excluded patients who had a 
seizure but who did not meet the criteria for a seizure disorder (n=1) or who had other seizure risk factors, 
including urinary tract infection with a fever (n=1), normal pressure hydrocephalus with a shunt and fever 
(n=1), and stroke (n=1). Among the remaining 158 DLB patients, 5 (3.2%) patients met the criteria for a 
seizure disorder and 34 (21.5%) patients were noted to have myoclonus. In 12 (7.6%) patients without the 
diagnosis of a seizure disorder EEGs had been obtained for suspected seizures. None of the patients with a 
seizure disorder, but one patient with myoclonus, had a history of mild head trauma with loss of 
consciousness for several minutes. A mixed effects linear model was fit to age of onset of cognitive 
impairment with sex, education, handedness, fluctuations, seizure disorder and myoclonus as independent 
variables. The presence versus absence of a clinical history of fluctuations, a seizure disorder, or 
myoclonus was quantified using 1 or 0, respectively. Reported p-values were derived from the mixed 
effects linear model including all variables. Significance was retained in a mixed effects linear model of 
age of onset of cognitive impairment using only sex (p=0.002) and myoclonus (p=0.009) as independent 
variables. 
Incidence rates for myoclonus and a first unprovoked seizure (FUS) were calculated separately using 6 
person-years per DLB patient in the study (Figure A.1). Fourteen patients with myoclonus and 2 patients 
with FUS prior to 2007 were excluded from the respective incidence calculations. Two patients who were 
unaffected during the incidence study period (2007–2012) developed myoclonus in 2013. There were 18 
new cases of myoclonus and 3 new cases of FUS in our population between 2007 and 2012. As onset of 
myoclonus was not usually noted in the clinical history, the time of onset of myoclonus was estimated 





+2 years relative to diagnosis, range –5 to +9) and seizure (median: –1 year relative to diagnosis, range –4 
to +1) incidence tended to occur near the diagnosis of dementia. Therefore, the age of dementia diagnosis 
was used to stratify the DLB population without myoclonus or seizures. Relative rates and confidence 
intervals were calculated according to published formulas
470
.  
Twelve DLB cases came to autopsy. The likelihood that clinical dementia was caused by Lewy body 
pathology seen on autopsy was estimated using McKeith criteria
330
. The presence of neocortical DLB was 
either directly stated by the pathologist (n=9) or inferred from the distribution of Lewy body pathology 
(n=2). The presence of AD pathology was based on autopsy summary statements and NIA-Reagan 
criteria
471
. Because NIA-Reagan criteria require complete concordance between Braak and CERAD 
staging, two cases were not classifiable by these criteria: both cases had frequent plaques but a Braak stage 
below 5. In these cases, Braak stage was used as a surrogate to estimate the relative likelihood that 
dementia resulted from Lewy body pathology by McKeith criteria. All studies in human subjects were 
approved by the Committee on Human Research of the University of California, San Francisco. All human 
research subjects provided written informed consent before participating in protocols from which data were 
derived and were not required to re-consent for this analysis. 
EEG recordings in human subjects 
EEG recordings were obtained using an international 10–20 electrode placement. Participants were placed 
in the recumbent position with eyes closed and resting-state EEG activity was recorded for 50 min. One 
minute from the initial 20 min of recording, during which all subjects were awake, was used for analysis.  
Human tissues 
Human postmortem brain samples were obtained from the brain bank of the University of California at San 
Diego (UCSD) and the New York Brain Bank (NYBB) at Columbia University. The dentate gyrus was 
isolated over dry ice from larger tissue blocks. Calbindin mRNA levels, normalized to 18S RNA levels in 







RNA isolation and RT-qPCR analysis 
Frozen tissue (approximately half of the dissected dentate gyrus) was homogenized for 20 s in 500 µL of 
TRIzol reagent at 20,000–21,000 rpm (Polytron homogenizer) and incubated on ice for 5 min. Samples 
were then mixed with 100 µL chloroform, incubated briefly on ice, and centrifuged in heavy phase lock gel 
tubes at 12,000 x g and 4°C for 5 min. The supernatant was mixed with 250 µL isopropanol, incubated for 
10 min at room temperature, and centrifuged at 12,000 x g and 4°C for 10 min. The pellet was re-
suspended in 75% ethanol and briefly spun at 7,500 x g at 4°C. The resulting pellet was then dissolved in 
100 µL of water and incubated at 56°C for 10 min, followed by addition of 350 µL RLT buffer from the 
RNeasy Mini Kit (Qiagen) and 250 µL ethanol. The RNA was further purified using the RNeasy Mini Kit 
following the “On-column DNase digestion” protocol using 30 µL water for final elution. RNA 
concentration was measured by Nanodrop (ND-1000, Thermo Scientific). RNA integrity was determined 
on a 2100 Bioanalyzer (Aglient) according to the manufacturer’s instructions. All RNA samples were 
diluted to the same concentration and reverse transcribed with oligo-dTs and random hexamers according 
to the manufacturer’s instructions (TaqMan® Reverse Transcription Reagents, Applied Biosystems). 
Negative controls were generated by combining several samples and running RT-qPCR without reverse 
transcriptase. qPCR was carried out with SYBR green (SYBR green PCR Master Mix, Applied 
Biosystems) on a 7900HT Fast Real-Time PCR System (Applied Biosystems). To ensure that RNA quality 
was sufficient for RT-qPCR measurements, only samples with an RNA integrity number greater than 4.0 
were analyzed. RNA integrity was not significantly different between groups by one-way ANOVA (data 
not shown). The experimenter was blinded to the pathological diagnosis of human cases. 
Mice and mouse tissues 
Detailed lists of the mouse cohorts used in this manuscript are found in Appendix B. For most experiments 
in this study, we used mice expressing human wildtype α-synuclein (Thy1-SYN line 61
436
), human amyloid 
precursor protein with Swedish and Indiana mutations (PDGF-hAPP line J20
347
), or mice lacking 
endogenous tau
73
 on a pure C57Bl/6J background, as specified in the text. Heterozygous transgenic mice 
















 backgrounds. EEG studies on Thy1-SYN mice revealed 
similar levels of epileptiform activity and spectral alterations on both backgrounds (data not shown).  For 
all experiments involving Thy1-SYN mice, only male mice were used because the SYN transgene in line 
61 is located on the X-chromosome
272
. Food (Picolab Rodent Diet 20) and water were given ad libitum and 
mice were kept on a standard 12-h light/dark cycle. At the end of experiments, mice were deeply 
anesthetized with Avertin (2.5% w/v in 2.5% tert-amyl alcohol/phosphate-buffered saline) and killed by 
transcardial perfusion with saline. Usually, one hemibrain was fixed in 4% paraformaldehyde (from 32% 
solution, Electron Microscopy Services, PA) in phosphate buffer (pH 7.4) and one hemibrain was frozen on 
dry ice. For 6-OHDA experiments, both hemibrains were fixed. Sections from PDGF-SYN mice (line 
D
436
) were a gift from Dr. Eliezer Masliah (Departments of Neuroscience and Pathology, University of 
California at San Diego). All experiments were approved by the Institutional Animal Care and Use 
Committee of the University of California, San Francisco. 
Chemicals 
Phosphatase inhibitor cocktails 1 or 3, and 2 (100X, Sigma) and protease inhibitor tablets (cOmplete, 
EDTA-free and cOmplete-mini, EDTA-free; Roche) were used interchangeably with Halt protease and 
phosphatase inhibitor cocktails (Thermo Scientific); all were used at 1X according to the manufacturers’ 
instructions. Thiamet G (4390, Tocris) was used in a range of concentrations, as specified. Trichostatin A 
([R-(E,E)]-7-[4-(Dimethylamino)phenyl]-N-hydroxy-4,6-dimethyl-7-oxo-2,4-heptadienamide, Sigma) and 
niacinamide (pyridine-3-carboxylic acid amide, Sigma) were used at a concentration of 3 µM and 10 mM, 
respectively. Other chemical reagents used were: ketamine HCl (Bionichepharma), medetomidine 
(dexdomitor, Henry Schein), perchloric acid (Fisher), methanol (Fisher), 4-(2-hydroxyethyl)piperazine-1-
ethanesulfonic acid (HEPES, Sigma), sodium chloride (5M solution, Cellgrow), sodium dodecyl sulfate 
(SDS from 10% solution, Teknova), TritonX-100 (Sigma), sodium deoxycholate (Sigma), avertin prepared 
from 99% purity tribromoethanol (A18706, Alfa Aesar), tert-amyl alcohol (Aldrich), 6-hydroxydopamine 
(Sigma), L-DOPA (Sigma), benserazide HCl (Sigma), phenobarbital sodium (5-ethyl-5-phenyl-2,4,6-
trioxohexahydropyrimidine sodium salt, P5178, Sigma), paraformaldehyde diluted from 32% solution 





(Fisher), ethylene glycol (Fisher), phosphate-buffered saline diluted from 10X stock solution (Mediatech, 
Inc., VA), and donepezil hydrochloride (4385, Tocris). The PC-PEG-biotin alkyne was synthesized by Dr. 
Wang using the published protocols
244
 and all other reagents for chemical/enzymatic tagging of O-GlcNAc 
modifications were purchased from Sigma. All reagents for peptide digestions were purchased from Sigma, 
except proteomic grade trypsin (Promega) and AspN (Roche). 
Hypothermia Induction 
Mice were injected intraperitoneally with ketamine HCl (75 mg/kg) and medetomidine (1 mg/kg), or with 
saline as a negative control, and returned to their home cage for 1 hour before analysis. Mice were killed by 
cervical dislocation and their brain tissues were immediately frozen on dry ice.  
6-OHDA injection 
Mice were anesthetized, placed in a stereotaxic device and injected with either 2 µl containing 4 µg of 6-
OHDA (Sigma, MO) in a solution of 2% L-ascorbic acid (Sigma, MO) in saline or the ascorbic acid-saline 
solution alone (vehicle). A single injection was performed in the striatum at the following coordinates 
relative to bregma: anterior-posterior = +0.4, medial-lateral = +2.0, dorsal-ventral = -3.3. Injections were 
made at a rate of 0.5 µl/min with a 10-µl syringe (Hamilton Company USA, NV). Behavioral testing for 
acute effects of 6-OHDA began on the third day after injection and was completed within seven days. 
Behavioral testing to assess recovery began 24 days after the injection and was also completed within seven 
days. 
EEG recordings in mice 
Lightweight EEG plugs were constructed in-house by soldering four Teflon-coated silver wires (0.125mm 
diameter) to a multichannel electrical connector. These plugs were surgically implanted into avertin-
anesthetized mice, placing the silver wire leads into the subdural space. Reference leads were placed 
approximately 1 mm posterior and ±1 mm mediolateral to bregma, and recording leads approximately 1 
mm anterior and ±2 mm mediolateral to lambda. Mice were allowed at least one week to recover from 





5.0b software (Stellate), with one of the rostral leads serving as the reference electrode. For experiments 
shown in Figure 5.4B-C, phenobarbital sodium (0.5 mg/mL in sterile saline) was injected i.p. after four or 
more hours of baseline recording. For experiments shown in Figure 5.4I, donepezil hydrochloride (0.1 
mg/mL in sterile saline) was injected i.p. every morning for 14 days; recording began immediately after the 
last injection. 
Spectral analysis 
For spectral analysis in humans, 60 s artifact-free EEG segments from the PZ electrode were selected 
manually. In two subjects (1 control and 1 DLB patient), who had no artifact-free periods, a recording 
segment with minimal artifacts was selected.  
For spectral analysis in mice, 20–140 s EEG segments were selected during daytime resting behavior; 
the exact segment length depended on the time mice displayed resting behavior. Resting behavior was 
defined as lack of movement in the absence of EEG patterns suggestive of sleep entry such as sinusoidal 
changes in EEG amplitudes in the 5–15 Hz range. This approach does not exclude the possibility that some 
time points analyzed occurred during early sleep. Spectral analysis in phenobarbital- or donepezil-treated 
mice was conducted during the period of spike reduction or 3–4 hours
472
 after the drug injection, 
respectively. EEG recordings were evaluated by a reader blinded to the Tau genotype. However, blinding 
to SYN genotype was not possible because of the epileptiform activity associated with this genotype. 
Selected segments were converted into European Data Format files and imported into LabChart 7 Pro 
(AD Instruments) for spectral analysis. A 60-Hz notch filter was applied to all cases in which an electrical 
artifact was observed. Spectral power was obtained by subjecting the recordings to a fast Fourier transform 
(FFT) using a Hann cosine-bell window with no overlap between windows. Using the EEG sampling rate, 
we calculated the FFT size necessary for a resolution of 0.5 Hz and selected the nearest higher FFT size 
available in LabChart. Human EEGs were recorded at a 600-Hz sampling rate and FFT was performed with 
a 2048 point FFT size to obtain a resolution of 0.29 Hz. Mouse EEGs were recorded at a 200-Hz sampling 
rate and FFT was performed with a 512 point FFT size to obtain a resolution of 0.39 Hz. Spectrogram text 
files were analyzed in Excel by removing time points containing movement or epileptiform activity and 





the total averaged power to obtain relative spectral power. Relative power cumulative distribution functions 
(CDF) were obtained using the integral function in Prism (GraphPad). 
For frequency band analysis in chapter 5, selected segments were exported as a text file and spectral 
power was obtained using a custom-written Matlab script and an FFT size of 1000 points to obtain data at 
5-s intervals
443
. Spectral frequency bands were defined as follows: delta 0.5–4 Hz, theta 4–10 Hz, alpha 10–
13 Hz, beta 13–20 Hz, and gamma 20.1–99.9 Hz. The EEG signal during resting behavior in was analyzed 
over time in each frequency band using a repeated measures mixed model analysis with a Holm p-value 
correction for multiple comparisons.  
Analysis of epileptiform activity 
Epileptiform activity was detected with the Gotman spike detector set to threshold 8 (Harmonie, Stellate). 
Events marked as epileptiform that coincided with large or sudden movements, such as rapid turns, 
grooming, digging and eating, were removed as possible artifacts. Myoclonic jerks, defined as epileptiform 
activity accompanied by sudden abnormal movements in an otherwise motionless mouse, were not 
excluded. Baseline epileptiform activity was quantified during 12–16 h of EEG recordings (50% during 
light cycle, 50% during dark cycle), excluding the first hour of recording and the first half hour after the 
change in light condition. Drug effects were assessed by comparing the extent of epileptiform activity 
during the 2 h preceding and 2.5 h following the injection, excluding from analysis the first half hour after 
the injection.  
Behavioral testing 
Unless specified otherwise, mice were acclimated to the testing room for at least one hour before testing. 
All testing apparatuses were cleaned with 70% ethanol between mice, unless otherwise indicated, and with 
10% bleach after each testing day. Open field, pole and balance beam tests were carried out as described
345
. 







Morris water maze 
Spatial learning and memory was assessed as described
473
 in a Morris water maze consisting of a pool (120 
cm in diameter) of water made opaque with white, non-toxic tempura paint. Water temperature was held at 
20±1°C. Extra maze cues were posted on the walls of the testing room. Data were acquired with Ethovision 
XT (Noldus Information Technology, the Netherlands).  
Pre-training: Before hidden platform training, mice were exposed to the water maze by having them swim 
down a rectangular channel for 4 trials. The hidden escape platform was placed in the middle of the 
channel. If a mouse was unable to find and mount the platform for 60 s, it was guided to it and allowed to 
sit on it for up to 10 s.  
Hidden platform training: Following pre-training, mice were trained for 5 days to locate a hidden platform 
(10x10 cm) submerged 1.5 cm below the water surface. The platform location was fixed, while the mouse 
drop locations were changed between trials. Mice were trained in four sessions per day with 3 hours of rest 
between sessions. Each session consisted of two trials with inter-trial intervals of approximately 15 min. 
Trials were terminated after 60 s. If a mouse did not find the platform within this time period, it was gently 
guided to the platform and allowed to sit on it for 15 s. Latency to locate the platform, as well as distance to 
the platform and swim speeds were recorded for the subsequent data analysis.  
Probe trials: Twenty four hours after the last hidden platform training, the platform was removed and mice 
were allowed to swim in the pool for 60 s. The drop location was opposite to where the platform used to be 
during hidden platform training. The percentage of time mice spent in the target quadrant and the number 
of times they crossed the original platform location were recorded.  
Novel object recognition (NOR) 
On two consecutive days, mice were placed into a Plexiglas chamber (20x20 cm) containing two identical 
objects and allowed to explore for 10 min. Forty-eight hours after training, mice were tested in the same 





object was recorded. The novel object position alternated between mice to eliminate any possible right-left 
bias. Objects were cleaned with 70% ethanol between each mouse.  
Open field 
Spontaneous movements in the open field were assessed using a Flex-Field/Open Field Photobeam Activity 
System (San Diego Instruments, CA). Each mouse was placed in the center of a clear plastic chamber 
(41x41x30 cm) with two 16x16 photobeam arrays and allowed to explore for 15 min. Movements were 
recorded through the number of beam breaks and rearing was determined by beam breaks on the higher of 
the two arrays.  
Rota rod 
Five mice were placed on the Rota Rod (Med Associates Inc, VT) for simultaneous testing and the 
computer recorded photobeam interruption when mice fell off the rotating rod. Photobeams were 
interrupted by the tester if the mouse held onto the rod without walking for three full rotations. Each mouse 
was given three trials with a maximum time on the Rota Rod of 300 seconds and with a 10-min rest 
between trials. The mice were first trained on the Rota Rod at a constant speed of 16 rpm. For the next two 
days they were trained on the Rota Rod in the morning and afternoon at an accelerating speed of 4 rpm to 
40 rpm over 300 s. The average latency to fall off the Rota Rod was analyzed on the afternoon of day 2 for 
SYN Tau
–/–
 cohorts and on the afternoon of day 3 for older Tau
–/–
 mouse cohorts.  
Pole test 
The pole consisted of a thin wooden dowel and a cross-shaped wooden base placed in a clean cage. Rubber 
bands were wrapped around the dowel at intervals of approximately 1.5 inches to increase traction. Mice 
were placed at the top of the pole facing downwards and latency to descend the pole was measured. Trials 
were excluded if the mouse jumped or slid down the pole rather than climbed down. On the first day, mice 
were trained in two trials with approximately 10 min of rest between trials. On the second day, they were 
given five trials and the shortest latency to descend the pole was analyzed. The pole was cleaned with 70% 





Pole test with 3,4-dihydroxyphenylalanine (L-DOPA)/benserazide treatments 
Acute treatment with L-DOPA/benserazide was designed as a cross-over trial. On day 1, mice were trained 
twice on the pole without injection. On day 2, mice were given an intraperitoneal (i.p.) injection of saline or 
of L-DOPA (20 mg/kg) and benserazide HCl (5 mg/kg) (Sigma) in saline. The mice were then transferred 
to the testing room and, 30 min later, given five pole test trials. On day 3, treatments were reversed, so that 
mice injected with saline on day 2 now received L-DOPA/benserazide and vice versa. Mice were then 
transferred to the testing room and tested as on day 2.  
The same cohort of mice was used to assess the effect of chronic L-DOPA/benserazide treatment. 
Three days after finishing the acute treatments, mice were given five trials on the pole test to assess their 
performance before chronic drug treatment. They were then given water bottles containing L-DOPA (200 
mg/L) and benserazide (50 mg/L) in 0.2% ascorbic acid (Sigma) as described
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. The bottles were changed 
daily and fluid/drug intake per cage of group-housed mice was monitored daily. The average weight of 
each mouse was calculated from measurements obtained at the beginning and end of the treatment. For 
each cage, the average daily drug intake was divided by the total weight of mice in the cage to estimate 
their approximate daily dose in mg of drug per kg of body weight. On the seventh day of chronic treatment, 
mice were given five trials in the pole test. Half of the mice were sacrificed the day after the last pole test. 
The remaining mice were placed on normal drinking water to allow for drug washout and sacrificed six 
days later. 
Gait analysis 
Gait analysis was done using the DigiGait software and treadmill (Mouse Specifics, Inc., MA). Mice were 
placed on the treadmill and the belt speed was set at a constant pace of 15 cm/s. Mice were allowed to walk 
for several seconds until a regular gaiting pattern was observed; 4-5 s of gait video were then recorded. 
Mice were excluded if a regular gait pattern could not be recorded. Variable thresholds were set on the 
DigiGait software to allow the computer to identify and analyze the mouse paws from the recorded video 





corresponded to actual paw placement. Any data that consistently misidentified paw placement on the belt 
was excluded from analysis. 
Hind limb clasp 
The hind limb clasp test was performed as described
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. Each mouse was lifted by the tail and slowly 
lowered toward a surface for 10 s. The hind limbs were observed and each mouse was given a score for 
each trial. A score of 0 indicated that the hind limbs were extended for >50% of the trial period, a score of 
1 indicated that one hind limb was retracted for >50% of the trial period, a score of 2 indicated that both 
hind limbs were partially retracted for >50% of the trial period, and a score of 3 indicated that both hind 
limbs were fully retracted and touching the abdomen for >50% of the trial period. Each mouse was tested 
three times and the scores were analyzed as described in the statistics section. 
Balance beam 
The balance beam consisted of two platforms connected by a removable plastic beam leading to an opaque 
box on top of one platform. On the first day, mice were trained on a thick, round beam by placing them first 
a few inches from the box and leading them into the box, and then by placing them halfway across the 
beam and leading them into the box, if leading was required. The mice were then trained three times across 
the whole length of the beam with approximately 10 min rest periods between trials. On the second day, 
mice were again trained three times on the thick beam. On the third day, the thick beam was replaced with 
a thin, square beam and the mice were tested three times. The average latency to cross the thin beam and 
the average number of times a foot slipped while crossing the beam during the testing sessions were 
analyzed. A trial was excluded from analysis if the mouse dragged its hind limbs across the beam for >50% 
of the distance. At 21-22 months of age, mice of all genotypes were unable to walk across the thin balance 
beam. 
Preparation of tau- and O-GlcNAc-enriched peptides from rat brain tissue 
Rat brain (3.4 g) was homogenized in 12.5 ml of ice-cold 1% perchloric acid (Polytron homogenizer, Glen 





for 20 min. The supernatant was passed through a 1-µm filter and concentrated with a 10-kDa molecular 
mass cutoff membrane with simultaneous buffer exchange to 10 mM HEPES, pH 7.5. The proteins (1.9 
mg) were fractionated on a Superose 12 PC 3.2/30 gel filtration column (GE Healthcare) by using a buffer 
containing 20 mM HEPES and 50 mM NaCl, pH 7.5 and tau-containing fractions were combined. The total 
protein amount was estimated by UV absorbance at 280 nm. An aliquot of this material (about 1.3 µg) was 
digested with trypsin (50:1 substrate/enzyme) in 100 mM ammonium bicarbonate, pH 8 overnight at 37 °C. 
Trypsin was removed with a 10-kDa molecular mass cutoff membrane (Millipore, Billerica, MA). Solvent 
was removed under vacuum, and the residue was then resuspended in 120 µl of 10 mM HEPES, pH 7.9 
containing 5 mM MnCl2, UDP-N-azidoacetylgalactosamine (UDP-GalNAz), and 10 units of GalT1 
(Invitrogen). The reaction mixture was incubated overnight at 4 °C, treated with 10 units calf intestine 
phosphatase (New England Biolabs, Ipswich, MA), incubated for an additional 2 h at room temperature, 
and then passed through a C18 spin column (Nest Group, Southborough, MA). UDP-GalNAz and the 
modified peptides were eluted in 0.1% TFA, 1% acetonitrile and 0.1% TFA, 80% acetonitrile, respectively. 
The solvent was removed under vacuum, and the sample was reconstituted in 20 µl solution containing 
0.05µmol of PC-PEG-biotin-alkyne, 10 mM sodium ascorbate, 1 mM tris[(1-benzyl-1H-1,2,3-triazol-4-yl) 
methyl]amine (in 4:1 t-butanol:DMSO), and 2 mM CuSO4. The reaction mixture was incubated overnight 
at room temperature with gentle agitation. To remove excess PC-PEG-biotin-alkyne, the sample was 
diluted into strong cation exchange (SCX) loading buffer (5 mM KH2PO4, 25% acetonitrile, pH 3.0) and 
then passed through an SCX spin column (Nest Group). The column was washed with several column 
volumes of loading buffer, and the retained peptides were eluted with high salt buffer (5 mM KH2PO4, 400 
mM KCl, 25% acetonitrile, pH 3.0). The eluent was adjusted to pH 7 with ammonium hydroxide and then 
allowed to interact with high capacity avidin beads (Pierce) for 2 h at room temperature. Avidin beads were 
washed 10 times with PBS solution and twice with 20% methanol/water and resuspended in 70% 
methanol/water. The suspension was transferred to a thin walled PCR tube, irradiated with 365 nm UV 
light (2 milliwatts/cm2) (Spectroline ENF-240C, Westbury, NY) for 25 min at a distance of 10 cm with 
rotation, and the supernatant was then dried under vacuum and stored at -20 °C. The overall process is 








Perchloric acid enrichment of mouse tissue 
Mouse hippocampus and cortex were isolated over ice and homogenized in 1% perchloric acid
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. The 
suspension was incubated for 20 min on ice and then spun at 20,000xg at 4°C for 30 min. The supernatant 
was neutralized with NaOH and 1 M Tris (pH 7.4), phosphatase inhibitors and 25 µM Thiamet G were 
added, and the solution was concentrated over a 10-kDa MW filter (Vivaspin 20, Vivaproducts; Ultrafree, 
Millipore). For large-scale lectin weak affinity chromatography (LWAC) preparations, 10–14 hemibrains 
were combined from 8–10 mice. For the first quantitative experiment (Figure 3.3) wildtype mice were 
selected randomly, while the three most hyperactive hAPP mice were selected from a total of seven hAPP 
mice based on their behavior in the open field test. 
Whole lysate preparation for immunoprecipitation 
Mouse cortex and hippocampus were isolated on ice, then homogenized in Thermo IP Lysis buffer 
containing 25 µM Thiamet G and protease and phosphatase inhibitors. Trichostatin A and niacinamide 
were also added to the buffer for Chapter 3 quantitative experiments. The lysates were sonicated (Episonic 
multi-functional bioprocessor 1000, Epigentek Group Inc.) at an amplitude of 40% on ice twice for 5 min 
and spun for 10 min at 10,000xg at 4°C. The supernatant was collected and the protein concentration was 
measured by Bradford (Bio-Rad) assay according to the manufacturer’s instructions. 
Post-synaptic density preparation 
Combined hippocampus and cortex from one whole mouse brain was homogenized with a Dounce 
homogenizer in 1 mL of buffer A (40 mM Tris-acetate (pH 7.5), 10 mM niacinamide, 3 µM trichostatin A, 
1 µM Thiamet G, 0.3 M sucrose, and phosphatase and protease inhibitors. The suspension was transferred 
to a centrifuge tube, washed with an additional 1 mL of buffer A, and spun at 850xg (IEC CENTRA 
GP&R, rotor 216) at 4°C for 20 min. The supernatant was collected and stored on ice while the pellet was 
re-suspended in 2 mL buffer A and spun again. The resulting supernatant was combined with the first and 
50 µL was retained as the cytosolic/membrane fraction. 8 mL of 40 mM Tris-acetate buffer were layered on 
top of the combined supernatants and then spun at 17,000xg (SW41 Ti rotor) at 4°C for 25 min. This 





µL set aside for the membrane fraction, and loaded onto a sucrose density gradient consisting of 2.2 mL 
each of buffer A containing 1.2 M, 1.0 M or 0.8 M sucrose. 4 mL of 40 mM Tris-acetate buffer were added 
to the top and the samples were spun at 85,000xg (SW41 Ti rotor) at 4°C for 2 hours. The white layer at the 
1.0 M/1.2 M sucrose interface were collected, re-suspended in 10–11 mL buffer A and spun at 85,000xg 
(SW41 Ti rotor) at 4°C for 30 min. The pellet was kept at -80°C overnight. The thawed pellet was then re-
suspended using a 26-gauge needle in buffer B (10 mM Bicine-Tris (pH 7.5), 10 mM niacinamide, 3 µM 
trichostatin A, 1 µM Thiamet G, 5% N-octylglucoside, and phosphatase and protease inhibitors, and 50 µL 
was set aside for the synaptosomal fraction. The remaining suspension was loaded onto a sucrose gradient 
consisting of 3 mL each of buffer B/1% N-octylglucoside containing 2.2 M, 1.4 M or 1.0 M sucrose. 
Trichostatin A and niacinamide were used for PSD preparation only in the second and third quantitative 
PSD experiments in Chapter 3.  Samples were spun at 85,000xg (SW41 Ti rotor) at 4°C for 2 hours and the 
top layer was collected for the non-PSD fraction. The translucent white layer at the 1.4 M/2.2 M sucrose 
interface was collected, resuspended in 12 mL of 10 mM Bicine-Tris (pH 7.5) and spun again at 85,000xg 
(SW41 Ti rotor) at 4°C for 2 hours. The pellet was stored at -80°C until immunoprecipitation. The pellet 
was resuspended in 35 µL of PSD buffer (20 mM HEPES, 5 mM sodium chloride, 1% TritonX-100, 1% 
SDS, 1% sodium deoxycholate, 25 µM Thiamet G, 3µM trichostatin A, 10mM niacinamide, and 
phosphatase inhibitors), then either used for western blotting or tau immunoprecipitation. Samples for 
immunoprecipitation were diluted with 565 µL of IP lysis buffer (Pierce Crosslink IP kit) containing 25 
µM Thiamet G, 3 µM trichostatin A, 10 mM niacinamide, and protease and phosphatase inhibitors. In the 
final quantitative PSD experiment (Chapter 3), tau was enriched prior to immunoprecipitation by heating 
the 600 µL solution at 95°C for 10 min, incubating on ice for 5–10 min, and spinning the sample at 
20,817xg at 4°C for 30 min, and collecting the supernatant. 
Tau immunoprecipitation 
Tau was immunoprecipitated from brain whole lysate or PSD using BSA- and azide-free tau5 antibody 
(Abcam, ab80579) and a cross-link immunoprecipitation kit (Thermo-Pierce) following the manufacturer’s 
instructions. Columns were used up to twice without noticeable loss of immunoprecipitation efficiency and 





For experiments using in-gel trypsin digestion of proteins prior to mass spectrometry, the 
immunoprecipitated proteins were run on a 4–12% bis-tris gel and stained with SafeStain (Life 
Technologies). A broad band around 50 kDa was then cut out for mass spectrometry analysis. For 
experiments using in-solution trypsin digestion prior to mass spectrometry, immunoprecipitated samples 
were neutralized with 1 M Tris (pH 9.6) containing 25 µM Thiamet G and phosphatase inhibitors; 3 µM 
trichostatin A and 10 mM niacinamide were also added for quantitative experiments. During the initial 
assignment of tau modifications, we used 1 mg whole lysate from cortex and hippocampus and 30 µg of 
tau5. For quantitative immunoprecipitation experiments, we used 215 µg of whole lysate from cortex and 
hippocampus or the entire PSD fraction from one mouse (approximately 215 µg), and 10–20 µg of tau5 
antibody.  
Peptide identification and label-free quantitation by mass spectrometry 
Peptides in tau-enriched samples were identified by peptide sequencing with mass spectrometry. In-gel 
digestion was performed according to the UCSF Mass Spectrometry Facility protocol 
(https://msf.ucsf.edu/ingel.html). For in-solution digestion of tau enriched samples, the samples were 
incubated with urea (5 M final) and 10 mM tris(2-carboxyethyl)phosphine (TCEP) for 10 min at 56°C. 
Following reduction, the samples were alkylated with 20 mM iodoacetamide (30 min, dark, room 
temperature), then quenched with 10 mM additional TCEP, and the final volume was brought up to 250 µL 
with 100 mM ammonium bicarbonate buffer. Trypsin and AspN digestions were performed overnight at 
37°C using an enzyme to total protein ratio of 1:50. Samples were then acidified with 10% formic acid to 
pH 2–3, desalted using C18 Omix tips, and the extracted peptides were dried in a speedvac before analysis. 
To target O-GlcNAcylated peptides, lectin weak affinity chromatography (LWAC) enrichment
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was performed on 1.2-1.8 mg of tau-enriched protein samples generated from large scale perchloric acid 
enrichment. 
Peptide sequencing was performed using either LTQ-Orbitrap Velos or LTQ-Orbitrap XL (Thermo) 
mass spectrometers, each equipped with a 10,000 psi system nanoACUITY (Waters) UPLC instrument for 





liquid chromatography (LC) was operated at 600 nL/min flow rate, and peptides were separated using a 
linear gradient over 60 or 90 min from 2% to 30% acetonitrile in 0.1% formic acid.  
Tau enriched samples were analyzed by several tandem mass spectrometry (MS/MS) techniques. For 
collision-induced dissociation (CID) and electron-transfer dissociation (ETD) experiments, survey scans 
were recorded over a 350–1500 m/z range and MS/MS was performed with CID or ETD activation on the 
three most intense precursor ions, with a minimum of 10,000 counts and 35% normalized collision energy. 
ETD isolation width was 3.0 amu with 200 µs activation time; CID isolation width was 2.0 amu with 30 µs 
activation time. For the higher-energy collisional dissociation (HCD) experiments, survey scans were 
recorded over a 350–1400 m/z range and MS/MS was performed with HCD activation on the ten most 
intense precursor ions, with minimum signal of 4000 counts, isolation width 2.5 amu, 0.1 µs activation 
time, and 30% normalized collision energy over a mass range of 350–1500 m/z. Internal recalibration to a 
polydimethylcyclosiloxane (PCM) ion with m/z = 445.120025 was used for both MS and MS/MS scans
478
.  
Mass spectrometry centroid peak lists were generated using in-house software called PAVA, and data 
were searched using Protein Prospector software v. 5.10.1
479
. For protein identification, database searches 
were performed against the Mus musculus subset of the UniProtKB database (downloaded March 21, 2012) 
totaling 77,771 entries. This database was concatenated with a fully randomized set of 77,771 entries for 
estimation of false discovery rate
480
. Data were also searched against a targeted library of tau isoform 
sequences (P10637, P10637-2, P10637-3, P10637-4, P10637-5 and P10637-6). Peptide sequences were 
matched as tryptic peptides with 0, 1 or 2 missed cleavages, and carbamidomethylated cysteines as a fixed 
modification. Variable modifications included: oxidation of methionine, N-terminal pyroglutamate from 
glutamine, start methionine processing, protein N-terminal acetylation, phosphorylation on serine, 
threonine, or tyrosine, O-GlcNAcylated serine and threonine, acetylated lysine, methylation on lysine or 
arginine, and diglycyl modified lysine. Mass accuracy tolerance was set to 20 ppm for parent and 30 ppm 
for fragment masses. 
For reporting of protein identifications from this database search, score thresholds were selected that 
resulted in a protein false discovery rate of approximately 1%. The Protein Prospector parameters were: 





protein and 0.05 for peptide matches. Post-translational modification assignments on tau were scored by 
“SLIP” scoring within Protein Prospector
359
, with unambiguous site assignments receiving a score ≥6, and 
site assignments were manually confirmed. Ambiguous site assignments are denoted in tables using a 
vertical bar between the potential modification sites. 
For label-free quantitation by selective reaction monitoring with HCD ionization, a list of parent 
masses was developed with a ±10 ppm exclusion mass width window. The parent mass list included 
experimentally observed as well as predicted masses for tryptic peptides containing up to three 
phosphorylations on serine/threonine/tyrosine, O-GlcNAcylation on serine/threonine, diglycyl modified 
lysine, acetylation on lysine or arginine, and mono- or di-methylation on lysine or arginine, with up to two 
missed cleavages, as well as unmodified peptides that uniquely identify the known mouse isoforms of tau 
(SwissProt P10637, P10637-1, P10637-2, P10637-3, P10637-4, P10637-5, P10637-6). Dynamic exclusion 
was applied over a 10 second duration after a single repeat count, with an exclusion list size of 25 masses. 
All peptides utilized for site assignments were manually checked with alternate site-assignment hypotheses 
and the mass accuracy was sufficient to distinguish acetylation from potential tri-methylation modification. 
Data were searched as described above for information-dependent acquisition mode experiments. 
Quantitative analysis was performed with a previously reported label-free quantitation method that 
integrates the base peak intensity for each identified species
481
.  
Spectra and results for all identified tau peptides may be viewed with the freely available software MS 
Viewer, which can be accessed through the Protein Prospector suite of software at the following url: 
http://prospector2.ucsf.edu/prospector/cgi-bin/msform.cgi?form=msviewer. Search keys for the PTM site 
assignment data are listed for each set of experiments: Velos HCD: jtuvjpmrvc, OrbitrapXL CID: 
kfjt07okcs, and OrbitrapXL ETD: m5jt1eadj7. Search keys for the peptides identified in the label free 








Quantitative comparison of tau modifications 
The value of modified tau peptides in each experiment was normalized to the median peak area of 
unmodified tau peptides from that sample, excluding unmodified tau peptides with a value of zero for more 
than 2 samples. Any peptide with a peak width of zero was assigned a value of zero for the quantitative 
analysis. Peptides with the same mass to charge ratio (m/z) represent different possible peptide species 
within the same quantified peak and were averaged to obtain the value for that tau modification. To obtain 
a value for one tau modification represented by multiple peptides, the value of peptides with the same m/z 
were averaged and added to the value of peptides with a different m/z. For each cohort, quantified values 
were normalized to the average value of that modification in wildtype mice and the normalized values of 
each modification were compared between wildtype and hAPP mice, excluding the zero values. To 
determine whether a modification appeared more frequently in one genotype, we also compared the number 
of zero values across genotypes for each tau modification. 
Striatal tissue dissection 
Frozen hemibrains were covered in 2% agarose and chopped into 450 µm slices (McIlwain Tissue 
Chopper, Mickle Laboratory Engineering Co. Ltd., UK). Slices were microdissected in sterile PBS on ice. 
The striatum was isolated from 4-5 slices per mouse. Striatal tissues were immediately frozen on dry ice 
and stored at -80˚C. For each mouse, half of the striatal tissue was sent to the Vanderbilt Neurochemistry 
Core Laboratory for determination of bioamine levels by HPLC. The other half was homogenized in 100µL 
buffer (PBS, 1mM DTT, 0.5mM EDTA, 0.5% Triton-X100, 0.1M PMSF, phosphatase inhibitor cocktails 2 
and 3 (Sigma) and protease inhibitor tablets (Roche complete mini)) with a hand-held homogenizer. 
Samples were then sonicated (Episonic multi-functional bioprocessor 1000, Epigentek Group Inc., NY) at 
an amplitude of 40% in an ice bath twice for 5 min, incubated for 20-30 min on ice, and spun at 10,000xg 
at 4˚C for 10 min. The supernatant was collected. 
Western blotting 
Protein concentration was measured by BCA assay (Thermo Scientific). Samples were run on a 4-12% bis-





(Invitrogen), which was blocked for 1 hour in 5% milk/PBS. For western blotting of fractionation samples 
(Chapter 3), the 4-12% bis-tris gel was incubated in 10% methanol/2xNuPAGE transfer buffer (NP0006-1, 
Life Technologies) for 10 minutes, then transferred by iBlot onto a nitrocellulose membrane (Invitrogen) 
and blocked for 1 hour in Odyssey blocking buffer (927-40000, LI-COR Biosciences). Blots were 
incubated overnight with primary antibodies (rabbit anti-tyrosine hydroxylase (1:1000 AB152, Millipore) 
plus anti-alpha tubulin (1:500,000 B512, Sigma), mouse anti-PSD95 (1:2000 MABN68, Millipore), or 
mouse anti-α-synuclein (1:2000 610787, BD Transduction laboratories) plus rabbit anti-tau (1/2000 
EP2456Y, Millipore)), followed by incubation with secondary antibodies (680LT donkey anti-mouse 
(1:10,000-20,000, LI-COR Biosciences) and 800CW anti-rabbit (1:10,000-20,000, LI-COR Biosciences)) 
and quantitation of signals by an Odyssey system (LI-COR Biosciences). Membranes that were exposed to 
several primary antibodies in succession were not stripped between exposures. 
Immunohistochemistry 
Fixed hemibrains were stored at 4º C in phosphate-buffered saline (PBS) for 24 h and then in 30% 
sucrose/PBS until they were sectioned by microtome (Leica Microsystems Inc., IL) into 30 µm sections, 
which were then stored at -20˚C in a solution containing 30% glycerol (Fisher, PA), 30% ethylene glycol 
(Fisher, PA) and 40% phosphate-buffered saline (from 10X stock solution, Mediatech, Inc., VA) until 
immunostaining. Primary antibodies were rabbit anti-TH (1:2000 ab152, Abcam, MA), rabbit anti-
calbindin (1:50,000, Swant), rabbit anti-NPY (1:8,000, Immunostar) and rabbit anti-cfos (1:10,000, Ab-5, 
Calbiochem). Primary antibody binding was detected with biotinylated donkey anti-rabbit (1:500, Jackson 
Immunoresearch), followed by avidin-biotin complex (Vector, CA). To determine the extent of the loss of 
striatal dopaminergic projections after 6-OHDA injection, the percent area occupied by TH 
immunoreactivity was determined with the BIOQUANT (BIOQUANT Image Analysis Corporation, TN) 
percent area function, in which the entire striatum was outlined by a variable region of interest and the 
percent area showing a staining signal above a set threshold was measured. Percent area on the injected 
side of the striatum was normalized to the percent area on the contralateral uninjected side. In SYN 
transgenic mice, striatal TH immunoreactivity was quantitated by densitometry. Calbindin, NPY and cfos 
quantification was done as described
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immunoreactivity in the dentate gyrus was not normalized to that in CA1, because calbindin was reduced in 
the latter region also. The experimenter was blinded to mouse treatment and genotype. 
Perl iron staining 
Brain sections were stained as previously described 
482
. Briefly, sections were stained in a solution of 1% 
potassium ferrocyanide and 1% hydrochloric acid. They were then rinsed with distilled water and 
counterstained at 60˚C for 15 s in a solution of 0.1% nuclear fast red, 5% aluminum sulfate and trace 
amounts of thymol (storage preservative). The sections were rinsed well in water and then mounted and 
analyzed. Focal brain injury, elicited in anesthetized wildtype mice as described 
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, was used as a positive 
control. 
Statistical analysis 
Investigators were blinded with respect to the genotype and treatment of mice during behavioral testing, 
biochemistry and immunohistochemistry. Most data was analyzed by GraphPad Prism (GraphPad Software 
Inc., CA). Generally analyses were done using one- or two-way ANOVA, as appropriate, with the specified 
post hoc test. Tukey testing was used to compare between all groups, Bonferroni was used when only 
selected groups were compared. Findings were considered significant at p≤0.05 and outliers in mouse 
analyses were defined a priori as greater than 2SD from the mean. A p-value correction was used for 
multiple comparisons, as specified in the figure legends. 
Power calculations for TH western blotting were done using the Statistical Solutions, LLC Power & 




 groups within each age group. 
Alpha was defined as 0.0167 for each test to correct for multiple comparisons. The lower sample number 
and the higher standard deviation between the two groups were used in power calculations for striatal 
dopamine and tyrosine hydroxylase levels. All comparisons made had power higher than 0.80 to detect a 
40% decrease from levels in Tau
+/+
 mice.  
The TH quantification of 6-OHDA-treated mice was analyzed by one-way t-tests compared to 100% 





compare treated groups to each other. To assess genotype effects and genotype interaction in the hind limb 
clasp test, the raw score data was analyzed by probit regression with random effects taken into account 
(Stata, StataCorp LP, TX). Comparisons between individual genotype groups were made by Welch’s t-test 
of the average hind limb clasp scores for each mouse with a Benjamini-Hochberg p-value correction for 
multiple comparisons.  
Contingency analysis was done in Prizm (GraphPad) to determine significant enrichment of tau 
modifications in the microtubule binding repeat domain using a Holm correction for multiple comparisons. 
A chi-square test was used when all expected counts were more than 5 (acetylation, ubiquitination); 
otherwise, we used Fisher’s exact test (methylation, phosphorylation). Pearsons’s chi-squared test and the 
likelihood ratio test to determine lysine targeting above chance was done in R (R-project).  
For each tau modification found in more than 3 mice per genotype per cohort with a value greater 
than zero, values in hAPP and wildtype mice were compared by Student’s t-test in Excel. P-values were 
adjusted using a Benjamini-Hochberg correction in R (R-project). 
In behavioral data where the variance between groups was severely unequal (Bartlett’s test p<0.0001), 
the data was transformed by either a square-root, cube-root or log transformation to normalize variance 
between the groups. Whichever transformation best normalized variance was then analyzed by two-way 
ANOVA and a Bonferroni post-hoc test. All transformed data displayed equal variance across groups 
except rearing after four-weeks of recovery from a 6-OHDA injection (Bartlett’s test p=0.03).  
Cumulative distribution functions were generated using the integral function in Prism. Repeated 
measures mixed effects model analysis in Stata was used to analyze the frequency band graph with multiple 
time points (Figure 5.1E). A mixed effects linear model in Stata was fit to the age of onset of cognitive 
impairment of DLB patients, as detailed in the chart review section above. Incidence rate ratios and 95% 









Appendix B: Mouse Cohorts Studied 
Table B.1: Mouse cohorts used in aged tau knockout studies 
Fig. Panel Analysis Mice per Group (M/F) 
Age at 
Analysis (mo) Cohort  




, 8 (3/5) 
Tau
–/–




Water maze, Novel object 
recognition, Weight, Open 
field, Rota rod, Pole test 
Tau
+/+
, 12-13a (6/7) 
Tau
+/–
, 12-13a (6/7) 
Tau
–/–




Weight, Rota rod, Pole 
test, Balance beam 
Tau
+/+
, 13 (0/13) 
Tau
+/–
, 14 (0/14) 
Tau
–/–
, 13 (0/13) 
12-15 C 
2.2B,C Open field Tau
+/+
, 11 (0/11) 
Tau
+/–
, 13 (0/13) 
Tau
–/–
, 12 (0/12) 
12-15 C 




, 4-5b (5/0) 
Tau
+/–
, 5 (5/0) 
Tau
–/–
, 5 (5/0) 
9-11 D 




, 7 (2/5) 
Tau
–/–
, 6 (2/4) 
14-20 A 




, 7 (0/7) 15-17 C 




, 10 (5/5) 
Tau
+/–
, 8 (4/4) 
Tau
–/–
, 7 (4/3) 
25-26 B 
2.4D Pole test with drug Tau
+/+
, 14 (5/9) 
Tau
+/–
, 14 (9/5) 
Tau
–/–
, 11 (3/8) 
12-15 E 
2.5B Perl staining analysis Tau
+/+
, 3 (1/2) 
Tau
–/–
, 3 (1/2) 
14 F 
mo, months; M, male; F, female 
a
Some mice died over the course of testing 
b







Table B.2: Summary of mice and experiments used to identify post-translational modifications of tau 
(reporting data available for viewing through MASSive) 
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47 7 M + - PSD IP Solution - HCD 
MS, mass spectrometry method; hAPP, human amyloid precursor protein transgenic; F, female; M, male; 
IP, immunoprecipitation; PCA, 1% perchloric acid enrichment; PSD, post-synaptic density fractionation; 
Gel, in gel digestion; Solution, in solution digestion; ETD, electron transfer dissociation; CID, collision-
induced dissociation; HCD, higher energy collisional dissociation 
a
Each mouse was assigned a unique number for the inclusion list
  
b
Age in months 
c














A 3 WT (none)       
3 hAPP (none) 
3M per 
group 
6 Perchloric Acid 
B 12 WT (none)       
12 hAPP (none)          
10 WT (PSD)       





C 12 WT (PSD)         




D 10 WT (PSD)         











Table B.4: Mouse cohorts used in PD model studies 
Fig. Panel Analysis Mice per Group (M/F) Age at 
Analysis (mo) 
Cohort 
4.1-4.3 Open field, Rota Rod, 






























4.4 Rota Rod, stride length, 




, 15 (15/0) 
Tau
+/–
, 15 (15/0) 
Tau
–/–
, 15 (15/0) 
SYN Tau
+/+












mo, months; M, male; F, female 
a






Table B.5: Mouse cohorts used in SYN transgenic studies of neural network dysfunction 
Fig. 
Panel 
Analysis Mice per Group (M/F)
 
Age at  
Analysis (mo) 
Cohort 
5.1C-E EEG NTG, 6 (6/0) 

















5.2F-K IHC NTG, 12 (12/0) 
Thy1-SYN, 11 (11/0) 
5–7 C 
5.2K IHC NTG, 3 (3/0) 
Thy1-SYN, 2 (3/0) 
5–7 D 
5.3 IHC NTG, 8 (4/4) 
PDGF-SYN, 8 (3/5)  
3–17 E 
5.4A-C EEG NTG, 7 (6/1)  
Thy1-SYN, 3 (3/0)  
hAPP, 5 (4/1)  
4–5 F 











































5.4I EEG NTG, 3 (3/0) 
SYN, 6 (6/0) 
4–6 J 
mo, months; IHC, immunohistochemistry 
a
One mouse was excluded from the spectral analysis because no suitable resting state could be found. 
b
SYN mice were compared to themselves before and after treatment. 
c
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